[
    {
        "path": [
            907040000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine.",
            " 8 Information to be included on the label (2) (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine's main label on the primary pack displays the name and quantity of an active ingredient that has a non-therapeutically relevant descriptor in accordance with subsection 8(2), can the name of the therapeutically active moiety be displayed instead of the active ingredient name if the text size is 2.5 millimeters and no quantity information is shown?",
                    "Answer": "No",
                    "Answer Explanation": "According to subsection 9(7)(d), if a medicine's active ingredient name includes non-therapeutically relevant descriptors and the name and quantity are displayed per 8(2), the therapeutically active moiety name can be displayed instead only if the text size is at least 3.0 millimeters and no quantity information is shown for any active ingredients. Since the given text size is 2.5 millimeters, the conditions are not met to allow displaying the moiety name instead of the full active ingredient name."
                },
                {
                    "Question": "Assuming a medicine label includes critical health information and the information required by 8(2)(c), (d) and (e), what color text and background must be used to present this information?",
                    "Answer": "The text must be black or dark colored, using only one color, on a white or contrasting background.",
                    "Answer Explanation": "Subsection 8(2)(f) states that the critical health information and any information from 8(2)(c), (d) or (e) that is included must be presented in black or other dark colored text, using only one color, on a white or other contrasting background."
                },
                {
                    "Question": "Assuming a medicine is registered goods and its active ingredient name has non-therapeutically relevant descriptors, if the active ingredient name and quantity are shown on the main label per 8(2) with 4mm text and no quantity is shown, can the therapeutically active moiety name be displayed instead of the full active ingredient name?",
                    "Answer": "Yes",
                    "Answer Explanation": "Subsection 9(7)(d) allows the therapeutically active moiety name to be displayed on the main label instead of the full active ingredient name if: the medicine is registered goods, the active ingredient name has non-relevant descriptors, the name and quantity are shown per 8(2), the moiety name text size is at least 3.0mm, and no quantity is shown for any active ingredients. The scenario meets all these conditions, with the 4mm text exceeding the 3mm minimum, so displaying the moiety name is permitted."
                },
                {
                    "Question": "Assuming a medicine label must display certain information required by 8(2)(c)-(e), can the text be in multiple colors if a white background is used?",
                    "Answer": "No",
                    "Answer Explanation": "Subsection 8(2)(f) requires that any information from 8(2)(c), (d) or (e) must be presented in black or dark colored text using only one color on a white or contrasting background. Using multiple text colors is not permitted even if the background is white."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine's main label on the primary pack displays the name and quantity of an active ingredient that has a non-therapeutically relevant descriptor in accordance with subsection 8(2), can the name of the therapeutically active moiety be displayed instead of the active ingredient name if the text size is 2.5 millimeters and no quantity information is shown?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"According to subsection 9(7)(d), if a medicine's active ingredient name includes non-therapeutically relevant descriptors and the name and quantity are displayed per 8(2), the therapeutically active moiety name can be displayed instead only if the text size is at least 3.0 millimeters and no quantity information is shown for any active ingredients. Since the given text size is 2.5 millimeters, the conditions are not met to allow displaying the moiety name instead of the full active ingredient name.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine label includes critical health information and the information required by 8(2)(c), (d) and (e), what color text and background must be used to present this information?\",\n    \"Answer\": \"The text must be black or dark colored, using only one color, on a white or contrasting background.\",\n    \"Answer Explanation\": \"Subsection 8(2)(f) states that the critical health information and any information from 8(2)(c), (d) or (e) that is included must be presented in black or other dark colored text, using only one color, on a white or other contrasting background.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is registered goods and its active ingredient name has non-therapeutically relevant descriptors, if the active ingredient name and quantity are shown on the main label per 8(2) with 4mm text and no quantity is shown, can the therapeutically active moiety name be displayed instead of the full active ingredient name?\", \n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Subsection 9(7)(d) allows the therapeutically active moiety name to be displayed on the main label instead of the full active ingredient name if: the medicine is registered goods, the active ingredient name has non-relevant descriptors, the name and quantity are shown per 8(2), the moiety name text size is at least 3.0mm, and no quantity is shown for any active ingredients. The scenario meets all these conditions, with the 4mm text exceeding the 3mm minimum, so displaying the moiety name is permitted.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine label must display certain information required by 8(2)(c)-(e), can the text be in multiple colors if a white background is used?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Subsection 8(2)(f) requires that any information from 8(2)(c), (d) or (e) must be presented in black or dark colored text using only one color on a white or contrasting background. Using multiple text colors is not permitted even if the background is white.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "label",
                    "information",
                    "active ingredient"
                ]
            ]
        }
    },
    {
        "path": [
            908030000,
            907000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a composite pack contains multiple medicines with the same active ingredient in different formulations, how would the number of active ingredients be counted for determining which labeling requirements apply under sections 9(6)(b) or 9(7)?",
                    "Answer": "Each instance of the same active ingredient would be counted separately.",
                    "Answer Explanation": "Section 9(8)(c)(ii) states that if the same active ingredient is contained in two or more formulations in a composite pack, each of those active ingredients is to be counted separately for the purposes of determining if paragraph 9(6)(b) applies or which paragraph in 9(7) applies to the labeling of the composite pack."
                },
                {
                    "Question": "For a registered medicine that includes active ingredients with therapeutically irrelevant name descriptors, what conditions must be met to display the therapeutically active moiety names instead of the full active ingredient names on the main label, assuming the requirements of section 8(2) are followed?",
                    "Answer": "The moiety names must be in a text size of at least 3.0mm and no quantity or proportion information can be displayed for any of the active ingredients.",
                    "Answer Explanation": "Section 9(7)(d) allows the therapeutically active moiety names to be displayed instead of the full active ingredient names on the main label of a registered medicine, provided that: the requirements of 8(2) for displaying ingredient names and quantities are met, the moiety names are in a text size of at least 3.0mm, and no quantity or proportion information is displayed for any of the active ingredients."
                },
                {
                    "Question": "Consider a composite pack containing multiple medicines. One medicine has two active ingredients, Chemical A and Chemical B. Another medicine in the pack also contains Chemical A in a different formulation. Assuming no other active ingredients are present, how many total active ingredients would be counted for the composite pack when determining applicable labeling requirements?",
                    "Answer": "The composite pack would be considered to have three active ingredients in total.",
                    "Answer Explanation": "Based on sections 9(8)(c)(i) and (ii), the total number of active ingredients in the different formulations are counted, and if the same active ingredient is in multiple formulations, each instance is counted separately. So Chemical A would be counted twice (once for each formulation) and Chemical B once, totaling three active ingredients for labeling purposes."
                },
                {
                    "Question": "For a registered medicine named 'Example' that follows the naming requirements in section 8(2), can the therapeutically active moiety name be displayed on the main label instead of the full active ingredient name if the active ingredient name includes a chemical salt that is not therapeutically relevant?",
                    "Answer": "Yes, provided the moiety name has a text size of at least 3.0mm and no quantity or proportion is displayed for any active ingredient.",
                    "Answer Explanation": "Section 9(7)(d) permits the therapeutically active moiety name to be displayed on the main label of the registered medicine 'Example' instead of the full active ingredient name when: 'Example' follows 8(2) naming requirements, the active ingredient name includes a therapeutically irrelevant chemical salt, the moiety name text size is minimum 3.0mm, and active ingredient quantities\/proportions are not displayed."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a composite pack contains multiple medicines with the same active ingredient in different formulations, how would the number of active ingredients be counted for determining which labeling requirements apply under sections 9(6)(b) or 9(7)?\",\n    \"Answer\": \"Each instance of the same active ingredient would be counted separately.\",\n    \"Answer Explanation\": \"Section 9(8)(c)(ii) states that if the same active ingredient is contained in two or more formulations in a composite pack, each of those active ingredients is to be counted separately for the purposes of determining if paragraph 9(6)(b) applies or which paragraph in 9(7) applies to the labeling of the composite pack.\"\n  },\n  {\n    \"Question\": \"For a registered medicine that includes active ingredients with therapeutically irrelevant name descriptors, what conditions must be met to display the therapeutically active moiety names instead of the full active ingredient names on the main label, assuming the requirements of section 8(2) are followed?\",\n    \"Answer\": \"The moiety names must be in a text size of at least 3.0mm and no quantity or proportion information can be displayed for any of the active ingredients.\",\n    \"Answer Explanation\": \"Section 9(7)(d) allows the therapeutically active moiety names to be displayed instead of the full active ingredient names on the main label of a registered medicine, provided that: the requirements of 8(2) for displaying ingredient names and quantities are met, the moiety names are in a text size of at least 3.0mm, and no quantity or proportion information is displayed for any of the active ingredients.\"\n  },\n  {\n    \"Question\": \"Consider a composite pack containing multiple medicines. One medicine has two active ingredients, Chemical A and Chemical B. Another medicine in the pack also contains Chemical A in a different formulation. Assuming no other active ingredients are present, how many total active ingredients would be counted for the composite pack when determining applicable labeling requirements?\",\n    \"Answer\": \"The composite pack would be considered to have three active ingredients in total.\",\n    \"Answer Explanation\": \"Based on sections 9(8)(c)(i) and (ii), the total number of active ingredients in the different formulations are counted, and if the same active ingredient is in multiple formulations, each instance is counted separately. So Chemical A would be counted twice (once for each formulation) and Chemical B once, totaling three active ingredients for labeling purposes.\"\n  },\n  {\n    \"Question\": \"For a registered medicine named 'Example' that follows the naming requirements in section 8(2), can the therapeutically active moiety name be displayed on the main label instead of the full active ingredient name if the active ingredient name includes a chemical salt that is not therapeutically relevant?\",\n    \"Answer\": \"Yes, provided the moiety name has a text size of at least 3.0mm and no quantity or proportion is displayed for any active ingredient.\",\n    \"Answer Explanation\": \"Section 9(7)(d) permits the therapeutically active moiety name to be displayed on the main label of the registered medicine 'Example' instead of the full active ingredient name when: 'Example' follows 8(2) naming requirements, the active ingredient name includes a therapeutically irrelevant chemical salt, the moiety name text size is minimum 3.0mm, and active ingredient quantities\/proportions are not displayed.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "composite pack",
                    "medicine",
                    "example"
                ]
            ]
        }
    },
    {
        "path": [
            802060000,
            802050000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming the critical health information, including information mentioned in 8(2)(c), 8(2)(d) or 8(2)(e), is being presented on a medicine label, what colour text and background must be used?",
                    "Answer": "The critical health information and any included information from 8(2)(c), 8(2)(d) or 8(2)(e) must be presented in black or other dark coloured text, using only one colour, on a white or other contrasting background.",
                    "Answer Explanation": "This is directly stated in regulation 8(2)(f). It specifies the required text and background colours for presenting the critical health information and other information from 8(2)(c), 8(2)(d) or 8(2)(e) on the label."
                },
                {
                    "Question": "If information other than the critical health information or that mentioned in 8(2)(c) or 8(2)(d) is included on a medicine label, under what heading should it be placed?",
                    "Answer": "If other information is included beyond the critical health information and that from 8(2)(c) or 8(2)(d), it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the headings mentioned in 8(2)(b).",
                    "Answer Explanation": "Regulation 8(2)(e) states the requirement for where to place other information on the label beyond the critical health information and that from 8(2)(c) and 8(2)(d). It must go under the 'Other information' heading or another appropriate heading below those from 8(2)(b)."
                },
                {
                    "Question": "Assuming other information is included under the 'Other information' heading as per 8(2)(e), what are the only additional details that can be included there?",
                    "Answer": "If other information is included under the 'Other information' heading, the only additional details allowed are: requirements relating to storage conditions, information about package features to prevent tampering, names of all excipients, and sponsor or distributor contact details.",
                    "Answer Explanation": "The list of allowable additional details under the 'Other information' heading is explicitly provided in regulation 8(2)(e). No other additional information beyond those listed items is permitted."
                },
                {
                    "Question": "Based on the given regulations, how should the critical health information be visually presented on the label in relation to any other information allowed under 8(2)(e)?",
                    "Answer": "The critical health information must be presented in black or dark coloured text on a white or contrasting background, separate from and above any other information allowed under the 'Other information' heading as per 8(2)(e).",
                    "Answer Explanation": "Regulation 8(2)(f) mandates the visual presentation of the critical health information in dark text on a contrasting background. Regulation 8(2)(e) states that any other information must be placed under a separate 'Other information' heading below the critical information. Taken together, the regulations require the critical health information to be visually distinct and positioned above the other information on the label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming the critical health information, including information mentioned in 8(2)(c), 8(2)(d) or 8(2)(e), is being presented on a medicine label, what colour text and background must be used?\", \"Answer\": \"The critical health information and any included information from 8(2)(c), 8(2)(d) or 8(2)(e) must be presented in black or other dark coloured text, using only one colour, on a white or other contrasting background.\", \"Answer Explanation\": \"This is directly stated in regulation 8(2)(f). It specifies the required text and background colours for presenting the critical health information and other information from 8(2)(c), 8(2)(d) or 8(2)(e) on the label.\"}, {\"Question\": \"If information other than the critical health information or that mentioned in 8(2)(c) or 8(2)(d) is included on a medicine label, under what heading should it be placed?\", \"Answer\": \"If other information is included beyond the critical health information and that from 8(2)(c) or 8(2)(d), it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the headings mentioned in 8(2)(b).\", \"Answer Explanation\": \"Regulation 8(2)(e) states the requirement for where to place other information on the label beyond the critical health information and that from 8(2)(c) and 8(2)(d). It must go under the 'Other information' heading or another appropriate heading below those from 8(2)(b).\"}, {\"Question\": \"Assuming other information is included under the 'Other information' heading as per 8(2)(e), what are the only additional details that can be included there?\", \"Answer\": \"If other information is included under the 'Other information' heading, the only additional details allowed are: requirements relating to storage conditions, information about package features to prevent tampering, names of all excipients, and sponsor or distributor contact details.\", \"Answer Explanation\": \"The list of allowable additional details under the 'Other information' heading is explicitly provided in regulation 8(2)(e). No other additional information beyond those listed items is permitted.\"}, {\"Question\": \"Based on the given regulations, how should the critical health information be visually presented on the label in relation to any other information allowed under 8(2)(e)?\", \"Answer\": \"The critical health information must be presented in black or dark coloured text on a white or contrasting background, separate from and above any other information allowed under the 'Other information' heading as per 8(2)(e).\", \"Answer Explanation\": \"Regulation 8(2)(f) mandates the visual presentation of the critical health information in dark text on a contrasting background. Regulation 8(2)(e) states that any other information must be placed under a separate 'Other information' heading below the critical information. Taken together, the regulations require the critical health information to be visually distinct and positioned above the other information on the label.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "heading",
                    "critical health information",
                    "presentation"
                ]
            ]
        }
    },
    {
        "path": [
            907030000,
            901030000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {},
        "result_str": "Here is my attempt at generating the requested question-answer pairs in the specified JSON format:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine is intended to be registered goods and contains five active ingredients, is compliance with paragraphs 9(1)(b) and 9(1)(c) required if subsection 8(2) applies?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"According to section 9(7)(c), if the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required, even if the medicine is intended to be registered goods. Since the medicine in question has five active ingredients, compliance is not required under the stated conditions.\"\n    },\n    {\n      \"Question\": \"Assuming subsection 8(2) does not apply, what information must be included on the main label of a medicine intended to be registered goods that has three active ingredients, according to the regulation?\", \n      \"Answer\": \"The quantity or proportion of all active ingredients\",\n      \"Answer Explanation\": \"Section 9(1)(c) states that subject to qualifications and special requirements, the main label of a medicine must include the quantity or proportion of all active ingredients. Section 9(7)(c) provides an exception to this requirement only if the medicine has four or more ingredients and subsection 8(2) applies. Since neither of those conditions are met, the quantity or proportion of the three active ingredients must be on the main label to comply with 9(1)(c).\"\n    },\n    {\n      \"Question\": \"For a medicine with five active ingredients that is intended to be registered goods, does subsection 8(2) applying have any impact on the labeling requirements specified in section 9(1)?\",\n      \"Answer\": \"Yes, it exempts the medicine from 9(1)(b) and 9(1)(c)\", \n      \"Answer Explanation\": \"Section 9(7)(c) states that if a medicine intended to be registered goods contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Therefore, subsection 8(2) applying to this five ingredient medicine impacts the labeling by removing the section 9(1) requirements to include on the label the quantity or proportion of all active ingredients.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine with two active ingredients is not intended to be registered goods, does section 9(1)(c) still require listing the quantity or proportion of active ingredients on the main label?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 9(1) states its labeling requirements, including 9(1)(c) on listing active ingredient quantity, apply subject to the qualifications and special requirements specified in section 9 and section 10. Section 9(7)(c) waives compliance with 9(1)(c) only for registered goods with 4+ ingredients where 8(2) applies. It does not waive 9(1)(c) for medicines not intended as registered goods. Therefore, 9(1)(c) still requires listing the two active ingredients' quantities on the label.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "compliance",
                    "medicine",
                    "special requirement"
                ]
            ]
        }
    },
    {
        "path": [
            1009020000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a listed medicine has 3 active ingredients and is intended to be in a blister pack, what information must be displayed on the label of the blister pack to comply with sections 8 and 9 of the regulation?",
                    "Answer": "The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.",
                    "Answer Explanation": "Section 10(9)(b)(ii) states that for listed goods with 2 or more active ingredients in a strip, blister or dial dispenser pack, to comply with sections 8 and 9, the label must display the name of the medicine (iii), batch number with prefix (iv), expiry date with prefix (v), and name of sponsor\/distributor or identifying trademark (vi)."
                },
                {
                    "Question": "Assuming a listed medicine is a sunscreen preparation intended to be in a container with a main label and rear label, can the active ingredients and their quantities be listed on the rear label and still comply with section 9?",
                    "Answer": "Yes, for a listed sunscreen preparation, the name, quantity and proportion of every active ingredient, along with the dosage form name, may appear on a rear label and still comply with section 9.",
                    "Answer Explanation": "Section 9(6)(a) allows that for a listed medicine that is a sunscreen preparation, the name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a rear panel or rear label and still comply with the section 9 labeling requirements for the main label."
                },
                {
                    "Question": "Assuming a medicine has 5 active ingredients and is intended to be registered goods in a blister pack, what information must the label on the blister pack display to comply with sections 8 and 9?",
                    "Answer": "The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.",
                    "Answer Explanation": "Section 10(9)(b)(i) states that for registered goods with 4 or more active ingredients in a strip, blister or dial dispenser pack, to comply with sections 8 and 9, the label must display the name of the medicine (iii), batch number with prefix (iv), expiry date with prefix (v), and name of sponsor\/distributor or identifying trademark (vi)."
                },
                {
                    "Question": "Assuming a listed medicine has 1 active ingredient and is intended to be in a dial dispenser pack, is the information required in section 10(9)(b)(iii)-(vi) sufficient for the label to comply with sections 8 and 9?",
                    "Answer": "No, section 10(9)(b) only provides reduced labeling requirements for listed goods in a dial dispenser pack if the medicine has 2 or more active ingredients. With only 1 active ingredient, the label would need to fully comply with all of sections 8 and 9.",
                    "Answer Explanation": "Section 10(9)(b)(ii) specifies that the reduced labeling requirements in (iii)-(vi) for strip, blister or dial dispenser packs only apply to listed goods with 2 or more active ingredients. Therefore, a listed medicine with only 1 active ingredient would not qualify for this, and would need to have a label fully compliant with sections 8 and 9."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a listed medicine has 3 active ingredients and is intended to be in a blister pack, what information must be displayed on the label of the blister pack to comply with sections 8 and 9 of the regulation?\", \"Answer\": \"The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.\", \"Answer Explanation\": \"Section 10(9)(b)(ii) states that for listed goods with 2 or more active ingredients in a strip, blister or dial dispenser pack, to comply with sections 8 and 9, the label must display the name of the medicine (iii), batch number with prefix (iv), expiry date with prefix (v), and name of sponsor\/distributor or identifying trademark (vi).\"}, {\"Question\": \"Assuming a listed medicine is a sunscreen preparation intended to be in a container with a main label and rear label, can the active ingredients and their quantities be listed on the rear label and still comply with section 9?\", \"Answer\": \"Yes, for a listed sunscreen preparation, the name, quantity and proportion of every active ingredient, along with the dosage form name, may appear on a rear label and still comply with section 9.\", \"Answer Explanation\": \"Section 9(6)(a) allows that for a listed medicine that is a sunscreen preparation, the name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a rear panel or rear label and still comply with the section 9 labeling requirements for the main label.\"}, {\"Question\": \"Assuming a medicine has 5 active ingredients and is intended to be registered goods in a blister pack, what information must the label on the blister pack display to comply with sections 8 and 9?\", \"Answer\": \"The name of the medicine, batch number preceded by the batch number prefix, expiry date preceded by the expiry date prefix, and the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor.\", \"Answer Explanation\": \"Section 10(9)(b)(i) states that for registered goods with 4 or more active ingredients in a strip, blister or dial dispenser pack, to comply with sections 8 and 9, the label must display the name of the medicine (iii), batch number with prefix (iv), expiry date with prefix (v), and name of sponsor\/distributor or identifying trademark (vi).\"}, {\"Question\": \"Assuming a listed medicine has 1 active ingredient and is intended to be in a dial dispenser pack, is the information required in section 10(9)(b)(iii)-(vi) sufficient for the label to comply with sections 8 and 9?\", \"Answer\": \"No, section 10(9)(b) only provides reduced labeling requirements for listed goods in a dial dispenser pack if the medicine has 2 or more active ingredients. With only 1 active ingredient, the label would need to fully comply with all of sections 8 and 9.\", \"Answer Explanation\": \"Section 10(9)(b)(ii) specifies that the reduced labeling requirements in (iii)-(vi) for strip, blister or dial dispenser packs only apply to listed goods with 2 or more active ingredients. Therefore, a listed medicine with only 1 active ingredient would not qualify for this, and would need to have a label fully compliant with sections 8 and 9.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "rear label",
                    "listed good",
                    "compliance"
                ]
            ]
        }
    },
    {
        "path": [
            1005000000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (5) Sunscreen preparations If: (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other information is displayed in a text size of not less than 1.0 millimetres.",
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a sunscreen preparation is in a 20 ml container, what is the minimum font size required for the sun protection factor and all other information on the label to comply with sections 8 and 9?",
                    "Answer": "1.5 mm for sun protection factor, 1.0 mm for all other information",
                    "Answer Explanation": "Section 10(5)(b) states that for sunscreen preparations in containers of 25 ml or less, the sun protection factor must be displayed in a text size of at least 1.5 mm and all other information in at least 1.0 mm to comply with sections 8 and 9."
                },
                {
                    "Question": "If a medicine's main label lists the active ingredients separated by text identifying different formulations in a composite pack, does this violate the labeling requirements? Assume no other exceptions apply.",
                    "Answer": "No, it does not violate the requirements.",
                    "Answer Explanation": "Section 9(3)(b) requires the medicine name and active ingredients to not be separated by any text or graphics. However, 9(3)(b)(ii) provides an exception for text relating to identifying different formulations of medicines in a composite pack. So separating the ingredients by such text is permitted and does not violate the requirements."
                },
                {
                    "Question": "Assuming a 15 ml sunscreen container lists the SPF in 1.5 mm text and other info in 0.8 mm text, and no other exceptions apply, does the label meet the minimum text size requirements of sections 8-10?",
                    "Answer": "No, the label does not meet the minimum text size requirements.",
                    "Answer Explanation": "Section 10(5)(b) allows sunscreens 25 ml or less to have the SPF in minimum 1.5 mm text (which is met) and all other info in minimum 1.0 mm text. However, the other info is in 0.8 mm text which is less than the 1.0 mm minimum required by 10(5)(b)(ii) to comply with sections 8-9. No other exceptions are stated to apply."
                },
                {
                    "Question": "For a 30 ml sunscreen, can the active ingredients on the main label be separated by text indicating the product is part of a composite pack of different formulations? Assume sections 8-9 are met.",
                    "Answer": "Yes, the active ingredients can be separated by that text.",
                    "Answer Explanation": "Section 9(3)(b) generally prohibits medicine names and active ingredients from being separated by text. However, 9(3)(b)(ii) allows separating them with text identifying different formulations in a composite pack. Section 10(5)(b) text size allowances only apply to sunscreens 25 ml or less. At 30 ml, this sunscreen does not get that allowance, but sections 8-9 are assumed to be met, so the composite pack text exception in 9(3)(b)(ii) applies without violating the regulations."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a sunscreen preparation is in a 20 ml container, what is the minimum font size required for the sun protection factor and all other information on the label to comply with sections 8 and 9?\", \"Answer\": \"1.5 mm for sun protection factor, 1.0 mm for all other information\", \"Answer Explanation\": \"Section 10(5)(b) states that for sunscreen preparations in containers of 25 ml or less, the sun protection factor must be displayed in a text size of at least 1.5 mm and all other information in at least 1.0 mm to comply with sections 8 and 9.\"}, {\"Question\": \"If a medicine's main label lists the active ingredients separated by text identifying different formulations in a composite pack, does this violate the labeling requirements? Assume no other exceptions apply.\", \"Answer\": \"No, it does not violate the requirements.\", \"Answer Explanation\": \"Section 9(3)(b) requires the medicine name and active ingredients to not be separated by any text or graphics. However, 9(3)(b)(ii) provides an exception for text relating to identifying different formulations of medicines in a composite pack. So separating the ingredients by such text is permitted and does not violate the requirements.\"}, {\"Question\": \"Assuming a 15 ml sunscreen container lists the SPF in 1.5 mm text and other info in 0.8 mm text, and no other exceptions apply, does the label meet the minimum text size requirements of sections 8-10?\", \"Answer\": \"No, the label does not meet the minimum text size requirements.\", \"Answer Explanation\": \"Section 10(5)(b) allows sunscreens 25 ml or less to have the SPF in minimum 1.5 mm text (which is met) and all other info in minimum 1.0 mm text. However, the other info is in 0.8 mm text which is less than the 1.0 mm minimum required by 10(5)(b)(ii) to comply with sections 8-9. No other exceptions are stated to apply.\"}, {\"Question\": \"For a 30 ml sunscreen, can the active ingredients on the main label be separated by text indicating the product is part of a composite pack of different formulations? Assume sections 8-9 are met.\", \"Answer\": \"Yes, the active ingredients can be separated by that text.\", \"Answer Explanation\": \"Section 9(3)(b) generally prohibits medicine names and active ingredients from being separated by text. However, 9(3)(b)(ii) allows separating them with text identifying different formulations in a composite pack. Section 10(5)(b) text size allowances only apply to sunscreens 25 ml or less. At 30 ml, this sunscreen does not get that allowance, but sections 8-9 are assumed to be met, so the composite pack text exception in 9(3)(b)(ii) applies without violating the regulations.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "capacity",
                    "relation",
                    "different formulation"
                ]
            ]
        }
    },
    {
        "path": [
            907020000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or",
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming the non-prescription medicine has four active ingredients, no critical health information, and storage condition B information needs to be included, where on the label should the names and quantities of the active ingredients be placed, and where should the storage condition B information be placed?",
                    "Answer": "The names and quantities of the active ingredients should be placed on a side panel, side label, rear panel, or rear label in a text size of at least 2.5 millimetres. The storage condition B information should be placed under the 'Other information' heading or another appropriate heading immediately below the headings mentioned in 8(2)(b).",
                    "Answer Explanation": "According to section 9(7)(b), if the medicine has four or more active ingredients and section 8(2) does not apply, the names and quantities of the active ingredients may be placed on a side panel, side label, rear panel, or rear label, with a text size of at least 2.5 millimetres. Section 8(2)(e) states that if information other than critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, such as storage conditions, it must be placed under the 'Other information' heading or another appropriate heading immediately below the headings in 8(2)(b)."
                },
                {
                    "Question": "Assuming a non-prescription medicine has five active ingredients and no critical health information, can the names and quantities of the active ingredients be placed on the rear label if displayed in a text size of 2.0 millimetres?",
                    "Answer": "No, the names and quantities of the active ingredients cannot be placed on the rear label if displayed in a text size of 2.0 millimetres.",
                    "Answer Explanation": "Section 9(7)(b) allows the names and quantities of active ingredients to be placed on a side panel, side label, rear panel, or rear label only if the text size is at least 2.5 millimetres. Since the given text size is 2.0 millimetres, which is less than the required 2.5 millimetres, placing the information on the rear label would not comply with the regulation."
                },
                {
                    "Question": "Assuming a non-prescription medicine has three active ingredients, no critical health information, and sponsor contact details need to be included, where should the sponsor contact details be placed on the label?",
                    "Answer": "The sponsor contact details should be placed under the 'Other information' heading or another appropriate heading immediately below the headings mentioned in 8(2)(b).",
                    "Answer Explanation": "Section 8(2)(e) states that if information other than critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, such as sponsor contact details, it must be placed under the 'Other information' heading or another appropriate heading immediately below the headings mentioned in 8(2)(b)."
                },
                {
                    "Question": "Assuming a non-prescription medicine has six active ingredients and no critical health information, can the names and quantities of the active ingredients be placed on the rear label if displayed in a text size of 3.0 millimetres, and can storage condition B information be placed under the same heading as the names of excipients?",
                    "Answer": "Yes, the names and quantities of the active ingredients can be placed on the rear label if displayed in a text size of 3.0 millimetres, as this complies with section 9(7)(b). However, storage condition B information cannot be placed under the same heading as the names of excipients, as section 8(2)(e) requires storage condition information to be placed under the 'Other information' heading or another appropriate heading, separate from the names of excipients.",
                    "Answer Explanation": "Section 9(7)(b) allows the names and quantities of active ingredients to be placed on a side panel, side label, rear panel, or rear label if the text size is at least 2.5 millimetres. Since the given text size is 3.0 millimetres, placing the information on the rear label complies with the regulation. However, section 8(2)(e) requires storage condition information to be placed under the 'Other information' heading or another appropriate heading, separate from other information such as the names of excipients. Therefore, placing storage condition B information under the same heading as the names of excipients would not comply with the regulation."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming the non-prescription medicine has four active ingredients, no critical health information, and storage condition B information needs to be included, where on the label should the names and quantities of the active ingredients be placed, and where should the storage condition B information be placed?\", \"Answer\": \"The names and quantities of the active ingredients should be placed on a side panel, side label, rear panel, or rear label in a text size of at least 2.5 millimetres. The storage condition B information should be placed under the 'Other information' heading or another appropriate heading immediately below the headings mentioned in 8(2)(b).\", \"Answer Explanation\": \"According to section 9(7)(b), if the medicine has four or more active ingredients and section 8(2) does not apply, the names and quantities of the active ingredients may be placed on a side panel, side label, rear panel, or rear label, with a text size of at least 2.5 millimetres. Section 8(2)(e) states that if information other than critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, such as storage conditions, it must be placed under the 'Other information' heading or another appropriate heading immediately below the headings in 8(2)(b).\"}, {\"Question\": \"Assuming a non-prescription medicine has five active ingredients and no critical health information, can the names and quantities of the active ingredients be placed on the rear label if displayed in a text size of 2.0 millimetres?\", \"Answer\": \"No, the names and quantities of the active ingredients cannot be placed on the rear label if displayed in a text size of 2.0 millimetres.\", \"Answer Explanation\": \"Section 9(7)(b) allows the names and quantities of active ingredients to be placed on a side panel, side label, rear panel, or rear label only if the text size is at least 2.5 millimetres. Since the given text size is 2.0 millimetres, which is less than the required 2.5 millimetres, placing the information on the rear label would not comply with the regulation.\"}, {\"Question\": \"Assuming a non-prescription medicine has three active ingredients, no critical health information, and sponsor contact details need to be included, where should the sponsor contact details be placed on the label?\", \"Answer\": \"The sponsor contact details should be placed under the 'Other information' heading or another appropriate heading immediately below the headings mentioned in 8(2)(b).\", \"Answer Explanation\": \"Section 8(2)(e) states that if information other than critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, such as sponsor contact details, it must be placed under the 'Other information' heading or another appropriate heading immediately below the headings mentioned in 8(2)(b).\"}, {\"Question\": \"Assuming a non-prescription medicine has six active ingredients and no critical health information, can the names and quantities of the active ingredients be placed on the rear label if displayed in a text size of 3.0 millimetres, and can storage condition B information be placed under the same heading as the names of excipients?\", \"Answer\": \"Yes, the names and quantities of the active ingredients can be placed on the rear label if displayed in a text size of 3.0 millimetres, as this complies with section 9(7)(b). However, storage condition B information cannot be placed under the same heading as the names of excipients, as section 8(2)(e) requires storage condition information to be placed under the 'Other information' heading or another appropriate heading, separate from the names of excipients.\", \"Answer Explanation\": \"Section 9(7)(b) allows the names and quantities of active ingredients to be placed on a side panel, side label, rear panel, or rear label if the text size is at least 2.5 millimetres. Since the given text size is 3.0 millimetres, placing the information on the rear label complies with the regulation. However, section 8(2)(e) requires storage condition information to be placed under the 'Other information' heading or another appropriate heading, separate from other information such as the names of excipients. Therefore, placing storage condition B information under the same heading as the names of excipients would not comply with the regulation.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "rear label",
                    "information",
                    "storage condition B information"
                ]
            ]
        }
    },
    {
        "path": [
            601150000,
            801030000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine label only includes the quantity of active ingredients, but is missing all other critical health information, would this label meet the requirements specified in the given regulation sections?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 6, 'critical health information' includes the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), which is critical for safe use of self-selected medicines. Section 8(1)(c) states that the quantity of active ingredients must be included on the label. However, if the label is missing the other pieces of critical health information required by 8(1)(b), (j), (k), (l) and (n), it would not meet the requirements specified in the given regulation sections for safe use of the medicine."
                },
                {
                    "Question": "Assuming a non-prescription medicine label includes all critical health information except the quantity of active ingredients, would this label meet the requirements for safe use as specified in the given regulation sections?",
                    "Answer": "No",
                    "Answer Explanation": "Section 6 defines 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), which is critical for safe use of self-selected medicines. Section 8(1)(c) specifically states that the quantity of active ingredients must be included on the label. If this information is missing, even if all other pieces of critical health information are present, the label would not meet the requirements for safe use as specified in the given regulation sections."
                },
                {
                    "Question": "Assuming a non-prescription medicine label includes the quantity of active ingredients as well as all other critical health information specified in section 8(1), would this label meet the interpretation of 'critical health information' for safe use defined in section 6?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 6 defines 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) that is critical for safe use of self-selected medicines. Section 8(1)(c) states that the quantity of active ingredients must be included on the label. Therefore, if a label includes the quantity of active ingredients per 8(1)(c), as well as all the other pieces of critical health information required by 8(1)(b), (j), (k), (l) and (n), it would meet the interpretation of 'critical health information' for safe use as defined in section 6."
                },
                {
                    "Question": "Assuming the label of a non-prescription medicine includes all required information specified in section 8(1) except paragraphs (b), (j), (k), (l) and (n), would this label be considered to have 'critical health information' for safe use as per the interpretation in section 6?",
                    "Answer": "No",
                    "Answer Explanation": "Section 6 interprets 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) that is critical for safe use of self-selected medicines. While section 8(1)(c) regarding the quantity of active ingredients may be included, if the label is missing the information required by paragraphs 8(1)(b), (j), (k), (l) and (n), it would not be considered to have the 'critical health information' necessary for safe use as per the interpretation provided in section 6."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine label only includes the quantity of active ingredients, but is missing all other critical health information, would this label meet the requirements specified in the given regulation sections?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"According to section 6, 'critical health information' includes the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), which is critical for safe use of self-selected medicines. Section 8(1)(c) states that the quantity of active ingredients must be included on the label. However, if the label is missing the other pieces of critical health information required by 8(1)(b), (j), (k), (l) and (n), it would not meet the requirements specified in the given regulation sections for safe use of the medicine.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine label includes all critical health information except the quantity of active ingredients, would this label meet the requirements for safe use as specified in the given regulation sections?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"Section 6 defines 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), which is critical for safe use of self-selected medicines. Section 8(1)(c) specifically states that the quantity of active ingredients must be included on the label. If this information is missing, even if all other pieces of critical health information are present, the label would not meet the requirements for safe use as specified in the given regulation sections.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine label includes the quantity of active ingredients as well as all other critical health information specified in section 8(1), would this label meet the interpretation of 'critical health information' for safe use defined in section 6?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 6 defines 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) that is critical for safe use of self-selected medicines. Section 8(1)(c) states that the quantity of active ingredients must be included on the label. Therefore, if a label includes the quantity of active ingredients per 8(1)(c), as well as all the other pieces of critical health information required by 8(1)(b), (j), (k), (l) and (n), it would meet the interpretation of 'critical health information' for safe use as defined in section 6.\"\n    },\n    {\n      \"Question\": \"Assuming the label of a non-prescription medicine includes all required information specified in section 8(1) except paragraphs (b), (j), (k), (l) and (n), would this label be considered to have 'critical health information' for safe use as per the interpretation in section 6?\",\n      \"Answer\": \"No\",\n      \"Answer Explanation\": \"Section 6 interprets 'critical health information' as the information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) that is critical for safe use of self-selected medicines. While section 8(1)(c) regarding the quantity of active ingredients may be included, if the label is missing the information required by paragraphs 8(1)(b), (j), (k), (l) and (n), it would not be considered to have the 'critical health information' necessary for safe use as per the interpretation provided in section 6.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "label",
                    "medicine",
                    "safe use"
                ]
            ]
        }
    },
    {
        "path": [
            1102070000,
            1102060000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a pressurised metered dose inhaler contains an active ingredient and the dose was clinically established as the metered dose when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?",
                    "Answer": "The quantity of the active ingredient should be expressed as the quantity metered per actuation.",
                    "Answer Explanation": "According to section 11(2)(f)(ii), for pressurised metered dose inhalers where the Secretary accepted that the dose was clinically established as the metered dose when registering the medicine, the quantity of the active ingredient should be expressed as the quantity metered per actuation."
                },
                {
                    "Question": "Assuming a topical cream contains an active ingredient, how should the quantity or proportion of the active ingredient be expressed on the label?",
                    "Answer": "The quantity or proportion of the active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine.",
                    "Answer Explanation": "According to section 11(2)(g), for preparations applied to the skin and mucous membranes other than pressurised metered dose inhalers, the quantity or proportion of an active ingredient must be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine."
                },
                {
                    "Question": "Assuming a nasal spray contains an active ingredient and is a metered dose product, how should the quantity of the active ingredient be expressed on the label?",
                    "Answer": "The quantity of the active ingredient should be expressed as the quantity delivered per actuation.",
                    "Answer Explanation": "According to section 11(2)(f)(i), for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient should be expressed as the quantity delivered per actuation."
                },
                {
                    "Question": "Assuming an ointment contains an active ingredient and is not a pressurised metered dose inhaler, how should the quantity or proportion of the active ingredient be expressed on the label in terms of w\/w?",
                    "Answer": "The quantity or proportion of the active ingredient should be expressed as a percentage in terms of w\/w.",
                    "Answer Explanation": "According to section 11(2)(g), for preparations applied to the skin and mucous membranes other than pressurised metered dose inhalers, the quantity or proportion of an active ingredient must be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate. Since the question specifies w\/w, the answer is that it should be expressed as a percentage in terms of w\/w."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a pressurised metered dose inhaler contains an active ingredient and the dose was clinically established as the metered dose when the medicine was registered, how should the quantity of the active ingredient be expressed on the label?\", \"Answer\": \"The quantity of the active ingredient should be expressed as the quantity metered per actuation.\", \"Answer Explanation\": \"According to section 11(2)(f)(ii), for pressurised metered dose inhalers where the Secretary accepted that the dose was clinically established as the metered dose when registering the medicine, the quantity of the active ingredient should be expressed as the quantity metered per actuation.\"}, {\"Question\": \"Assuming a topical cream contains an active ingredient, how should the quantity or proportion of the active ingredient be expressed on the label?\", \"Answer\": \"The quantity or proportion of the active ingredient should be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine.\", \"Answer Explanation\": \"According to section 11(2)(g), for preparations applied to the skin and mucous membranes other than pressurised metered dose inhalers, the quantity or proportion of an active ingredient must be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine.\"}, {\"Question\": \"Assuming a nasal spray contains an active ingredient and is a metered dose product, how should the quantity of the active ingredient be expressed on the label?\", \"Answer\": \"The quantity of the active ingredient should be expressed as the quantity delivered per actuation.\", \"Answer Explanation\": \"According to section 11(2)(f)(i), for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient should be expressed as the quantity delivered per actuation.\"}, {\"Question\": \"Assuming an ointment contains an active ingredient and is not a pressurised metered dose inhaler, how should the quantity or proportion of the active ingredient be expressed on the label in terms of w\/w?\", \"Answer\": \"The quantity or proportion of the active ingredient should be expressed as a percentage in terms of w\/w.\", \"Answer Explanation\": \"According to section 11(2)(g), for preparations applied to the skin and mucous membranes other than pressurised metered dose inhalers, the quantity or proportion of an active ingredient must be expressed as a percentage in terms of w\/w, w\/v, v\/v or v\/w, as appropriate. Since the question specifies w\/w, the answer is that it should be expressed as a percentage in terms of w\/w.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "pressurised metered dose inhaler",
                    "expression",
                    "w  w"
                ]
            ]
        }
    },
    {
        "path": [
            805000000,
            801000000
        ],
        "contexts": [
            " 8 Information to be included on the label (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (k) relevant warning statements, where these are required in relation to a particular medicine or in specified circumstances applying to a particular medicine, such as the following: (i) where the medicine is for external use the required statement is \u2018Caution: Not to be Swallowed\u2019 or \u2018For External Use Only\u2019 or words to this effect; (ii) where: (A) the medicine is for oral use; and (B) the medicine contains active ingredient(s) included in category 'B' (including 'B1', 'B2', 'B3') or category 'C' in the document titled \u2018Prescribing medicines in pregnancy database\u2019 published on the TGA website as on the date of commencement of this Order; and (C) the medicine is not subject to other specific warning statement(s) relating to use during pregnancy, the required statement is: \u2018If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use\u2019 or words to this effect; and (iii) where: (A) the medicine is a registered goods for oral use; and (B) the medicine contains active ingredient(s) included in category \u2018D\u2019 (except nicotine for smoking cessation) in the document titled \u2018Prescribing medicines in pregnancy database\u2019 published on the TGA website as at the date of commencement of this Order; and (C) the medicine is not subject to other specific warning statements(s) relating to use during pregnancy, the required statement is \u2018Do not use this medicine if pregnant or likely to become pregnant\u2019 or words to this effect; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains an active ingredient in category B of the 'Prescribing medicines in pregnancy database', is for oral use, and has no other specific pregnancy warning, what warning statement is required on the label if the medicine is in a container that cannot be removed from its delivery device?",
                    "Answer": "The required warning statement is: 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or words to this effect.",
                    "Answer Explanation": "Section 8(1)(k)(ii) states that for an oral medicine containing a category B ingredient with no other specific pregnancy warnings, the required label statement is 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or similar wording. Section 8(5) specifies that if the container cannot be removed from the delivery device, the required label information must be on the delivery device. Together, these sections indicate the pregnancy warning must appear on the delivery device in this scenario."
                },
                {
                    "Question": "For a registered oral medicine containing a category D ingredient (except nicotine for smoking cessation) and no other specific pregnancy warnings, assuming the container can be removed from the delivery device, what pregnancy warning is required and where must it appear?",
                    "Answer": "The required warning statement 'Do not use this medicine if pregnant or likely to become pregnant' or similar wording must appear on the label of the container.",
                    "Answer Explanation": "Section 8(1)(k)(iii) mandates the warning 'Do not use this medicine if pregnant or likely to become pregnant' or similar for a registered oral medicine with a category D ingredient (excluding nicotine for smoking cessation) and no other specific pregnancy warnings. Since section 8(5) about delivery devices preventing container removal does not apply, the default rule in 8(1) locating the required information on the container label governs in this case."
                },
                {
                    "Question": "Assuming an external use medicine is in a container that cannot be removed from the delivery device, what warning statement is required and where must the information appear?",
                    "Answer": "The required warning statement 'Caution: Not to be Swallowed' or 'For External Use Only' or similar wording must appear on the delivery device, not the container.",
                    "Answer Explanation": "Section 8(1)(k)(i) requires the warning 'Caution: Not to be Swallowed', 'For External Use Only', or similar for external use medicines. Section 8(5) states that when the container cannot be removed from the delivery device, the required label information in 8(1) must go on the delivery device rather than the container. Combining these provisions, the external use warning must be on the delivery device in this scenario."
                },
                {
                    "Question": "Suppose an oral medicine contains both a category B and a category D ingredient from the 'Prescribing medicines in pregnancy database', with no other specific pregnancy warnings. Assuming the container is removable from the delivery device, what pregnancy warning statement is required on the label?",
                    "Answer": "The required warning statement is 'Do not use this medicine if pregnant or likely to become pregnant' or words to this effect.",
                    "Answer Explanation": "While section 8(1)(k)(ii) requires a certain pregnancy warning for category B ingredients, section 8(1)(k)(iii) mandates a stronger warning for category D ingredients in oral medicines. When a medicine contains both, the category D warning takes precedence as the stricter requirement. Since 8(5) does not apply when the container is removable, this warning goes on the container label per the default rule in 8(1)."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine contains an active ingredient in category B of the 'Prescribing medicines in pregnancy database', is for oral use, and has no other specific pregnancy warning, what warning statement is required on the label if the medicine is in a container that cannot be removed from its delivery device?\",\n      \"Answer\": \"The required warning statement is: 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or words to this effect.\",\n      \"Answer Explanation\": \"Section 8(1)(k)(ii) states that for an oral medicine containing a category B ingredient with no other specific pregnancy warnings, the required label statement is 'If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use' or similar wording. Section 8(5) specifies that if the container cannot be removed from the delivery device, the required label information must be on the delivery device. Together, these sections indicate the pregnancy warning must appear on the delivery device in this scenario.\"\n    },\n    {\n      \"Question\": \"For a registered oral medicine containing a category D ingredient (except nicotine for smoking cessation) and no other specific pregnancy warnings, assuming the container can be removed from the delivery device, what pregnancy warning is required and where must it appear?\",\n      \"Answer\": \"The required warning statement 'Do not use this medicine if pregnant or likely to become pregnant' or similar wording must appear on the label of the container.\",\n      \"Answer Explanation\": \"Section 8(1)(k)(iii) mandates the warning 'Do not use this medicine if pregnant or likely to become pregnant' or similar for a registered oral medicine with a category D ingredient (excluding nicotine for smoking cessation) and no other specific pregnancy warnings. Since section 8(5) about delivery devices preventing container removal does not apply, the default rule in 8(1) locating the required information on the container label governs in this case.\"\n    },\n    {\n      \"Question\": \"Assuming an external use medicine is in a container that cannot be removed from the delivery device, what warning statement is required and where must the information appear?\",\n      \"Answer\": \"The required warning statement 'Caution: Not to be Swallowed' or 'For External Use Only' or similar wording must appear on the delivery device, not the container.\",\n      \"Answer Explanation\": \"Section 8(1)(k)(i) requires the warning 'Caution: Not to be Swallowed', 'For External Use Only', or similar for external use medicines. Section 8(5) states that when the container cannot be removed from the delivery device, the required label information in 8(1) must go on the delivery device rather than the container. Combining these provisions, the external use warning must be on the delivery device in this scenario.\"\n    },\n    {\n      \"Question\": \"Suppose an oral medicine contains both a category B and a category D ingredient from the 'Prescribing medicines in pregnancy database', with no other specific pregnancy warnings. Assuming the container is removable from the delivery device, what pregnancy warning statement is required on the label?\",\n      \"Answer\": \"The required warning statement is 'Do not use this medicine if pregnant or likely to become pregnant' or words to this effect.\",\n      \"Answer Explanation\": \"While section 8(1)(k)(ii) requires a certain pregnancy warning for category B ingredients, section 8(1)(k)(iii) mandates a stronger warning for category D ingredients in oral medicines. When a medicine contains both, the category D warning takes precedence as the stricter requirement. Since 8(5) does not apply when the container is removable, this warning goes on the container label per the default rule in 8(1).\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "container",
                    "information",
                    "pregnancy"
                ]
            ]
        }
    },
    {
        "path": [
            1008030000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (8) Individually wrapped medicines (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (a) where the medicine is supplied in a small container; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming an individually wrapped herbal medicine consists of dry herbs in a bag that is retained during preparation, and the bags are in a primary pack with a compliant label, does each individual bag need to be labelled with the information in sections 8 and 9?",
                    "Answer": "No, the individual bag does not need to be labelled with the information in sections 8 and 9.",
                    "Answer Explanation": "Section 10(8)(c) states that if a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a compliant label, then the individual bags do not need to be labelled with the information referred to in sections 8 and 9."
                },
                {
                    "Question": "Assuming a medicine is supplied in a small container, does the exemption in subsection 9(10)(a) apply to the labelling requirements in subsection 9(9)?",
                    "Answer": "Yes, the exemption in subsection 9(10)(a) applies to the labelling requirements in subsection 9(9) for medicines supplied in small containers.",
                    "Answer Explanation": "Subsection 9(10)(a) explicitly states that subsection 9(9) does not apply where the medicine is supplied in a small container."
                },
                {
                    "Question": "Assuming an individually wrapped herbal medicine consists of dry herbs in bags retained during preparation, the bags are in a primary pack with a compliant label, and the primary pack is a small container, do the individual bags need to include the information from section 9(9)?",
                    "Answer": "No, the individual bags do not need to include the information from section 9(9).",
                    "Answer Explanation": "Section 10(8)(c) exempts the individual bags from the labelling requirements in sections 8 and 9 if they are in a compliant primary pack. Additionally, section 9(10)(a) exempts medicines in small containers from the requirements of section 9(9). Therefore, the individual bags are exempt from section 9(9) based on both the primary pack exemption and the small container exemption."
                },
                {
                    "Question": "Assuming a medicine consists of dry herbs in individual bags that are not retained during preparation, and the bags are supplied in a small container serving as the primary pack, do the individual bags need to be labelled with the information in sections 8 and 9?",
                    "Answer": "Yes, the individual bags need to be labelled with the information in sections 8 and 9.",
                    "Answer Explanation": "Section 10(8)(c) only exempts individual bags from the labelling requirements in sections 8 and 9 if the bags are retained during preparation and are in a primary pack with a compliant label. In this case, the bags are not retained during preparation, so the exemption does not apply. Section 9(10)(a) exempts small containers from the requirements of section 9(9), but not from the rest of sections 8 and 9. Therefore, the individual bags must be labelled with the applicable information from sections 8 and 9."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming an individually wrapped herbal medicine consists of dry herbs in a bag that is retained during preparation, and the bags are in a primary pack with a compliant label, does each individual bag need to be labelled with the information in sections 8 and 9?\", \"Answer\": \"No, the individual bag does not need to be labelled with the information in sections 8 and 9.\", \"Answer Explanation\": \"Section 10(8)(c) states that if a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a compliant label, then the individual bags do not need to be labelled with the information referred to in sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine is supplied in a small container, does the exemption in subsection 9(10)(a) apply to the labelling requirements in subsection 9(9)?\", \"Answer\": \"Yes, the exemption in subsection 9(10)(a) applies to the labelling requirements in subsection 9(9) for medicines supplied in small containers.\", \"Answer Explanation\": \"Subsection 9(10)(a) explicitly states that subsection 9(9) does not apply where the medicine is supplied in a small container.\"}, {\"Question\": \"Assuming an individually wrapped herbal medicine consists of dry herbs in bags retained during preparation, the bags are in a primary pack with a compliant label, and the primary pack is a small container, do the individual bags need to include the information from section 9(9)?\", \"Answer\": \"No, the individual bags do not need to include the information from section 9(9).\", \"Answer Explanation\": \"Section 10(8)(c) exempts the individual bags from the labelling requirements in sections 8 and 9 if they are in a compliant primary pack. Additionally, section 9(10)(a) exempts medicines in small containers from the requirements of section 9(9). Therefore, the individual bags are exempt from section 9(9) based on both the primary pack exemption and the small container exemption.\"}, {\"Question\": \"Assuming a medicine consists of dry herbs in individual bags that are not retained during preparation, and the bags are supplied in a small container serving as the primary pack, do the individual bags need to be labelled with the information in sections 8 and 9?\", \"Answer\": \"Yes, the individual bags need to be labelled with the information in sections 8 and 9.\", \"Answer Explanation\": \"Section 10(8)(c) only exempts individual bags from the labelling requirements in sections 8 and 9 if the bags are retained during preparation and are in a primary pack with a compliant label. In this case, the bags are not retained during preparation, so the exemption does not apply. Section 9(10)(a) exempts small containers from the requirements of section 9(9), but not from the rest of sections 8 and 9. Therefore, the individual bags must be labelled with the applicable information from sections 8 and 9.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "individual bag",
                    "medicine",
                    "small container"
                ]
            ]
        }
    },
    {
        "path": [
            905030000,
            901030000
        ],
        "contexts": [
            " 9 Information to be included on the main label (5) If the medicine contains: (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
            " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine is registered goods and contains one active ingredient, what is the minimum text size requirement for displaying the name and quantity or proportion of the active ingredient on the main label if subsection 8(2) does not apply?",
                    "Answer": "2.5 millimetres",
                    "Answer Explanation": "Section 9(5)(c)(i) states that if the medicine is registered goods, contains active ingredients, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres. Section 9(1)(c) also generally requires the quantity or proportion of all active ingredients to be included on the main label, subject to the specific requirements in section 9."
                },
                {
                    "Question": "Assuming a non-prescription medicine is registered goods and subsection 8(2) applies, is it required to include the quantity or proportion of all active ingredients on the main label as per section 9(1)(c)?",
                    "Answer": "No",
                    "Answer Explanation": "Section 9(5)(c)(ii) provides that if the medicine is registered goods and subsection 8(2) applies, then compliance with section 9(1)(c), which requires the quantity or proportion of all active ingredients to be included on the main label, is not required. This is an exception to the general requirement in 9(1)(c)."
                },
                {
                    "Question": "Assuming a non-prescription medicine is not registered goods, what information about the active ingredients is required on the main label as per the provided sections?",
                    "Answer": "The quantity or proportion of all active ingredients must be included on the main label.",
                    "Answer Explanation": "Section 9(1)(c) states that subject to the qualifications and special requirements specified in section 9, the information on the main label of the medicine must include the quantity or proportion of all active ingredients. For medicines that are not registered goods, the exception in 9(5)(c) for registered goods does not apply, so the general requirement in 9(1)(c) stands."
                },
                {
                    "Question": "Do the provided sections specify any qualifications or exceptions to the general requirement in section 9(1) to include certain information like active ingredient quantities on the main label of non-prescription medicines?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 9(1) states that the requirements to include information like the quantity or proportion of active ingredients in 9(1)(c) are 'Subject to the qualifications and special requirements specified in this section and section 10 of this Order'. Section 9(5)(c)(ii) then provides a qualification that compliance with 9(1)(c) is not required if the medicine is registered goods and subsection 8(2) applies. So there are specified qualifications and exceptions to the requirements in 9(1)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine is registered goods and contains one active ingredient, what is the minimum text size requirement for displaying the name and quantity or proportion of the active ingredient on the main label if subsection 8(2) does not apply?\", \"Answer\": \"2.5 millimetres\", \"Answer Explanation\": \"Section 9(5)(c)(i) states that if the medicine is registered goods, contains active ingredients, and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres. Section 9(1)(c) also generally requires the quantity or proportion of all active ingredients to be included on the main label, subject to the specific requirements in section 9.\"}, {\"Question\": \"Assuming a non-prescription medicine is registered goods and subsection 8(2) applies, is it required to include the quantity or proportion of all active ingredients on the main label as per section 9(1)(c)?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 9(5)(c)(ii) provides that if the medicine is registered goods and subsection 8(2) applies, then compliance with section 9(1)(c), which requires the quantity or proportion of all active ingredients to be included on the main label, is not required. This is an exception to the general requirement in 9(1)(c).\"}, {\"Question\": \"Assuming a non-prescription medicine is not registered goods, what information about the active ingredients is required on the main label as per the provided sections?\", \"Answer\": \"The quantity or proportion of all active ingredients must be included on the main label.\", \"Answer Explanation\": \"Section 9(1)(c) states that subject to the qualifications and special requirements specified in section 9, the information on the main label of the medicine must include the quantity or proportion of all active ingredients. For medicines that are not registered goods, the exception in 9(5)(c) for registered goods does not apply, so the general requirement in 9(1)(c) stands.\"}, {\"Question\": \"Do the provided sections specify any qualifications or exceptions to the general requirement in section 9(1) to include certain information like active ingredient quantities on the main label of non-prescription medicines?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 9(1) states that the requirements to include information like the quantity or proportion of active ingredients in 9(1)(c) are 'Subject to the qualifications and special requirements specified in this section and section 10 of this Order'. Section 9(5)(c)(ii) then provides a qualification that compliance with 9(1)(c) is not required if the medicine is registered goods and subsection 8(2) applies. So there are specified qualifications and exceptions to the requirements in 9(1).\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "qualification",
                    "medicine",
                    "active ingredient"
                ]
            ]
        }
    },
    {
        "path": [
            1009010000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine consists of individually enclosed suppositories in a blister pack, which is enclosed in a labeled primary pack, what information must be displayed on the label of the blister pack if the active ingredient name is listed in Schedule 2?",
                    "Answer": "The blister pack label must display the medicine name, names and quantities\/proportions of all active ingredients, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark.",
                    "Answer Explanation": "According to section 10(9)(a), if a medicine has individual dosage units like suppositories in a blister pack enclosed in a labeled primary pack, the blister pack label needs the medicine name (iv), active ingredient names (v) and quantities (vi), batch number with prefix (vii), expiry date with prefix (viii), and sponsor\/distributor name or trademark (ix). Section 9(9) further specifies that Schedule 2 active ingredients must have their names and quantities in at least 2.5mm text size on the main label."
                },
                {
                    "Question": "Assuming a medicine consists of suppositories individually enclosed in a strip pack, which is enclosed in a primary pack lacking a compliant label, what information must the strip pack label display if an active ingredient is listed in Schedule 2?",
                    "Answer": "If the primary pack label does not comply with sections 8 and 9, the strip pack label alone is insufficient and must fully comply with those sections, including having Schedule 2 active ingredients in at least 2.5mm text size.",
                    "Answer Explanation": "Section 10(9)(a) allows a reduced label on strip packs only if the primary pack has a label complying with sections 8 and 9. Without a compliant primary label, section 10(9)(a)(iii) is not met, so the strip label must fully comply itself. Section 9(9) requires Schedule 2 active ingredients to be listed with quantities in minimum 2.5mm text on the main label per sections 8 and 9."
                },
                {
                    "Question": "Assuming a single-dose powder medicine is in a sachet enclosed in a primary pack with a label lacking some required information, what must the sachet label display if it contains a Schedule 2 ingredient?",
                    "Answer": "The sachet is considered the primary pack and its label must fully comply with sections 8 and 9, including listing the Schedule 2 active ingredient and its quantity in minimum 2.5mm text size.",
                    "Answer Explanation": "Section 10(9)(a) specifies a reduced label is allowed for individually enclosed dosage units only if they are in a strip, blister or dial dispenser pack further enclosed in a labeled primary pack. A single-dose powder sachet does not meet these conditions, so it is considered the primary pack itself. Its label must therefore comply with sections 8 and 9, and section 9(9) mandates that Schedule 2 ingredients be listed by name and quantity in at least 2.5mm text."
                },
                {
                    "Question": "Assuming capsules are individually enclosed in unmarked blisters which are in a primary pack having a fully compliant label, what information linking the medicine to its active ingredients must be on the blister pack?",
                    "Answer": "No information linking the medicine to its active ingredients is required on the blister pack. Only the medicine name must be displayed, not the active ingredient names or quantities.",
                    "Answer Explanation": "Section 10(9)(a) allows a reduced label on a blister pack if the dosage units can only be extracted individually and the blister is in a primary pack with a label complying with sections 8 and 9. In this case, the blister pack label needs only the information in 10(9)(a)(iv)-(ix). This includes the medicine name (iv) but not the active ingredient names (v) or quantities (vi). Those can be omitted from the blister label since the primary pack has a compliant label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine consists of individually enclosed suppositories in a blister pack, which is enclosed in a labeled primary pack, what information must be displayed on the label of the blister pack if the active ingredient name is listed in Schedule 2?\", \"Answer\": \"The blister pack label must display the medicine name, names and quantities\/proportions of all active ingredients, batch number with prefix, expiry date with prefix, and sponsor\/distributor name or identifying trademark.\", \"Answer Explanation\": \"According to section 10(9)(a), if a medicine has individual dosage units like suppositories in a blister pack enclosed in a labeled primary pack, the blister pack label needs the medicine name (iv), active ingredient names (v) and quantities (vi), batch number with prefix (vii), expiry date with prefix (viii), and sponsor\/distributor name or trademark (ix). Section 9(9) further specifies that Schedule 2 active ingredients must have their names and quantities in at least 2.5mm text size on the main label.\"}, {\"Question\": \"Assuming a medicine consists of suppositories individually enclosed in a strip pack, which is enclosed in a primary pack lacking a compliant label, what information must the strip pack label display if an active ingredient is listed in Schedule 2?\", \"Answer\": \"If the primary pack label does not comply with sections 8 and 9, the strip pack label alone is insufficient and must fully comply with those sections, including having Schedule 2 active ingredients in at least 2.5mm text size.\", \"Answer Explanation\": \"Section 10(9)(a) allows a reduced label on strip packs only if the primary pack has a label complying with sections 8 and 9. Without a compliant primary label, section 10(9)(a)(iii) is not met, so the strip label must fully comply itself. Section 9(9) requires Schedule 2 active ingredients to be listed with quantities in minimum 2.5mm text on the main label per sections 8 and 9.\"}, {\"Question\": \"Assuming a single-dose powder medicine is in a sachet enclosed in a primary pack with a label lacking some required information, what must the sachet label display if it contains a Schedule 2 ingredient?\", \"Answer\": \"The sachet is considered the primary pack and its label must fully comply with sections 8 and 9, including listing the Schedule 2 active ingredient and its quantity in minimum 2.5mm text size.\", \"Answer Explanation\": \"Section 10(9)(a) specifies a reduced label is allowed for individually enclosed dosage units only if they are in a strip, blister or dial dispenser pack further enclosed in a labeled primary pack. A single-dose powder sachet does not meet these conditions, so it is considered the primary pack itself. Its label must therefore comply with sections 8 and 9, and section 9(9) mandates that Schedule 2 ingredients be listed by name and quantity in at least 2.5mm text.\"}, {\"Question\": \"Assuming capsules are individually enclosed in unmarked blisters which are in a primary pack having a fully compliant label, what information linking the medicine to its active ingredients must be on the blister pack?\", \"Answer\": \"No information linking the medicine to its active ingredients is required on the blister pack. Only the medicine name must be displayed, not the active ingredient names or quantities.\", \"Answer Explanation\": \"Section 10(9)(a) allows a reduced label on a blister pack if the dosage units can only be extracted individually and the blister is in a primary pack with a label complying with sections 8 and 9. In this case, the blister pack label needs only the information in 10(9)(a)(iv)-(ix). This includes the medicine name (iv) but not the active ingredient names (v) or quantities (vi). Those can be omitted from the blister label since the primary pack has a compliant label.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "information",
                    "medicine",
                    "suppository"
                ]
            ]
        }
    },
    {
        "path": [
            1001000000,
            1007000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include: (c) if the medicine is for multidose use - a statement to the effect that \u2018the medicine should not be used more than four weeks\u2019, or such shorter period as specified in the approved product details in relation to the medicine, after the container is first opened;",
            " 10 Qualifications and special requirements (7) Small containers If: (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a preparation for ophthalmic use and comes in a multidose container, what information must be included on the label of the container regarding the time period the medicine can be used after first opening the container?",
                    "Answer": "The label must include a statement that the medicine should not be used more than four weeks after the container is first opened, or a shorter period if specified in the approved product details for the medicine.",
                    "Answer Explanation": "Section 10(1)(c) states that if a medicine is a preparation for ophthalmic use and is for multidose use, the label on the container must include 'a statement to the effect that 'the medicine should not be used more than four weeks', or such shorter period as specified in the approved product details in relation to the medicine, after the container is first opened'."
                },
                {
                    "Question": "Assuming a medicine comes in a small container and has four or more active ingredients, what information must be displayed on the container in a text size of not less than 1.5 millimetres?",
                    "Answer": "The following information must be displayed in a text size of not less than 1.5 millimetres on the small container.",
                    "Answer Explanation": "Section 10(7)(d) states that if the container is small, the name(s) of all active ingredients do not need to be included on the container 'unless there are four or more active ingredients'. The last part of section 10(7) specifies that 'the following information' must be displayed in a text size of not less than 1.5 millimetres, referring to the required information listed in sections 8 and 9."
                },
                {
                    "Question": "Assuming a medicine is a preparation for ophthalmic use and comes in a small multidose container, what information must be included on the label of the container regarding the time period the medicine can be used after first opening?",
                    "Answer": "The label on the small multidose container of the ophthalmic preparation must include a statement that the medicine should not be used more than four weeks after first opening, or a shorter period if specified in the approved product details. This information must be displayed in a text size of not less than 1.5 millimetres.",
                    "Answer Explanation": "Combining the requirements from sections 10(1)(c) and 10(7): 10(1)(c) mandates including a statement about the time period of use after opening for ophthalmic multidose medicines. 10(7) allows some information to be omitted on small containers but specifies the mandatory inclusion of 'the following information' in a minimum text size, which refers to the information required by 10(1)(c)."
                },
                {
                    "Question": "Assuming a medicine comes in a small multidose container for ophthalmic use and has five active ingredients, which specific pieces of information are not required to be on the label of the container?",
                    "Answer": "The names of the active ingredients are not required to be on the label of the small container, since there are more than four active ingredients. However, the time period the medicine can be used after first opening the multidose container must still be included on the label in a text size of not less than 1.5 millimetres, as this is mandatory for ophthalmic preparations.",
                    "Answer Explanation": "Section 10(7)(d) allows the names of active ingredients to be omitted from the label of a small container if there are four or more active ingredients. However, section 10(1)(c) still requires the inclusion of the statement about the time period of use after opening for ophthalmic multidose medicines, and section 10(7) mandates this 'following information' must be in a minimum 1.5 millimetre text size on small containers."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a preparation for ophthalmic use and comes in a multidose container, what information must be included on the label of the container regarding the time period the medicine can be used after first opening the container?\", \"Answer\": \"The label must include a statement that the medicine should not be used more than four weeks after the container is first opened, or a shorter period if specified in the approved product details for the medicine.\", \"Answer Explanation\": \"Section 10(1)(c) states that if a medicine is a preparation for ophthalmic use and is for multidose use, the label on the container must include 'a statement to the effect that 'the medicine should not be used more than four weeks', or such shorter period as specified in the approved product details in relation to the medicine, after the container is first opened'.\"}, {\"Question\": \"Assuming a medicine comes in a small container and has four or more active ingredients, what information must be displayed on the container in a text size of not less than 1.5 millimetres?\", \"Answer\": \"The following information must be displayed in a text size of not less than 1.5 millimetres on the small container.\", \"Answer Explanation\": \"Section 10(7)(d) states that if the container is small, the name(s) of all active ingredients do not need to be included on the container 'unless there are four or more active ingredients'. The last part of section 10(7) specifies that 'the following information' must be displayed in a text size of not less than 1.5 millimetres, referring to the required information listed in sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine is a preparation for ophthalmic use and comes in a small multidose container, what information must be included on the label of the container regarding the time period the medicine can be used after first opening?\", \"Answer\": \"The label on the small multidose container of the ophthalmic preparation must include a statement that the medicine should not be used more than four weeks after first opening, or a shorter period if specified in the approved product details. This information must be displayed in a text size of not less than 1.5 millimetres.\", \"Answer Explanation\": \"Combining the requirements from sections 10(1)(c) and 10(7): 10(1)(c) mandates including a statement about the time period of use after opening for ophthalmic multidose medicines. 10(7) allows some information to be omitted on small containers but specifies the mandatory inclusion of 'the following information' in a minimum text size, which refers to the information required by 10(1)(c).\"}, {\"Question\": \"Assuming a medicine comes in a small multidose container for ophthalmic use and has five active ingredients, which specific pieces of information are not required to be on the label of the container?\", \"Answer\": \"The names of the active ingredients are not required to be on the label of the small container, since there are more than four active ingredients. However, the time period the medicine can be used after first opening the multidose container must still be included on the label in a text size of not less than 1.5 millimetres, as this is mandatory for ophthalmic preparations.\", \"Answer Explanation\": \"Section 10(7)(d) allows the names of active ingredients to be omitted from the label of a small container if there are four or more active ingredients. However, section 10(1)(c) still requires the inclusion of the statement about the time period of use after opening for ophthalmic multidose medicines, and section 10(7) mandates this 'following information' must be in a minimum 1.5 millimetre text size on small containers.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "container",
                    "medicine",
                    "following information"
                ]
            ]
        }
    },
    {
        "path": [
            905030000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (5) If the medicine contains: (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
            " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is registered goods and subsection 8(2) applies, what information must be displayed on the label regarding the names and quantities or proportions of the active ingredients?",
                    "Answer": "If a medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) regarding displaying the names and quantities or proportions of active ingredients is not required.",
                    "Answer Explanation": "Section 9(5)(c)(ii) states that if the medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraphs 9(1)(b) and 9(1)(c) relate to displaying the names and quantities or proportions of active ingredients on the label."
                },
                {
                    "Question": "Assuming a medicine is intended to be registered goods and subsection 8(2) does not apply, what is the minimum text size required for displaying the names and quantities or proportions of the active ingredients on the label?",
                    "Answer": "If a medicine is intended to be registered goods and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.",
                    "Answer Explanation": "Section 9(5)(c)(i) specifies that if the medicine is intended to be registered goods and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres."
                },
                {
                    "Question": "Under subsection 8(2)(c), what additional information may be included along with the pharmacological category when describing the purpose of the active ingredients on the label?",
                    "Answer": "Under subsection 8(2)(c), the information provided may include words describing the principal intended actions of the active ingredients that are not required by this Order, in addition to the pharmacological category.",
                    "Answer Explanation": "Section 8(2)(c) allows the information provided under paragraph 8(2)(b)(i) to include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
                },
                {
                    "Question": "Assuming a medicine is registered goods and subsection 8(2) applies, what specific paragraphs in section 9 are exempted from compliance regarding the display of active ingredient information on the label?",
                    "Answer": "If a medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) regarding displaying the names and quantities or proportions of active ingredients is not required.",
                    "Answer Explanation": "Section 9(5)(c)(ii) explicitly states that if the medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. These paragraphs relate to the display of active ingredient information on the label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is registered goods and subsection 8(2) applies, what information must be displayed on the label regarding the names and quantities or proportions of the active ingredients?\", \"Answer\": \"If a medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) regarding displaying the names and quantities or proportions of active ingredients is not required.\", \"Answer Explanation\": \"Section 9(5)(c)(ii) states that if the medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraphs 9(1)(b) and 9(1)(c) relate to displaying the names and quantities or proportions of active ingredients on the label.\"}, {\"Question\": \"Assuming a medicine is intended to be registered goods and subsection 8(2) does not apply, what is the minimum text size required for displaying the names and quantities or proportions of the active ingredients on the label?\", \"Answer\": \"If a medicine is intended to be registered goods and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\", \"Answer Explanation\": \"Section 9(5)(c)(i) specifies that if the medicine is intended to be registered goods and subsection 8(2) does not apply, then the names and quantities or proportions of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres.\"}, {\"Question\": \"Under subsection 8(2)(c), what additional information may be included along with the pharmacological category when describing the purpose of the active ingredients on the label?\", \"Answer\": \"Under subsection 8(2)(c), the information provided may include words describing the principal intended actions of the active ingredients that are not required by this Order, in addition to the pharmacological category.\", \"Answer Explanation\": \"Section 8(2)(c) allows the information provided under paragraph 8(2)(b)(i) to include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.\"}, {\"Question\": \"Assuming a medicine is registered goods and subsection 8(2) applies, what specific paragraphs in section 9 are exempted from compliance regarding the display of active ingredient information on the label?\", \"Answer\": \"If a medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) regarding displaying the names and quantities or proportions of active ingredients is not required.\", \"Answer Explanation\": \"Section 9(5)(c)(ii) explicitly states that if the medicine is registered goods and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. These paragraphs relate to the display of active ingredient information on the label.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "pharmacological category",
                    "label",
                    "compliance"
                ]
            ]
        }
    },
    {
        "path": [
            907030000,
            901020000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains five active ingredients and is intended to be registered goods, and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required on the main label?",
                    "Answer": "No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required in this case.",
                    "Answer Explanation": "According to subsection 9(7)(c), if the medicine contains four or more active ingredients, is intended to be registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label, subject to the qualifications and special requirements specified in section 9 and section 10. However, the special requirement in 9(7)(c) overrides this for medicines with four or more active ingredients when the other conditions are met."
                },
                {
                    "Question": "Assuming a medicine contains three active ingredients and is registered goods, and subsection 8(2) does not apply, is compliance with paragraph 9(1)(b) required on the main label?",
                    "Answer": "Yes, compliance with paragraph 9(1)(b) is required in this case.",
                    "Answer Explanation": "Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label, subject to the qualifications and special requirements specified in section 9 and section 10. Subsection 9(7)(c) provides a special requirement that exempts medicines with four or more active ingredients from complying with 9(1)(b) if the medicine is registered goods and subsection 8(2) applies. However, in this case, the medicine only has three active ingredients and subsection 8(2) does not apply, so the special requirement in 9(7)(c) is not relevant. Therefore, the general rule in 9(1)(b) applies and compliance is required."
                },
                {
                    "Question": "Assuming a medicine is not intended to be registered goods, contains five active ingredients, and subsection 8(2) applies, is compliance with paragraph 9(1)(c) required on the main label?",
                    "Answer": "Yes, compliance with paragraph 9(1)(c) is required in this case.",
                    "Answer Explanation": "Paragraph 9(1)(c) is mentioned alongside 9(1)(b) as information that must be included on the main label, subject to qualifications and special requirements. Subsection 9(7)(c) provides a special requirement that exempts medicines from complying with 9(1)(b) and 9(1)(c) if the medicine has four or more active ingredients, is intended to be registered goods, and subsection 8(2) applies. However, in this case, while the medicine has five active ingredients and subsection 8(2) applies, it is not intended to be registered goods. Therefore, the special requirement in 9(7)(c) does not apply, and compliance with the general rule in 9(1)(c) is still required."
                },
                {
                    "Question": "Assuming a medicine contains two active ingredients, is registered goods, and subsection 8(2) applies, is compliance with paragraph 9(1)(b) required on the main label?",
                    "Answer": "Yes, compliance with paragraph 9(1)(b) is required in this case.",
                    "Answer Explanation": "Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label, subject to the qualifications and special requirements specified in section 9 and section 10. Subsection 9(7)(c) provides a special requirement that exempts medicines with four or more active ingredients from complying with 9(1)(b) if the medicine is registered goods and subsection 8(2) applies. In this case, while the medicine is registered goods and subsection 8(2) applies, it only contains two active ingredients, which is less than the four required for the 9(7)(c) exemption. Therefore, the general rule in 9(1)(b) still applies and compliance is required."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains five active ingredients and is intended to be registered goods, and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required on the main label?\",\n    \"Answer\": \"No, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required in this case.\",\n    \"Answer Explanation\": \"According to subsection 9(7)(c), if the medicine contains four or more active ingredients, is intended to be registered goods, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required. Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label, subject to the qualifications and special requirements specified in section 9 and section 10. However, the special requirement in 9(7)(c) overrides this for medicines with four or more active ingredients when the other conditions are met.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine contains three active ingredients and is registered goods, and subsection 8(2) does not apply, is compliance with paragraph 9(1)(b) required on the main label?\", \n    \"Answer\": \"Yes, compliance with paragraph 9(1)(b) is required in this case.\",\n    \"Answer Explanation\": \"Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label, subject to the qualifications and special requirements specified in section 9 and section 10. Subsection 9(7)(c) provides a special requirement that exempts medicines with four or more active ingredients from complying with 9(1)(b) if the medicine is registered goods and subsection 8(2) applies. However, in this case, the medicine only has three active ingredients and subsection 8(2) does not apply, so the special requirement in 9(7)(c) is not relevant. Therefore, the general rule in 9(1)(b) applies and compliance is required.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is not intended to be registered goods, contains five active ingredients, and subsection 8(2) applies, is compliance with paragraph 9(1)(c) required on the main label?\",\n    \"Answer\": \"Yes, compliance with paragraph 9(1)(c) is required in this case.\",\n    \"Answer Explanation\": \"Paragraph 9(1)(c) is mentioned alongside 9(1)(b) as information that must be included on the main label, subject to qualifications and special requirements. Subsection 9(7)(c) provides a special requirement that exempts medicines from complying with 9(1)(b) and 9(1)(c) if the medicine has four or more active ingredients, is intended to be registered goods, and subsection 8(2) applies. However, in this case, while the medicine has five active ingredients and subsection 8(2) applies, it is not intended to be registered goods. Therefore, the special requirement in 9(7)(c) does not apply, and compliance with the general rule in 9(1)(c) is still required.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine contains two active ingredients, is registered goods, and subsection 8(2) applies, is compliance with paragraph 9(1)(b) required on the main label?\",\n    \"Answer\": \"Yes, compliance with paragraph 9(1)(b) is required in this case.\",\n    \"Answer Explanation\": \"Paragraph 9(1)(b) states that the names of all active ingredients must be included on the main label, subject to the qualifications and special requirements specified in section 9 and section 10. Subsection 9(7)(c) provides a special requirement that exempts medicines with four or more active ingredients from complying with 9(1)(b) if the medicine is registered goods and subsection 8(2) applies. In this case, while the medicine is registered goods and subsection 8(2) applies, it only contains two active ingredients, which is less than the four required for the 9(7)(c) exemption. Therefore, the general rule in 9(1)(b) still applies and compliance is required.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "compliance",
                    "medicine",
                    "special requirement"
                ]
            ]
        }
    },
    {
        "path": [
            1007000000,
            1001000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (7) Small containers If: (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:",
            " 10 Qualifications and special requirements (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include: (e) if the medicine consists of a solid ophthalmic medicine for preparing eye drops for multidose use - the words \u2018for eye drops\u2019."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use and contains three active ingredients, what is the minimum text size required for the names of the active ingredients on the label of the primary pack if the medicine is in a small container?",
                    "Answer": "1.5 millimetres",
                    "Answer Explanation": "According to subsection 10(7)(d), if a medicine is in a small container, the names of all active ingredients must be displayed on the label unless there are four or more active ingredients. Since the medicine in question contains three active ingredients, their names must be displayed. Subsection 10(7) also states that for small containers, the required information must be displayed in a text size of not less than 1.5 millimetres. Therefore, the minimum text size required for the names of the active ingredients on the label of the primary pack is 1.5 millimetres."
                },
                {
                    "Question": "Assuming a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use and is in a small container, what information must be included on the label of the primary pack?",
                    "Answer": "The label on the primary pack must include the words 'for eye drops' and the names of all active ingredients (unless there are four or more active ingredients) in a text size of not less than 1.5 millimetres.",
                    "Answer Explanation": "According to subsection 10(1)(e), if a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use, the label on the container and on the primary pack must include the words 'for eye drops'. Additionally, subsection 10(7)(d) states that for medicines in small containers, the names of all active ingredients must be displayed on the label unless there are four or more active ingredients. Subsection 10(7) also requires that for small containers, the information must be displayed in a text size of not less than 1.5 millimetres."
                },
                {
                    "Question": "Assuming a medicine is a preparation for ophthalmic use and is not in a small container, what is the minimum text size required for the names of the active ingredients on the label of the primary pack?",
                    "Answer": "The regulation does not specify a minimum text size for the names of active ingredients on the label of the primary pack for preparations for ophthalmic use that are not in small containers.",
                    "Answer Explanation": "Section 10(1) outlines additional requirements for preparations for ophthalmic use, but it does not specify a minimum text size for the names of active ingredients on the label of the primary pack. The minimum text size requirement of 1.5 millimetres mentioned in subsection 10(7) only applies to medicines in small containers. For preparations for ophthalmic use that are not in small containers, the general requirements in sections 8 and 9 would apply, but these sections are not provided in the given context."
                },
                {
                    "Question": "Assuming a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use, contains five active ingredients, and is in a small container, what information must be included on the label of the primary pack?",
                    "Answer": "The label on the primary pack must include the words 'for eye drops'. The names of the active ingredients are not required since there are more than four active ingredients.",
                    "Answer Explanation": "According to subsection 10(1)(e), if a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use, the label on the container and on the primary pack must include the words 'for eye drops'. Subsection 10(7)(d) states that for medicines in small containers, the names of all active ingredients must be displayed on the label unless there are four or more active ingredients. Since the medicine in question contains five active ingredients, their names are not required on the label of the primary pack. However, the words 'for eye drops' must still be included as per subsection 10(1)(e)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use and contains three active ingredients, what is the minimum text size required for the names of the active ingredients on the label of the primary pack if the medicine is in a small container?\", \"Answer\": \"1.5 millimetres\", \"Answer Explanation\": \"According to subsection 10(7)(d), if a medicine is in a small container, the names of all active ingredients must be displayed on the label unless there are four or more active ingredients. Since the medicine in question contains three active ingredients, their names must be displayed. Subsection 10(7) also states that for small containers, the required information must be displayed in a text size of not less than 1.5 millimetres. Therefore, the minimum text size required for the names of the active ingredients on the label of the primary pack is 1.5 millimetres.\"}, {\"Question\": \"Assuming a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use and is in a small container, what information must be included on the label of the primary pack?\", \"Answer\": \"The label on the primary pack must include the words 'for eye drops' and the names of all active ingredients (unless there are four or more active ingredients) in a text size of not less than 1.5 millimetres.\", \"Answer Explanation\": \"According to subsection 10(1)(e), if a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use, the label on the container and on the primary pack must include the words 'for eye drops'. Additionally, subsection 10(7)(d) states that for medicines in small containers, the names of all active ingredients must be displayed on the label unless there are four or more active ingredients. Subsection 10(7) also requires that for small containers, the information must be displayed in a text size of not less than 1.5 millimetres.\"}, {\"Question\": \"Assuming a medicine is a preparation for ophthalmic use and is not in a small container, what is the minimum text size required for the names of the active ingredients on the label of the primary pack?\", \"Answer\": \"The regulation does not specify a minimum text size for the names of active ingredients on the label of the primary pack for preparations for ophthalmic use that are not in small containers.\", \"Answer Explanation\": \"Section 10(1) outlines additional requirements for preparations for ophthalmic use, but it does not specify a minimum text size for the names of active ingredients on the label of the primary pack. The minimum text size requirement of 1.5 millimetres mentioned in subsection 10(7) only applies to medicines in small containers. For preparations for ophthalmic use that are not in small containers, the general requirements in sections 8 and 9 would apply, but these sections are not provided in the given context.\"}, {\"Question\": \"Assuming a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use, contains five active ingredients, and is in a small container, what information must be included on the label of the primary pack?\", \"Answer\": \"The label on the primary pack must include the words 'for eye drops'. The names of the active ingredients are not required since there are more than four active ingredients.\", \"Answer Explanation\": \"According to subsection 10(1)(e), if a medicine is a solid ophthalmic medicine for preparing eye drops for multidose use, the label on the container and on the primary pack must include the words 'for eye drops'. Subsection 10(7)(d) states that for medicines in small containers, the names of all active ingredients must be displayed on the label unless there are four or more active ingredients. Since the medicine in question contains five active ingredients, their names are not required on the label of the primary pack. However, the words 'for eye drops' must still be included as per subsection 10(1)(e).\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "text size",
                    "medicine",
                    "primary pack"
                ]
            ]
        }
    },
    {
        "path": [
            1009010000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a pessary medicine is packaged in a strip or blister pack enclosed in a primary pack whose label complies with sections 8 and 9, what specific information must be displayed on the label of the strip or blister pack itself?",
                    "Answer": "The name of the medicine, names and quantities\/proportions of all active ingredients, batch number preceded by batch number prefix, expiry date preceded by expiry date prefix, and name of sponsor\/distributor or identifying registered trademark.",
                    "Answer Explanation": "Section 10(9)(a) states that for a medicine consisting of dosage units like pessaries in a strip\/blister pack enclosed in a primary pack with a compliant label, the strip\/blister label itself must display the medicine name [10(9)(a)(iv)], active ingredient names [10(9)(a)(v)] and quantities [10(9)(a)(vi)], batch number with prefix [10(9)(a)(vii)], expiry date with prefix [10(9)(a)(viii)], and sponsor\/distributor name or trademark [10(9)(a)(ix)]."
                },
                {
                    "Question": "Suppose a pessary medicine's primary pack label information is obscured by intermediate packaging. Assuming no other exceptions apply, what information must the intermediate packaging label include?",
                    "Answer": "The intermediate packaging label must include at minimum the names of all active ingredients in the pessary medicine.",
                    "Answer Explanation": "Section 8(4)(b) specifies that if the information required on the primary container label is obscured by intermediate packaging, the label on the intermediate packaging must include the names of all active ingredients in the medicine."
                },
                {
                    "Question": "Consider a pessary medicine packaged in individual dosage units in a strip pack, with the strip pack inside a primary pack. Assuming the primary pack label is fully compliant with sections 8 and 9, is the strip pack label required to list inactive ingredients?",
                    "Answer": "No, the strip pack label is not required to list inactive ingredients in this scenario.",
                    "Answer Explanation": "Per section 10(9)(a), if a pessary medicine's dosage units are in a strip pack, the strip pack is in a primary pack, and the primary label is compliant with sections 8 and 9, then the strip label only needs to display the information specified in 10(9)(a)(iv)-(ix). This includes active ingredients but does not mention inactive ingredients."
                },
                {
                    "Question": "For a pessary medicine in individual dosage units packaged in a blister pack inside a fully labeled primary pack, how should the batch number and expiry date be shown on the blister pack label?",
                    "Answer": "The blister pack label should display the batch number preceded by the batch number prefix, and the expiry date preceded by the expiry date prefix.",
                    "Answer Explanation": "Section 10(9)(a)(vii) requires the batch number preceded by the batch prefix, and 10(9)(a)(viii) requires the expiry date preceded by the expiry prefix, on the blister label for a medicine like a pessary with dosage units in a blister inside a compliant primary pack."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a pessary medicine is packaged in a strip or blister pack enclosed in a primary pack whose label complies with sections 8 and 9, what specific information must be displayed on the label of the strip or blister pack itself?\",\n    \"Answer\": \"The name of the medicine, names and quantities\/proportions of all active ingredients, batch number preceded by batch number prefix, expiry date preceded by expiry date prefix, and name of sponsor\/distributor or identifying registered trademark.\",\n    \"Answer Explanation\": \"Section 10(9)(a) states that for a medicine consisting of dosage units like pessaries in a strip\/blister pack enclosed in a primary pack with a compliant label, the strip\/blister label itself must display the medicine name [10(9)(a)(iv)], active ingredient names [10(9)(a)(v)] and quantities [10(9)(a)(vi)], batch number with prefix [10(9)(a)(vii)], expiry date with prefix [10(9)(a)(viii)], and sponsor\/distributor name or trademark [10(9)(a)(ix)].\"\n  },\n  {\n    \"Question\": \"Suppose a pessary medicine's primary pack label information is obscured by intermediate packaging. Assuming no other exceptions apply, what information must the intermediate packaging label include?\",\n    \"Answer\": \"The intermediate packaging label must include at minimum the names of all active ingredients in the pessary medicine.\",\n    \"Answer Explanation\": \"Section 8(4)(b) specifies that if the information required on the primary container label is obscured by intermediate packaging, the label on the intermediate packaging must include the names of all active ingredients in the medicine.\"\n  },\n  {\n    \"Question\": \"Consider a pessary medicine packaged in individual dosage units in a strip pack, with the strip pack inside a primary pack. Assuming the primary pack label is fully compliant with sections 8 and 9, is the strip pack label required to list inactive ingredients?\",\n    \"Answer\": \"No, the strip pack label is not required to list inactive ingredients in this scenario.\",\n    \"Answer Explanation\": \"Per section 10(9)(a), if a pessary medicine's dosage units are in a strip pack, the strip pack is in a primary pack, and the primary label is compliant with sections 8 and 9, then the strip label only needs to display the information specified in 10(9)(a)(iv)-(ix). This includes active ingredients but does not mention inactive ingredients.\"\n  },\n  {\n    \"Question\": \"For a pessary medicine in individual dosage units packaged in a blister pack inside a fully labeled primary pack, how should the batch number and expiry date be shown on the blister pack label?\",\n    \"Answer\": \"The blister pack label should display the batch number preceded by the batch number prefix, and the expiry date preceded by the expiry date prefix.\",\n    \"Answer Explanation\": \"Section 10(9)(a)(vii) requires the batch number preceded by the batch prefix, and 10(9)(a)(viii) requires the expiry date preceded by the expiry prefix, on the blister label for a medicine like a pessary with dosage units in a blister inside a compliant primary pack.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "information",
                    "medicine",
                    "pessary"
                ]
            ]
        }
    },
    {
        "path": [
            910020000,
            911000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
            " 9 Information to be included on the main label (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine labelled according to subsection 9(11) and Part 1 of Schedule 2 is supplied in a container that is not considered small, when is the latest date that subsection 9(9) would not apply to the medicine?",
                    "Answer": "30 April 2026",
                    "Answer Explanation": "According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026."
                },
                {
                    "Question": "Assuming a medicine contains an active ingredient specified in Part 1 of Schedule 2 and is released for supply on 15 April 2026, can the active ingredient be included on the main label of the medicine?",
                    "Answer": "Yes",
                    "Answer Explanation": "Subsection 9(11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026. Since the medicine is released on 15 April 2026, which is before 1 May 2026, the active ingredient can be included on the main label."
                },
                {
                    "Question": "Assuming a medicine is not supplied in a small container and is labelled according to subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine if it is released for supply on 1 April 2026?",
                    "Answer": "No",
                    "Answer Explanation": "According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026. Since 1 April 2026 is before 30 April 2026, subsection 9(9) still applies to the medicine on this date."
                },
                {
                    "Question": "Assuming a medicine contains an active ingredient not specified in Part 1 of Schedule 2 and is released for supply on 30 April 2026, can the active ingredient be included on the main label of the medicine?",
                    "Answer": "No",
                    "Answer Explanation": "Subsection 9(11) allows an active ingredient specified in Part 1 of Schedule 2 to be included on the main label of a medicine containing that ingredient for medicine released before 1 May 2026. However, since the active ingredient is not specified in Part 1 of Schedule 2, it cannot be included on the main label regardless of the release date according to the provided regulation sections."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine labelled according to subsection 9(11) and Part 1 of Schedule 2 is supplied in a container that is not considered small, when is the latest date that subsection 9(9) would not apply to the medicine?\",\n    \"Answer\": \"30 April 2026\",\n    \"Answer Explanation\": \"According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine contains an active ingredient specified in Part 1 of Schedule 2 and is released for supply on 15 April 2026, can the active ingredient be included on the main label of the medicine?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Subsection 9(11) states that an active ingredient specified in Part 1 of Schedule 2 may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026. Since the medicine is released on 15 April 2026, which is before 1 May 2026, the active ingredient can be included on the main label.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is not supplied in a small container and is labelled according to subsection 9(11) and Part 1 of Schedule 2, does subsection 9(9) apply to the medicine if it is released for supply on 1 April 2026?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"According to subsection 9(10)(b), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2, after 30 April 2026. Since 1 April 2026 is before 30 April 2026, subsection 9(9) still applies to the medicine on this date.\"\n  },\n  {\n    \"Question\": \"Assuming a medicine contains an active ingredient not specified in Part 1 of Schedule 2 and is released for supply on 30 April 2026, can the active ingredient be included on the main label of the medicine?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Subsection 9(11) allows an active ingredient specified in Part 1 of Schedule 2 to be included on the main label of a medicine containing that ingredient for medicine released before 1 May 2026. However, since the active ingredient is not specified in Part 1 of Schedule 2, it cannot be included on the main label regardless of the release date according to the provided regulation sections.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "active ingredient",
                    "medicine",
                    "April"
                ]
            ]
        }
    },
    {
        "path": [
            907030000,
            802000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
            " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is registered goods and contains five active ingredients, is compliance with paragraphs 9(1)(b) and 9(1)(c) required if subsection 8(2) applies?",
                    "Answer": "No",
                    "Answer Explanation": "According to subsection 9(7)(c), if the medicine is intended to be, or is, registered goods, contains four or more active ingredients, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required."
                },
                {
                    "Question": "Assuming a medicine label must present critical health information, in what order should the 'Warnings' and 'Indications' be listed to ensure compliance with the labeling standard?",
                    "Answer": "Indications should be listed before Warnings",
                    "Answer Explanation": "Subsection 8(2)(b) states that critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. Therefore, to comply with the labeling standard, 'Indications' should be listed before 'Warnings'."
                },
                {
                    "Question": "Assuming a medicine is registered goods, contains six active ingredients, and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required on the main label?",
                    "Answer": "No",
                    "Answer Explanation": "According to subsection 9(7)(c), if the medicine is intended to be, or is, registered goods, contains four or more active ingredients, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required on the main label."
                },
                {
                    "Question": "Assuming critical health information must be presented on a medicine label, in what order should 'Active ingredients' and 'Directions for use' be listed to ensure compliance with subsection 8(2)(b)?",
                    "Answer": "Active ingredients should be listed before Directions for use",
                    "Answer Explanation": "Subsection 8(2)(b) specifies that critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. Therefore, to comply with subsection 8(2)(b), 'Active ingredients' should be listed before 'Directions for use' on the medicine label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is registered goods and contains five active ingredients, is compliance with paragraphs 9(1)(b) and 9(1)(c) required if subsection 8(2) applies?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to subsection 9(7)(c), if the medicine is intended to be, or is, registered goods, contains four or more active ingredients, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\"}, {\"Question\": \"Assuming a medicine label must present critical health information, in what order should the 'Warnings' and 'Indications' be listed to ensure compliance with the labeling standard?\", \"Answer\": \"Indications should be listed before Warnings\", \"Answer Explanation\": \"Subsection 8(2)(b) states that critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. Therefore, to comply with the labeling standard, 'Indications' should be listed before 'Warnings'.\"}, {\"Question\": \"Assuming a medicine is registered goods, contains six active ingredients, and subsection 8(2) applies, is compliance with paragraphs 9(1)(b) and 9(1)(c) required on the main label?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to subsection 9(7)(c), if the medicine is intended to be, or is, registered goods, contains four or more active ingredients, and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required on the main label.\"}, {\"Question\": \"Assuming critical health information must be presented on a medicine label, in what order should 'Active ingredients' and 'Directions for use' be listed to ensure compliance with subsection 8(2)(b)?\", \"Answer\": \"Active ingredients should be listed before Directions for use\", \"Answer Explanation\": \"Subsection 8(2)(b) specifies that critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. Therefore, to comply with subsection 8(2)(b), 'Active ingredients' should be listed before 'Directions for use' on the medicine label.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "label",
                    "information",
                    "compliance"
                ]
            ]
        }
    },
    {
        "path": [
            903020000,
            1102090000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh weight of herbal material and also the quantity of standardised constituents(s) in the herbal material; (ii) where the active ingredient is a herbal preparation, as the dry or fresh weight of the herbal material from which the preparation was derived except: (A) where standardisation of the herbal preparation is claimed on the label, then, the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituents(s) in the herbal preparation; or (B) where the active ingredient is a herbal preparation that is an essential oil; (iii) where the active ingredient is an enzyme \u2013the activity unit as specified in Column 1 of Schedule 3 to this Order in relation to a particular enzyme set out in Column 3 of that Schedule; (iv) for preparations containing Vitamin A or a derivative of Vitamin A - as the quantity or proportion of Vitamin A expressed in terms of microgram retinol equivalents; (v) for preparations containing biological organisms - as the number of organisms present per metric unit for liquids and powders and as the number of organisms present per dosage unit for other dosage forms;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine label has an active ingredient that is a powdered herb and no standardisation is claimed on the label, how should the quantity of the active ingredient be expressed on the main label according to the given regulation sections?",
                    "Answer": "The quantity of the active ingredient should be expressed as the weight of the herbal material on the main label.",
                    "Answer Explanation": "Section 11(2)(i)(i) states that where the active ingredient is a herbal material like a powdered herb, the quantity should be expressed as the weight of the herbal material, except where standardisation is claimed. Since the question specifies no standardisation is claimed, the quantity should be the weight of the powdered herb. Section 9(3)(b) requires that the name of the medicine and active ingredients on the main label must not be separated by any text or graphics, with some exceptions not relevant here. So the weight of the herbal material must be on the main label without intervening text or graphics."
                },
                {
                    "Question": "Based on the given regulation sections, if a non-prescription medicine label has an active ingredient that is a herbal preparation derived from 500mg of dry herbal material, and the label claims standardisation to 10mg of a specific constituent, what information about the quantity of the active ingredient is required to be on the main label?",
                    "Answer": "The main label is required to state both the minimum dry weight of herbal material the preparation was derived from (500mg) and the quantity of the standardised constituent (10mg).",
                    "Answer Explanation": "Section 11(2)(i)(ii)(A) specifies that for an active ingredient that is a herbal preparation where standardisation is claimed on the label, the label must state the minimum dry or fresh weight of herbal material the preparation is derived from and the quantity of the standardised constituent(s). In this case, that means stating both the 500mg of dry herbal material and the 10mg of the specific standardised constituent. Per section 9(3)(b), this information must be on the main label without being separated from the medicine and ingredient names by any intervening text or graphics, aside from some exceptions not relevant to this scenario."
                },
                {
                    "Question": "Suppose a non-prescription medicine label lists the active ingredient as 5000 units of a particular enzyme. According to the given regulation sections, in what units must this quantity be expressed on the main label?",
                    "Answer": "The quantity of the enzyme must be expressed in the activity unit specified for that particular enzyme in Column 1 of Schedule 3.",
                    "Answer Explanation": "Section 11(2)(i)(iii) states that where the active ingredient is an enzyme, the quantity must be expressed as the activity unit specified in Column 1 of Schedule 3 in relation to the particular enzyme listed in Column 3 of that Schedule. Section 9(3)(b) requires this information to be on the main label without being separated from the medicine and ingredient names by intervening text or graphics, aside from some exceptions not applicable here."
                },
                {
                    "Question": "Based on the given regulation sections, if a non-prescription medicine label lists the active ingredient as a biological organism present at a concentration of 10^6 organisms\/mL, how should this information be expressed on the main label?",
                    "Answer": "The concentration of the biological organism should be expressed on the main label as the number of organisms present per metric unit, since it is a liquid preparation.",
                    "Answer Explanation": "Section 11(2)(i)(v) specifies that for preparations containing biological organisms, the quantity should be expressed as the number of organisms present per metric unit for liquids and powders. In this case, the medicine is a liquid with a concentration of 10^6 organisms\/mL, so this concentration should be stated as the number of organisms per mL (a metric unit) on the label. Section 9(3)(b) requires the active ingredient information to be on the main label without being separated from the medicine and ingredient names by intervening text or graphics, with some exceptions not relevant here."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine label has an active ingredient that is a powdered herb and no standardisation is claimed on the label, how should the quantity of the active ingredient be expressed on the main label according to the given regulation sections?\", \"Answer\": \"The quantity of the active ingredient should be expressed as the weight of the herbal material on the main label.\", \"Answer Explanation\": \"Section 11(2)(i)(i) states that where the active ingredient is a herbal material like a powdered herb, the quantity should be expressed as the weight of the herbal material, except where standardisation is claimed. Since the question specifies no standardisation is claimed, the quantity should be the weight of the powdered herb. Section 9(3)(b) requires that the name of the medicine and active ingredients on the main label must not be separated by any text or graphics, with some exceptions not relevant here. So the weight of the herbal material must be on the main label without intervening text or graphics.\"}, {\"Question\": \"Based on the given regulation sections, if a non-prescription medicine label has an active ingredient that is a herbal preparation derived from 500mg of dry herbal material, and the label claims standardisation to 10mg of a specific constituent, what information about the quantity of the active ingredient is required to be on the main label?\", \"Answer\": \"The main label is required to state both the minimum dry weight of herbal material the preparation was derived from (500mg) and the quantity of the standardised constituent (10mg).\", \"Answer Explanation\": \"Section 11(2)(i)(ii)(A) specifies that for an active ingredient that is a herbal preparation where standardisation is claimed on the label, the label must state the minimum dry or fresh weight of herbal material the preparation is derived from and the quantity of the standardised constituent(s). In this case, that means stating both the 500mg of dry herbal material and the 10mg of the specific standardised constituent. Per section 9(3)(b), this information must be on the main label without being separated from the medicine and ingredient names by any intervening text or graphics, aside from some exceptions not relevant to this scenario.\"}, {\"Question\": \"Suppose a non-prescription medicine label lists the active ingredient as 5000 units of a particular enzyme. According to the given regulation sections, in what units must this quantity be expressed on the main label?\", \"Answer\": \"The quantity of the enzyme must be expressed in the activity unit specified for that particular enzyme in Column 1 of Schedule 3.\", \"Answer Explanation\": \"Section 11(2)(i)(iii) states that where the active ingredient is an enzyme, the quantity must be expressed as the activity unit specified in Column 1 of Schedule 3 in relation to the particular enzyme listed in Column 3 of that Schedule. Section 9(3)(b) requires this information to be on the main label without being separated from the medicine and ingredient names by intervening text or graphics, aside from some exceptions not applicable here.\"}, {\"Question\": \"Based on the given regulation sections, if a non-prescription medicine label lists the active ingredient as a biological organism present at a concentration of 10^6 organisms\/mL, how should this information be expressed on the main label?\", \"Answer\": \"The concentration of the biological organism should be expressed on the main label as the number of organisms present per metric unit, since it is a liquid preparation.\", \"Answer Explanation\": \"Section 11(2)(i)(v) specifies that for preparations containing biological organisms, the quantity should be expressed as the number of organisms present per metric unit for liquids and powders. In this case, the medicine is a liquid with a concentration of 10^6 organisms\/mL, so this concentration should be stated as the number of organisms per mL (a metric unit) on the label. Section 9(3)(b) requires the active ingredient information to be on the main label without being separated from the medicine and ingredient names by intervening text or graphics, with some exceptions not relevant here.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "main label",
                    "relation",
                    "metric unit"
                ]
            ]
        }
    },
    {
        "path": [
            1102080000,
            1102040000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (d) for a medicine required to be prepared before use, and: (i) where the process results in a medicine that is a liquid for ingestion: (A) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine; or (B) in the case where the medicine is one of a series of strengths containing the same active ingredient - as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively. (ii) for any other medicines - as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine intended for mineral supplementation is required to be prepared before use and the process results in a liquid for ingestion, how should the quantity or proportion of the active ingredient intended for mineral supplementation be expressed on the label?",
                    "Answer": "The quantity or proportion should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation. This is an exception to the general requirements in 11(2)(d) for medicines required to be prepared before use that result in a liquid for ingestion."
                },
                {
                    "Question": "Assuming a non-prescription medicine is required to be prepared before use and the process does not result in a liquid for ingestion, how should the quantity or proportion of active ingredients be expressed on the label?",
                    "Answer": "The quantity or proportion of active ingredients should be expressed as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine.",
                    "Answer Explanation": "According to paragraph 11(2)(d)(ii), for medicines required to be prepared before use that do not result in a liquid for ingestion, the quantity or proportion of active ingredients must be expressed as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine. This is in contrast to the requirements for medicines intended for mineral supplementation in 11(2)(h)."
                },
                {
                    "Question": "Assuming a non-prescription medicine is required to be prepared before use, the process results in a liquid for ingestion, and the medicine is one of a series of strengths containing the same active ingredient, how should the quantity or proportion of active ingredient be expressed on the label?",
                    "Answer": "The quantity or proportion of active ingredient should be expressed as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine, with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume.",
                    "Answer Explanation": "According to paragraph 11(2)(d)(i)(B), for a medicine required to be prepared before use that results in a liquid for ingestion and is one of a series of strengths containing the same active ingredient, the quantity or proportion of active ingredient must be expressed as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine, with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. The example provided illustrates that where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively."
                },
                {
                    "Question": "Assuming a non-prescription medicine contains an active ingredient intended for mineral supplementation, is required to be prepared before use, and the process results in a liquid for ingestion, how should the quantity or proportion of the active ingredient be expressed on the label?",
                    "Answer": "The quantity or proportion of the active ingredient should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation. This is an exception to the general requirements in 11(2)(d)(i) for medicines required to be prepared before use that result in a liquid for ingestion. The specific requirements for mineral supplementation in 11(2)(h) take precedence over the more general requirements in 11(2)(d)(i) when both apply."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a non-prescription medicine intended for mineral supplementation is required to be prepared before use and the process results in a liquid for ingestion, how should the quantity or proportion of the active ingredient intended for mineral supplementation be expressed on the label?\", \"Answer\": \"The quantity or proportion should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\", \"Answer Explanation\": \"According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation. This is an exception to the general requirements in 11(2)(d) for medicines required to be prepared before use that result in a liquid for ingestion.\"}, {\"Question\": \"Assuming a non-prescription medicine is required to be prepared before use and the process does not result in a liquid for ingestion, how should the quantity or proportion of active ingredients be expressed on the label?\", \"Answer\": \"The quantity or proportion of active ingredients should be expressed as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine.\", \"Answer Explanation\": \"According to paragraph 11(2)(d)(ii), for medicines required to be prepared before use that do not result in a liquid for ingestion, the quantity or proportion of active ingredients must be expressed as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine. This is in contrast to the requirements for medicines intended for mineral supplementation in 11(2)(h).\"}, {\"Question\": \"Assuming a non-prescription medicine is required to be prepared before use, the process results in a liquid for ingestion, and the medicine is one of a series of strengths containing the same active ingredient, how should the quantity or proportion of active ingredient be expressed on the label?\", \"Answer\": \"The quantity or proportion of active ingredient should be expressed as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine, with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume.\", \"Answer Explanation\": \"According to paragraph 11(2)(d)(i)(B), for a medicine required to be prepared before use that results in a liquid for ingestion and is one of a series of strengths containing the same active ingredient, the quantity or proportion of active ingredient must be expressed as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine, with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. The example provided illustrates that where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively.\"}, {\"Question\": \"Assuming a non-prescription medicine contains an active ingredient intended for mineral supplementation, is required to be prepared before use, and the process results in a liquid for ingestion, how should the quantity or proportion of the active ingredient be expressed on the label?\", \"Answer\": \"The quantity or proportion of the active ingredient should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\", \"Answer Explanation\": \"According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation. This is an exception to the general requirements in 11(2)(d)(i) for medicines required to be prepared before use that result in a liquid for ingestion. The specific requirements for mineral supplementation in 11(2)(h) take precedence over the more general requirements in 11(2)(d)(i) when both apply.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "weight",
                    "active ingredient",
                    "mineral supplementation"
                ]
            ]
        }
    },
    {
        "path": [
            1008030000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (8) Individually wrapped medicines (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
            " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (a) the name of the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a compliant label, do the individual bags need to be labelled with the information from sections 8 and 9?",
                    "Answer": "No, the individual bags do not need to be labelled with the information from sections 8 and 9.",
                    "Answer Explanation": "According to section 10(8)(c), if a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a compliant label, then the individual bags need not be labelled with the information referred to in sections 8 and 9."
                },
                {
                    "Question": "Assuming the information required on the label of a medicine container is obscured by intermediate packaging, what information must be included on the label of the intermediate packaging?",
                    "Answer": "The label on the intermediate packaging must include the name of the medicine.",
                    "Answer Explanation": "Section 8(4)(a) states that if the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include the name of the medicine."
                },
                {
                    "Question": "Assuming a medicine consists of dry herbs in individual unlabelled bags within a primary pack, and the primary pack label does not comply with the requirements of this Order, do the individual bags need to be labelled according to sections 8 and 9?",
                    "Answer": "Yes, in this case the individual bags would need to be labelled according to the requirements in sections 8 and 9.",
                    "Answer Explanation": "Section 10(8)(c) provides an exemption from individual bag labelling only if the primary pack label complies with the Order's requirements. Since in this case the primary label is stated to be non-compliant, the exemption in 10(8)(c) would not apply, so the individual bags would need to be labelled as per sections 8 and 9."
                },
                {
                    "Question": "Assuming a medicine container's label information is obscured by intermediate packaging that is also unlabelled, and the medicine consists of dry herbs in individual bags, what labelling is required on the individual bags?",
                    "Answer": "The individual bags would need to be labelled with the information required in sections 8 and 9.",
                    "Answer Explanation": "Section 8(4) requires the intermediate packaging to include at least the medicine name if it obscures the container label. Since the intermediate packaging is unlabelled, it does not meet this requirement. Section 10(8)(c) only exempts individual bag labelling if the primary pack label is compliant. With non-compliant intermediate and primary labelling, the individual bags must be labelled as per the full requirements of sections 8 and 9."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a compliant label, do the individual bags need to be labelled with the information from sections 8 and 9?\", \"Answer\": \"No, the individual bags do not need to be labelled with the information from sections 8 and 9.\", \"Answer Explanation\": \"According to section 10(8)(c), if a medicine consists of dry herbs in individual bags retained during preparation, and the bags are in a primary pack with a compliant label, then the individual bags need not be labelled with the information referred to in sections 8 and 9.\"}, {\"Question\": \"Assuming the information required on the label of a medicine container is obscured by intermediate packaging, what information must be included on the label of the intermediate packaging?\", \"Answer\": \"The label on the intermediate packaging must include the name of the medicine.\", \"Answer Explanation\": \"Section 8(4)(a) states that if the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include the name of the medicine.\"}, {\"Question\": \"Assuming a medicine consists of dry herbs in individual unlabelled bags within a primary pack, and the primary pack label does not comply with the requirements of this Order, do the individual bags need to be labelled according to sections 8 and 9?\", \"Answer\": \"Yes, in this case the individual bags would need to be labelled according to the requirements in sections 8 and 9.\", \"Answer Explanation\": \"Section 10(8)(c) provides an exemption from individual bag labelling only if the primary pack label complies with the Order's requirements. Since in this case the primary label is stated to be non-compliant, the exemption in 10(8)(c) would not apply, so the individual bags would need to be labelled as per sections 8 and 9.\"}, {\"Question\": \"Assuming a medicine container's label information is obscured by intermediate packaging that is also unlabelled, and the medicine consists of dry herbs in individual bags, what labelling is required on the individual bags?\", \"Answer\": \"The individual bags would need to be labelled with the information required in sections 8 and 9.\", \"Answer Explanation\": \"Section 8(4) requires the intermediate packaging to include at least the medicine name if it obscures the container label. Since the intermediate packaging is unlabelled, it does not meet this requirement. Section 10(8)(c) only exempts individual bag labelling if the primary pack label is compliant. With non-compliant intermediate and primary labelling, the individual bags must be labelled as per the full requirements of sections 8 and 9.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "container",
                    "medicine",
                    "qualification"
                ]
            ]
        }
    },
    {
        "path": [
            1102080000,
            1102020000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming the regulation only covers oral preparations with active ingredients intended for mineral supplementation, how should the quantity or proportion of an active ingredient be expressed on the label?",
                    "Answer": "The quantity or proportion should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, the quantity or proportion of the active ingredient can be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation. This is an exception to the general rules in paragraphs 11(2)(a) - 11(2)(d), as stated by the phrase 'Subject to paragraph 11(2)(i)' at the beginning of 11(2)."
                },
                {
                    "Question": "Assuming a solid for ingestion has no discrete dosage unit, contains active ingredients for mineral supplementation, and the elements are clearly stated, how should the quantity of active ingredients be expressed on the label?",
                    "Answer": "The quantity should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "Although paragraph 11(2)(b) states that for a solid for ingestion with no discrete dosage unit, the quantity should be expressed as the quantity of the active ingredient in a suitable dose, paragraph 11(2)(h) provides an exception. It states that for oral preparations with active ingredients for mineral supplementation, expressing the name of the active ingredient and the name and quantity of the element is sufficient. The phrase 'Subject to paragraph 11(2)(i)' at the start of 11(2) indicates 11(2)(h) takes precedence over 11(2)(b) in this case."
                },
                {
                    "Question": "Assuming an oral preparation contains multiple active ingredients, some for mineral supplementation and some not, and has no discrete dosage units, how should the quantities be expressed on the label?",
                    "Answer": "For the active ingredients intended for mineral supplementation, the name of the active ingredient and the name and quantity of the element should be stated. For the other active ingredients, the quantity contained in the stated weight of a suitable dose of the preparation should be expressed.",
                    "Answer Explanation": "Paragraph 11(2)(h) allows the quantity of active ingredients for mineral supplementation to be expressed as the name of the ingredient and the name and quantity of the element. However, this is an exception that only applies to those specific ingredients, as indicated by the phrase 'Subject to paragraph 11(2)(i)' in 11(2). For the other active ingredients with no discrete dosage unit, 11(2)(b) applies, requiring the quantity in a suitable dose to be stated."
                },
                {
                    "Question": "Assuming an oral preparation only contains active ingredients not intended for mineral supplementation and has no discrete dosage units, how should the quantity of active ingredients be expressed on the label?",
                    "Answer": "The quantity of each active ingredient should be expressed as the quantity contained in the stated weight of a suitable dose of the preparation.",
                    "Answer Explanation": "Paragraph 11(2)(b) states that for a solid for ingestion where there is no discrete dosage unit, the quantity of the active ingredient must be expressed as the quantity contained in the stated weight of a suitable dose. Paragraph 11(2)(h) provides an exception for active ingredients for mineral supplementation, but since the preparation in question contains no such ingredients, 11(2)(b) applies to all the active ingredients."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming the regulation only covers oral preparations with active ingredients intended for mineral supplementation, how should the quantity or proportion of an active ingredient be expressed on the label?\",\n    \"Answer\": \"The quantity or proportion should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\",\n    \"Answer Explanation\": \"According to paragraph 11(2)(h), for oral preparations that contain active ingredients intended for mineral supplementation, the quantity or proportion of the active ingredient can be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation. This is an exception to the general rules in paragraphs 11(2)(a) - 11(2)(d), as stated by the phrase 'Subject to paragraph 11(2)(i)' at the beginning of 11(2).\"\n  },\n  {\n    \"Question\": \"Assuming a solid for ingestion has no discrete dosage unit, contains active ingredients for mineral supplementation, and the elements are clearly stated, how should the quantity of active ingredients be expressed on the label?\",\n    \"Answer\": \"The quantity should be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation.\",\n    \"Answer Explanation\": \"Although paragraph 11(2)(b) states that for a solid for ingestion with no discrete dosage unit, the quantity should be expressed as the quantity of the active ingredient in a suitable dose, paragraph 11(2)(h) provides an exception. It states that for oral preparations with active ingredients for mineral supplementation, expressing the name of the active ingredient and the name and quantity of the element is sufficient. The phrase 'Subject to paragraph 11(2)(i)' at the start of 11(2) indicates 11(2)(h) takes precedence over 11(2)(b) in this case.\"\n  },  \n  {\n    \"Question\": \"Assuming an oral preparation contains multiple active ingredients, some for mineral supplementation and some not, and has no discrete dosage units, how should the quantities be expressed on the label?\",\n    \"Answer\": \"For the active ingredients intended for mineral supplementation, the name of the active ingredient and the name and quantity of the element should be stated. For the other active ingredients, the quantity contained in the stated weight of a suitable dose of the preparation should be expressed.\",\n    \"Answer Explanation\": \"Paragraph 11(2)(h) allows the quantity of active ingredients for mineral supplementation to be expressed as the name of the ingredient and the name and quantity of the element. However, this is an exception that only applies to those specific ingredients, as indicated by the phrase 'Subject to paragraph 11(2)(i)' in 11(2). For the other active ingredients with no discrete dosage unit, 11(2)(b) applies, requiring the quantity in a suitable dose to be stated.\"\n  },\n  {\n    \"Question\": \"Assuming an oral preparation only contains active ingredients not intended for mineral supplementation and has no discrete dosage units, how should the quantity of active ingredients be expressed on the label?\",\n    \"Answer\": \"The quantity of each active ingredient should be expressed as the quantity contained in the stated weight of a suitable dose of the preparation.\",\n    \"Answer Explanation\": \"Paragraph 11(2)(b) states that for a solid for ingestion where there is no discrete dosage unit, the quantity of the active ingredient must be expressed as the quantity contained in the stated weight of a suitable dose. Paragraph 11(2)(h) provides an exception for active ingredients for mineral supplementation, but since the preparation in question contains no such ingredients, 11(2)(b) applies to all the active ingredients.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "ingestion",
                    "expression",
                    "element"
                ]
            ]
        }
    },
    {
        "path": [
            802050000,
            802030000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
        ],
        "result_dict": {},
        "result_str": "Here is the JSON object with the requested 4 question-answer pairs:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a non-prescription medicine label contains critical health information and storage conditions, under what heading must the storage conditions be placed according to section 8(2)(e)?\",\n      \"Answer\": \"Under the 'Other information' heading\",\n      \"Answer Explanation\": \"Section 8(2)(e) states that if information other than critical health information is included, such as storage conditions, it must be placed under the 'Other information' heading or another separate appropriate heading that follows immediately below the headings mentioned in 8(2)(b).\"\n    },\n    {\n      \"Question\": \"Suppose a non-prescription medicine label includes the pharmacological category of the active ingredients to describe their purpose, as allowed by section 8(2)(c). Assuming this is not part of the critical health information, where on the label must this information be placed based on section 8(2)(e)?\", \n      \"Answer\": \"Under the headings mentioned in 8(2)(b)\",\n      \"Answer Explanation\": \"Section 8(2)(c) allows including the pharmacological category to describe the purpose of the active ingredients under 8(2)(b)(i). Section 8(2)(e) requires any information other than critical health information to be placed under 'Other information' or another heading below the 8(2)(b) headings. Therefore, the pharmacological category words must be under the 8(2)(b) headings.\"\n    },\n    {\n      \"Question\": \"Consider a non-prescription medicine label that lists the names of all excipients. Assuming this is not critical health information and no other non-critical information is included, which heading defined in section 8(2)(e) must this excipient information fall under?\",\n      \"Answer\": \"Under the 'Other information' heading\",\n      \"Answer Explanation\": \"Section 8(2)(e) allows the names of all excipients to be included under the 'Other information' heading, as long as it is not critical health information. Since the excipient names are the only non-critical information in this case, they must be placed under 'Other information' according to 8(2)(e).\"\n    },\n    {\n      \"Question\": \"Suppose a non-prescription medicine label contains critical health information described in 8(2)(b), along with words indicating the principal intended actions of the active ingredients allowed by 8(2)(c). Assuming no other information is included, is an 'Other information' heading required on this label according to section 8(2)(e)?\",\n      \"Answer\": \"No, an 'Other information' heading is not required\",\n      \"Answer Explanation\": \"Section 8(2)(e) only requires an 'Other information' heading if information other than critical health information or the information allowed in 8(2)(c) and 8(2)(d) is included. In this case, the label only contains critical health information under 8(2)(b) and words allowed by 8(2)(c), so no 'Other information' heading is necessary based on 8(2)(e).\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "critical health information",
                    "label",
                    "word"
                ]
            ]
        }
    },
    {
        "path": [
            910030000,
            913000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.",
            " 9 Information to be included on the main label (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, is subsection 9(9) applicable to the medicine's main label after 30 April 2028?",
                    "Answer": "No",
                    "Answer Explanation": "According to subsection 9(10)(c), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after 30 April 2028."
                },
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is released for supply before 1 May 2028, can the active ingredient be included on the main label of the medicine as per Part 2 of Schedule 2, either alone or in combination with other descriptors?",
                    "Answer": "Yes",
                    "Answer Explanation": "As per subsection 9(13), an active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028."
                },
                {
                    "Question": "Assuming a medicine is supplied in a small container, does the note under subsection 9(10) indicate that the minimum text size for active ingredients on the label is less than 2.5 millimetres and specified elsewhere in the Order?",
                    "Answer": "Yes",
                    "Answer Explanation": "The note under subsection 9(10) states that the minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in the Order."
                },
                {
                    "Question": "Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is not supplied in a small container, is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, and is released for supply before 1 May 2028, is subsection 9(9) applicable to its main label?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to subsection 9(10)(c), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after 30 April 2028. However, since the medicine is released for supply before 1 May 2028, subsection 9(9) is still applicable to its main label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, is subsection 9(9) applicable to the medicine's main label after 30 April 2028?\", \"Answer\": \"No\", \"Answer Explanation\": \"According to subsection 9(10)(c), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after 30 April 2028.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is released for supply before 1 May 2028, can the active ingredient be included on the main label of the medicine as per Part 2 of Schedule 2, either alone or in combination with other descriptors?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"As per subsection 9(13), an active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028.\"}, {\"Question\": \"Assuming a medicine is supplied in a small container, does the note under subsection 9(10) indicate that the minimum text size for active ingredients on the label is less than 2.5 millimetres and specified elsewhere in the Order?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"The note under subsection 9(10) states that the minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in the Order.\"}, {\"Question\": \"Assuming a medicine containing an active ingredient specified in Part 2 of Schedule 2 is not supplied in a small container, is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, and is released for supply before 1 May 2028, is subsection 9(9) applicable to its main label?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"According to subsection 9(10)(c), subsection 9(9) does not apply where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2, after 30 April 2028. However, since the medicine is released for supply before 1 May 2028, subsection 9(9) is still applicable to its main label.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "note",
                    "medicine",
                    "combination"
                ]
            ]
        }
    },
    {
        "path": [
            908030000,
            906020000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
            " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is a composite pack or medicine kit containing the same active ingredient in two different formulations, how many times should that active ingredient be counted when determining which labeling requirements apply under paragraphs 9(6)(b) and 9(7)?",
                    "Answer": "The active ingredient should be counted separately for each formulation.",
                    "Answer Explanation": "According to paragraph 9(8)(c)(ii), if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately for the purposes of determining if paragraph 9(6)(b) applies or which paragraph in subsection 9(7) applies to the composite pack or medicine kit."
                },
                {
                    "Question": "Assuming a medicine is intended to be listed goods and contains four or more active ingredients, where may the name, quantity, and proportion of each active ingredient appear on the label?",
                    "Answer": "The name, quantity, and proportion of each active ingredient may appear on a side panel, side label, rear panel, or rear label.",
                    "Answer Explanation": "Paragraph 9(6)(b) states that if the medicine is intended to be listed goods and there are four or more active ingredients in the medicine, the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
                },
                {
                    "Question": "Assuming a composite pack or medicine kit contains different formulations of a medicine, how are the total number of active ingredients determined for the purposes of labeling requirements under paragraphs 9(6)(b) and 9(7)?",
                    "Answer": "The total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted.",
                    "Answer Explanation": "As per paragraph 9(8)(c)(i), where a medicine is a composite pack or medicine kit containing different formulations, the total number of active ingredients in the different formulations are to be counted for the purposes of determining if paragraph 9(6)(b) applies or which paragraph in subsection 9(7) applies to the composite pack or medicine kit."
                },
                {
                    "Question": "Assuming a medicine is a composite pack or medicine kit containing two formulations with the same active ingredient, and the medicine is intended to be listed goods, how should the active ingredients be counted and where can their names, quantities, and proportions be displayed on the label?",
                    "Answer": "The same active ingredient should be counted separately for each formulation. If the total count of active ingredients across the different formulations is four or more, the names, quantities, and proportions of every active ingredient may appear on a side panel, side label, rear panel, or rear label.",
                    "Answer Explanation": "Paragraph 9(8)(c)(ii) requires that if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately. Paragraph 9(6)(b) allows the name, quantity, and proportion of every active ingredient to appear on a side panel, side label, rear panel, or rear label if the medicine is intended to be listed goods and contains four or more active ingredients in total, as determined by the counting method in 9(8)(c)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is a composite pack or medicine kit containing the same active ingredient in two different formulations, how many times should that active ingredient be counted when determining which labeling requirements apply under paragraphs 9(6)(b) and 9(7)?\", \"Answer\": \"The active ingredient should be counted separately for each formulation.\", \"Answer Explanation\": \"According to paragraph 9(8)(c)(ii), if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately for the purposes of determining if paragraph 9(6)(b) applies or which paragraph in subsection 9(7) applies to the composite pack or medicine kit.\"}, {\"Question\": \"Assuming a medicine is intended to be listed goods and contains four or more active ingredients, where may the name, quantity, and proportion of each active ingredient appear on the label?\", \"Answer\": \"The name, quantity, and proportion of each active ingredient may appear on a side panel, side label, rear panel, or rear label.\", \"Answer Explanation\": \"Paragraph 9(6)(b) states that if the medicine is intended to be listed goods and there are four or more active ingredients in the medicine, the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label.\"}, {\"Question\": \"Assuming a composite pack or medicine kit contains different formulations of a medicine, how are the total number of active ingredients determined for the purposes of labeling requirements under paragraphs 9(6)(b) and 9(7)?\", \"Answer\": \"The total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted.\", \"Answer Explanation\": \"As per paragraph 9(8)(c)(i), where a medicine is a composite pack or medicine kit containing different formulations, the total number of active ingredients in the different formulations are to be counted for the purposes of determining if paragraph 9(6)(b) applies or which paragraph in subsection 9(7) applies to the composite pack or medicine kit.\"}, {\"Question\": \"Assuming a medicine is a composite pack or medicine kit containing two formulations with the same active ingredient, and the medicine is intended to be listed goods, how should the active ingredients be counted and where can their names, quantities, and proportions be displayed on the label?\", \"Answer\": \"The same active ingredient should be counted separately for each formulation. If the total count of active ingredients across the different formulations is four or more, the names, quantities, and proportions of every active ingredient may appear on a side panel, side label, rear panel, or rear label.\", \"Answer Explanation\": \"Paragraph 9(8)(c)(ii) requires that if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately. Paragraph 9(6)(b) allows the name, quantity, and proportion of every active ingredient to appear on a side panel, side label, rear panel, or rear label if the medicine is intended to be listed goods and contains four or more active ingredients in total, as determined by the counting method in 9(8)(c).\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "different formulation",
                    "medicine",
                    "proportion"
                ]
            ]
        }
    },
    {
        "path": [
            302020000,
            500000000
        ],
        "contexts": [
            "3 Application - Therapeutic goods to which this Order applies(2) To avoid doubt, this Order will apply to the following medicines:(b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order.",
            "5 Exemptions \u2013 Medicines to which this Order does not apply (2) The requirements of this Order do not apply to a transparent covering that encloses or wraps the container or primary pack containing a medicine and where the information that is required to be set out on the label of the container or the primary pack is clearly visible through that transparent covering."
        ],
        "result_dict": null,
        "result_str": null,
        "misc_info": null
    },
    {
        "path": [
            802050000,
            802040000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " 8 Information to be included on the label (2) (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements)."
        ],
        "result_dict": {},
        "result_str": "Here is my attempt at generating the question-answer pairs as a valid JSON object conforming to the specified schema:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine label includes allergen advice and a caution statement that are not required by the regulation, under which heading on the label must this safety related information be placed according to sections 8(2)(d) and 8(2)(e)?\",\n      \"Answer\": \"Under the critical health information heading.\",\n      \"Answer Explanation\": \"Section 8(2)(d) states that safety related information not required by the regulation, such as allergen advice and caution statements, may be included under the critical health information heading specified in 8(2)(b)(iii). Section 8(2)(e) further clarifies that if any other non-critical information is included, it must be placed under the 'Other information' heading or another appropriate heading below the ones mentioned in 8(2)(b), which includes the critical health information heading.\"\n    },\n    {\n      \"Question\": \"Based on sections 8(2)(d) and 8(2)(e), if a distributor wants to include their contact details on a medicine label that already has critical health information, under which heading should the distributor contact details be placed?\",\n      \"Answer\": \"Under the 'Other information' heading or another appropriate heading below the critical health information.\",\n      \"Answer Explanation\": \"Section 8(2)(e) states that information like distributor contact details must be placed under the 'Other information' heading or another appropriate heading that follows immediately below the headings mentioned in 8(2)(b), which includes the critical health information heading. Section 8(2)(d) allows safety related information to be included under the critical health information heading, but distributor contact details do not fall under this category.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine label includes a warning statement required by the regulation and an additional advisory statement not required, according to sections 8(2)(d) and 8(2)(e), under which headings can each of these pieces of safety related information be placed?\",\n      \"Answer\": \"Both statements can be placed under the critical health information heading.\",\n      \"Answer Explanation\": \"The warning statement required by the regulation would fall under the critical health information heading per section 8(2)(b)(iii). Section 8(2)(d) allows additional safety related information like advisory statements that are not required by the regulation to also be included under this same critical health information heading. Section 8(2)(e) specifies other non-safety information must go under 'Other information' or another heading below critical health information, but does not restrict placement of additional safety information.\"\n    },\n    {\n      \"Question\": \"Based on sections 8(2)(d) and 8(2)(e), if a medicine label includes storage condition requirements, distributor contact details, and an allergen advice statement not required by the regulation, under which heading(s) should each piece of information be placed?\",\n      \"Answer\": \"Storage conditions and distributor contact details under 'Other information', allergen advice under critical health information.\",\n      \"Answer Explanation\": \"Section 8(2)(e) states storage condition requirements and distributor contact details must be under the 'Other information' heading or another appropriate heading below the ones in 8(2)(b). The critical health information heading in 8(2)(b)(iii) is one of those that 'Other information' must follow below. However, section 8(2)(d) allows additional safety related information like non-mandatory allergen advice to be included under that critical health information heading above 'Other information'.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "distributor contact detail",
                    "label",
                    "safety related information"
                ]
            ]
        }
    },
    {
        "path": [
            403000000,
            402000000
        ],
        "contexts": [
            "4 Transition arrangements (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017).",
            "4 Transition arrangements (2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine was imported into Australia on 1 August 2020 and supplied by a person other than the sponsor on 15 September 2020, which Order must it comply with at the time of release for supply if it complied with TGO 69 (2017) when supplied?",
                    "Answer": "The medicine must comply with TGO 69 (2017).",
                    "Answer Explanation": "Section 4(3) states that despite sections 4(1) and 4(2), medicines imported before 1 September 2020 but supplied by someone other than the sponsor after that date must comply with TGO 69 (2017) if they complied with TGO 69 (2017) at the time of their release for supply. Since the medicine was imported on 1 August 2020 and complied with TGO 69 (2017) when supplied on 15 September 2020, it must comply with TGO 69 (2017)."
                },
                {
                    "Question": "Assuming a medicine is manufactured in Australia on 1 September 2020 and supplied by the sponsor on the same date, which Order's requirements must it comply with?",
                    "Answer": "The medicine must comply with the requirements specified in this Order.",
                    "Answer Explanation": "Section 4(2) states that on and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. Since the medicine was manufactured on 1 September 2020 and supplied by the sponsor on the same date, it must comply with the requirements of this Order as per section 4(2)."
                },
                {
                    "Question": "Assuming a medicine was manufactured in Australia on 31 August 2020 and supplied by a person other than the sponsor on 2 September 2020, which Order must it comply with if it complied with TGO 69 (2017) at the time of release for supply?",
                    "Answer": "The medicine must comply with TGO 69 (2017).",
                    "Answer Explanation": "As per section 4(3), despite sections 4(1) and 4(2), medicines manufactured before 1 September 2020 but supplied by someone other than the sponsor after that date must comply with TGO 69 (2017) if they complied with it at the time of release for supply. Since the medicine was manufactured on 31 August 2020 and complied with TGO 69 (2017) when supplied on 2 September 2020, section 4(3) applies and it must comply with TGO 69 (2017)."
                },
                {
                    "Question": "Assuming a medicine is imported into Australia on 1 September 2020 and supplied by the sponsor on the same date, which Order's requirements must it comply with?",
                    "Answer": "The medicine must comply with the requirements specified in this Order.",
                    "Answer Explanation": "Section 4(2) states that on and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. Since the medicine was imported on 1 September 2020 and supplied by the sponsor on the same date, it falls under the scope of section 4(2) and must therefore comply with the requirements of this Order."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine was imported into Australia on 1 August 2020 and supplied by a person other than the sponsor on 15 September 2020, which Order must it comply with at the time of release for supply if it complied with TGO 69 (2017) when supplied?\",\n    \"Answer\": \"The medicine must comply with TGO 69 (2017).\",\n    \"Answer Explanation\": \"Section 4(3) states that despite sections 4(1) and 4(2), medicines imported before 1 September 2020 but supplied by someone other than the sponsor after that date must comply with TGO 69 (2017) if they complied with TGO 69 (2017) at the time of their release for supply. Since the medicine was imported on 1 August 2020 and complied with TGO 69 (2017) when supplied on 15 September 2020, it must comply with TGO 69 (2017).\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is manufactured in Australia on 1 September 2020 and supplied by the sponsor on the same date, which Order's requirements must it comply with?\",\n    \"Answer\": \"The medicine must comply with the requirements specified in this Order.\",\n    \"Answer Explanation\": \"Section 4(2) states that on and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. Since the medicine was manufactured on 1 September 2020 and supplied by the sponsor on the same date, it must comply with the requirements of this Order as per section 4(2).\"\n  },\n  {\n    \"Question\": \"Assuming a medicine was manufactured in Australia on 31 August 2020 and supplied by a person other than the sponsor on 2 September 2020, which Order must it comply with if it complied with TGO 69 (2017) at the time of release for supply?\",\n    \"Answer\": \"The medicine must comply with TGO 69 (2017).\",\n    \"Answer Explanation\": \"As per section 4(3), despite sections 4(1) and 4(2), medicines manufactured before 1 September 2020 but supplied by someone other than the sponsor after that date must comply with TGO 69 (2017) if they complied with it at the time of release for supply. Since the medicine was manufactured on 31 August 2020 and complied with TGO 69 (2017) when supplied on 2 September 2020, section 4(3) applies and it must comply with TGO 69 (2017).\"\n  },\n  {\n    \"Question\": \"Assuming a medicine is imported into Australia on 1 September 2020 and supplied by the sponsor on the same date, which Order's requirements must it comply with?\",\n    \"Answer\": \"The medicine must comply with the requirements specified in this Order.\",\n    \"Answer Explanation\": \"Section 4(2) states that on and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order. Since the medicine was imported on 1 September 2020 and supplied by the sponsor on the same date, it falls under the scope of section 4(2) and must therefore comply with the requirements of this Order.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "requirement",
                    "transition arrangement",
                    "time"
                ]
            ]
        }
    },
    {
        "path": [
            301000000,
            500000000
        ],
        "contexts": [
            "3 Application - Therapeutic goods to which this Order applies(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
            "5 Exemptions \u2013 Medicines to which this Order does not apply (2) The requirements of this Order do not apply to a transparent covering that encloses or wraps the container or primary pack containing a medicine and where the information that is required to be set out on the label of the container or the primary pack is clearly visible through that transparent covering."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is supplied in Australia and not specified under section 3 of the Therapeutic Goods Order No. 91, does this Order apply to the medicine's primary pack?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the medicine is supplied in Australia and not specified under the mentioned exception, this Order would apply to the medicine's primary pack."
                },
                {
                    "Question": "If a primary pack containing a medicine supplied in Australia is enclosed in a transparent covering, and the required label information is clearly visible through the covering, do the requirements of this Order still apply?",
                    "Answer": "No",
                    "Answer Explanation": "Section 5(2) provides an exemption stating that the requirements of this Order do not apply if the primary pack containing the medicine is enclosed in a transparent covering, and the required label information is clearly visible through that covering."
                },
                {
                    "Question": "Assuming a medicine is supplied in Australia and this Order applies, would the Order's requirements apply to both the medicine itself and its primary pack?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 3(1) states that this Order applies to medicines supplied in Australia, subject to some exceptions. It does not limit the application to only the medicine itself or only the primary pack. Therefore, the Order's requirements would apply to both the medicine and its primary pack, unless exempted under section 5(2)."
                },
                {
                    "Question": "If a medicine supplied in Australia has its primary pack wrapped in opaque packaging that obscures the required label information, would this Order's labeling requirements still apply to that primary pack?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 5(2) only exempts a primary pack from this Order's requirements if it is enclosed in a transparent covering through which the required label information is clearly visible. An opaque packaging obscuring the label would not meet this exemption criteria. Thus, the Order's labeling requirements would still apply to the primary pack in this scenario, as per section 3(1)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is supplied in Australia and not specified under section 3 of the Therapeutic Goods Order No. 91, does this Order apply to the medicine's primary pack?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 3(1) states that this Order applies to medicines supplied in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the medicine is supplied in Australia and not specified under the mentioned exception, this Order would apply to the medicine's primary pack.\"}, {\"Question\": \"If a primary pack containing a medicine supplied in Australia is enclosed in a transparent covering, and the required label information is clearly visible through the covering, do the requirements of this Order still apply?\", \"Answer\": \"No\", \"Answer Explanation\": \"Section 5(2) provides an exemption stating that the requirements of this Order do not apply if the primary pack containing the medicine is enclosed in a transparent covering, and the required label information is clearly visible through that covering.\"}, {\"Question\": \"Assuming a medicine is supplied in Australia and this Order applies, would the Order's requirements apply to both the medicine itself and its primary pack?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 3(1) states that this Order applies to medicines supplied in Australia, subject to some exceptions. It does not limit the application to only the medicine itself or only the primary pack. Therefore, the Order's requirements would apply to both the medicine and its primary pack, unless exempted under section 5(2).\"}, {\"Question\": \"If a medicine supplied in Australia has its primary pack wrapped in opaque packaging that obscures the required label information, would this Order's labeling requirements still apply to that primary pack?\", \"Answer\": \"Yes\", \"Answer Explanation\": \"Section 5(2) only exempts a primary pack from this Order's requirements if it is enclosed in a transparent covering through which the required label information is clearly visible. An opaque packaging obscuring the label would not meet this exemption criteria. Thus, the Order's labeling requirements would still apply to the primary pack in this scenario, as per section 3(1).\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "primary pack",
                    "medicine",
                    "Australia"
                ]
            ]
        }
    },
    {
        "path": [
            1102080000,
            1102030000
        ],
        "contexts": [
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming there are no other relevant regulations or exceptions, and that the medicine is an oral liquid for mineral supplementation, how must the quantity or proportion of the active ingredient intended for mineral supplementation be expressed on the label?",
                    "Answer": "The quantity or proportion of the active ingredient must be expressed as the name of the active ingredient, and the name and quantity of the element intended for mineral supplementation.",
                    "Answer Explanation": "This is clearly stated in paragraph 11(2)(h). It provides an exception for oral preparations containing active ingredients intended for mineral supplementation, allowing the quantity or proportion to be expressed simply as the name of the active ingredient along with the name and quantity of the element intended for supplementation. No other parts of the regulation contradict or modify this requirement for the stated assumptions."
                },
                {
                    "Question": "For an oral liquid medicine that is part of a series of strengths containing the same active ingredient, and assuming a suitable dose is 5 mL, how must the quantity of active ingredient be expressed on the label?",
                    "Answer": "The quantity of active ingredient must be expressed as the amount contained in 5 mL, and this must be consistent across the different strengths in the series. For example, if the series includes 1 mg\/mL and 5 mg\/mL strengths, they would be labeled as 5 mg in 5 mL and 25 mg in 5 mL respectively.",
                    "Answer Explanation": "Paragraph 11(2)(c)(ii) states that for a liquid for ingestion that is part of a series of strengths, the quantity of active ingredient must be expressed as the amount in the stated dose volume, and this expression must be consistent across the series using the same dose volume. The example given matches the scenario in the question, illustrating how the labeling would be done for a 5 mL dose volume. Nothing in 11(2)(h) overrides this, as that applies specifically to ingredients for mineral supplementation, which is not mentioned in the question."
                },
                {
                    "Question": "Suppose an oral liquid medicine contains an active ingredient for mineral supplementation. The medicine is also part of a series of strengths containing the same active ingredient, with a suitable dose of 10 mL. What information must be included on the label regarding the quantity or proportion of the active ingredient?",
                    "Answer": "The label must include the name of the active ingredient, and the name and quantity of the element intended for mineral supplementation. The quantity should be the amount contained in a 10 mL dose, expressed consistently this way across the different strengths in the series.",
                    "Answer Explanation": "Per 11(2)(h), since the active ingredient is for mineral supplementation, the quantity can be expressed as just the name of the ingredient and the name and amount of the mineral element. However, 11(2)(c)(ii) still applies, requiring the quantity to be the amount in a 10 mL dose (the stated suitable dose), and for this to be consistent across the series of strengths. So both the simplified mineral supplementation labeling and the series labeling requirements must be satisfied."
                },
                {
                    "Question": "If an oral liquid medicine contains multiple active ingredients, one of which is intended for mineral supplementation, while the others are not, and the suitable dose is 5 mL, how must the quantities or proportions of the various active ingredients be expressed on the label?",
                    "Answer": "For the active ingredient intended for mineral supplementation, the label can simply include the name of the active ingredient along with the name and quantity of the mineral element. For the other active ingredients not intended for mineral supplementation, the label must express the quantity of each active ingredient contained in a 5 mL dose.",
                    "Answer Explanation": "Paragraph 11(2)(h) allows the simpler labeling for active ingredients for mineral supplementation, but does not apply to other active ingredients. So only the mineral supplementation ingredient can be labeled with just its name and the name and amount of the mineral. The other ingredients are subject to the requirement in 11(2)(c)(i), which states that for a liquid for ingestion, the quantity of each active ingredient must be expressed as the amount contained in the stated suitable dose volume, which is given as 5 mL in this case."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\":[{\"Question\":\"Assuming there are no other relevant regulations or exceptions, and that the medicine is an oral liquid for mineral supplementation, how must the quantity or proportion of the active ingredient intended for mineral supplementation be expressed on the label?\",\"Answer\":\"The quantity or proportion of the active ingredient must be expressed as the name of the active ingredient, and the name and quantity of the element intended for mineral supplementation.\",\"Answer Explanation\":\"This is clearly stated in paragraph 11(2)(h). It provides an exception for oral preparations containing active ingredients intended for mineral supplementation, allowing the quantity or proportion to be expressed simply as the name of the active ingredient along with the name and quantity of the element intended for supplementation. No other parts of the regulation contradict or modify this requirement for the stated assumptions.\"},{\"Question\":\"For an oral liquid medicine that is part of a series of strengths containing the same active ingredient, and assuming a suitable dose is 5 mL, how must the quantity of active ingredient be expressed on the label?\",\"Answer\":\"The quantity of active ingredient must be expressed as the amount contained in 5 mL, and this must be consistent across the different strengths in the series. For example, if the series includes 1 mg\/mL and 5 mg\/mL strengths, they would be labeled as 5 mg in 5 mL and 25 mg in 5 mL respectively.\",\"Answer Explanation\":\"Paragraph 11(2)(c)(ii) states that for a liquid for ingestion that is part of a series of strengths, the quantity of active ingredient must be expressed as the amount in the stated dose volume, and this expression must be consistent across the series using the same dose volume. The example given matches the scenario in the question, illustrating how the labeling would be done for a 5 mL dose volume. Nothing in 11(2)(h) overrides this, as that applies specifically to ingredients for mineral supplementation, which is not mentioned in the question.\"},{\"Question\":\"Suppose an oral liquid medicine contains an active ingredient for mineral supplementation. The medicine is also part of a series of strengths containing the same active ingredient, with a suitable dose of 10 mL. What information must be included on the label regarding the quantity or proportion of the active ingredient?\",\"Answer\":\"The label must include the name of the active ingredient, and the name and quantity of the element intended for mineral supplementation. The quantity should be the amount contained in a 10 mL dose, expressed consistently this way across the different strengths in the series.\",\"Answer Explanation\":\"Per 11(2)(h), since the active ingredient is for mineral supplementation, the quantity can be expressed as just the name of the ingredient and the name and amount of the mineral element. However, 11(2)(c)(ii) still applies, requiring the quantity to be the amount in a 10 mL dose (the stated suitable dose), and for this to be consistent across the series of strengths. So both the simplified mineral supplementation labeling and the series labeling requirements must be satisfied.\"},{\"Question\":\"If an oral liquid medicine contains multiple active ingredients, one of which is intended for mineral supplementation, while the others are not, and the suitable dose is 5 mL, how must the quantities or proportions of the various active ingredients be expressed on the label?\",\"Answer\":\"For the active ingredient intended for mineral supplementation, the label can simply include the name of the active ingredient along with the name and quantity of the mineral element. For the other active ingredients not intended for mineral supplementation, the label must express the quantity of each active ingredient contained in a 5 mL dose.\",\"Answer Explanation\":\"Paragraph 11(2)(h) allows the simpler labeling for active ingredients for mineral supplementation, but does not apply to other active ingredients. So only the mineral supplementation ingredient can be labeled with just its name and the name and amount of the mineral. The other ingredients are subject to the requirement in 11(2)(c)(i), which states that for a liquid for ingestion, the quantity of each active ingredient must be expressed as the amount contained in the stated suitable dose volume, which is given as 5 mL in this case.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "suitable dose",
                    "expression",
                    "mineral supplementation"
                ]
            ]
        }
    },
    {
        "path": [
            903020000,
            1102080000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription medicine contains an oral preparation with active ingredients intended for mineral supplementation, what information must be included on the main label to express the quantity or proportion of those active ingredients, and where should that information be located in relation to the medicine name?",
                    "Answer": "The quantity or proportion of the active ingredients must be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation. This information must be located together with the medicine name on the main label without any intervening text or graphics.",
                    "Answer Explanation": "Paragraph 11(2)(h) allows the quantity of active ingredients for oral preparations intended for mineral supplementation to be expressed as just the ingredient name and element name\/quantity. Paragraph 9(3)(b)(i)(A) specifies this mineral supplementation information is permitted to be located with the medicine name without being separated by text or graphics."
                },
                {
                    "Question": "Assuming a non-prescription medicine label must include the name and quantity of an element intended for mineral supplementation per paragraph 11(2)(h), can any text or graphics appear between the mineral supplementation information and the medicine name on the main label?",
                    "Answer": "No, the mineral supplementation active ingredient information cannot be separated from the medicine name by any intervening text or graphics on the main label.",
                    "Answer Explanation": "Paragraph 9(3)(b) states the medicine name and active ingredient name(s) must not be separated by text or graphics, with an exception in 9(3)(b)(i)(A) allowing the mineral supplementation information required by 11(2)(h) to be grouped with the medicine name without intervening text\/graphics."
                },
                {
                    "Question": "For a non-prescription oral preparation medicine containing active ingredients for mineral supplementation, is it acceptable for the main label to express the quantity of the active ingredients as the ingredient name, element name and element quantity, without specifying the ingredient quantity or proportion?",
                    "Answer": "Yes, for this type of medicine, paragraph 11(2)(h) considers it sufficient to express the quantity of mineral supplementation active ingredients as just the name of the active ingredient along with the name and quantity of the mineral element. The exact quantity or proportion of the active ingredient itself is not required.",
                    "Answer Explanation": "Paragraph 11(2)(h) provides an exception to the general active ingredient quantity requirements in 11(2)(a)-(d). It allows oral preparations with mineral supplementation ingredients to have their quantity expressed as the ingredient name plus the element name and quantity, rather than specifying the ingredient quantity or proportion itself."
                },
                {
                    "Question": "Assuming an oral preparation medicine contains multiple active ingredients for mineral supplementation, can the label express their quantities as specified in paragraph 11(2)(h) if it would result in that information being separated from the medicine name by other text on the main label?",
                    "Answer": "No, even though 11(2)(h) permits mineral supplementation ingredients to have their quantities expressed as the ingredient name + element name\/quantity, paragraph 9(3)(b) requires that this information be grouped with the medicine name without any text or graphics between them on the main label.",
                    "Answer Explanation": "Paragraph 11(2)(h) provides an alternate way to express the quantity of mineral ingredients, but 9(3)(b)(i)(A) still requires this information to be located with the medicine name without intervening text\/graphics. The mineral ingredient details cannot be separated from the medicine name even if 11(2)(h) is followed."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription medicine contains an oral preparation with active ingredients intended for mineral supplementation, what information must be included on the main label to express the quantity or proportion of those active ingredients, and where should that information be located in relation to the medicine name?\",\n    \"Answer\": \"The quantity or proportion of the active ingredients must be expressed as the name of the active ingredient and the name and quantity of the element intended for mineral supplementation. This information must be located together with the medicine name on the main label without any intervening text or graphics.\",\n    \"Answer Explanation\": \"Paragraph 11(2)(h) allows the quantity of active ingredients for oral preparations intended for mineral supplementation to be expressed as just the ingredient name and element name\/quantity. Paragraph 9(3)(b)(i)(A) specifies this mineral supplementation information is permitted to be located with the medicine name without being separated by text or graphics.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription medicine label must include the name and quantity of an element intended for mineral supplementation per paragraph 11(2)(h), can any text or graphics appear between the mineral supplementation information and the medicine name on the main label?\",\n    \"Answer\": \"No, the mineral supplementation active ingredient information cannot be separated from the medicine name by any intervening text or graphics on the main label.\",\n    \"Answer Explanation\": \"Paragraph 9(3)(b) states the medicine name and active ingredient name(s) must not be separated by text or graphics, with an exception in 9(3)(b)(i)(A) allowing the mineral supplementation information required by 11(2)(h) to be grouped with the medicine name without intervening text\/graphics.\"\n  },\n  {\n    \"Question\": \"For a non-prescription oral preparation medicine containing active ingredients for mineral supplementation, is it acceptable for the main label to express the quantity of the active ingredients as the ingredient name, element name and element quantity, without specifying the ingredient quantity or proportion?\",\n    \"Answer\": \"Yes, for this type of medicine, paragraph 11(2)(h) considers it sufficient to express the quantity of mineral supplementation active ingredients as just the name of the active ingredient along with the name and quantity of the mineral element. The exact quantity or proportion of the active ingredient itself is not required.\",\n    \"Answer Explanation\": \"Paragraph 11(2)(h) provides an exception to the general active ingredient quantity requirements in 11(2)(a)-(d). It allows oral preparations with mineral supplementation ingredients to have their quantity expressed as the ingredient name plus the element name and quantity, rather than specifying the ingredient quantity or proportion itself.\"\n  },\n  {\n    \"Question\": \"Assuming an oral preparation medicine contains multiple active ingredients for mineral supplementation, can the label express their quantities as specified in paragraph 11(2)(h) if it would result in that information being separated from the medicine name by other text on the main label?\",\n    \"Answer\": \"No, even though 11(2)(h) permits mineral supplementation ingredients to have their quantities expressed as the ingredient name + element name\/quantity, paragraph 9(3)(b) requires that this information be grouped with the medicine name without any text or graphics between them on the main label.\",\n    \"Answer Explanation\": \"Paragraph 11(2)(h) provides an alternate way to express the quantity of mineral ingredients, but 9(3)(b)(i)(A) still requires this information to be located with the medicine name without intervening text\/graphics. The mineral ingredient details cannot be separated from the medicine name even if 11(2)(h) is followed.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "active ingredient",
                    "information",
                    "medicine"
                ]
            ]
        }
    },
    {
        "path": [
            802030000,
            802020000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
            " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a non-prescription drug label includes the pharmacological category of the active ingredients under the 'Active ingredients' heading, is this allowed under the regulation?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 8(2)(b)(i) requires the active ingredients to be listed under the 'Active ingredients' heading. Section 8(2)(c) allows including the pharmacological category of the active ingredients under 8(2)(b)(i), even though it is not required by the regulation."
                },
                {
                    "Question": "Assuming a non-prescription drug label lists the active ingredients but does not include any information on the pharmacological category or principal intended actions, does this violate the regulation?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(2)(b)(i) requires listing the active ingredients under the 'Active ingredients' heading. However, section 8(2)(c) specifies that including the pharmacological category or principal intended actions under 8(2)(b)(i) is optional and not required by the regulation."
                },
                {
                    "Question": "Assuming a non-prescription drug label includes a description of the principal intended actions of the active ingredients, under which of the required headings in 8(2)(b) would this information be permitted?",
                    "Answer": "Active ingredients",
                    "Answer Explanation": "Section 8(2)(b) requires specific headings in a defined order, one of which is 'Active ingredients' in 8(2)(b)(i). Section 8(2)(c) then allows optional inclusion of the principal intended actions under the information provided in 8(2)(b)(i), which is the 'Active ingredients' heading."
                },
                {
                    "Question": "Assuming a non-prescription drug label includes the pharmacological category and principal intended actions, but lists them under the 'Indications' heading defined in 8(2)(b)(ii), would this be permitted under the regulation?",
                    "Answer": "No",
                    "Answer Explanation": "While section 8(2)(c) allows optionally including the pharmacological category and principal intended actions, it specifies this information may be included under paragraph 8(2)(b)(i), which is the 'Active ingredients' heading. Listing this information under the 'Indications' heading in 8(2)(b)(ii) would not comply with the permitted location specified in 8(2)(c)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a non-prescription drug label includes the pharmacological category of the active ingredients under the 'Active ingredients' heading, is this allowed under the regulation?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 8(2)(b)(i) requires the active ingredients to be listed under the 'Active ingredients' heading. Section 8(2)(c) allows including the pharmacological category of the active ingredients under 8(2)(b)(i), even though it is not required by the regulation.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription drug label lists the active ingredients but does not include any information on the pharmacological category or principal intended actions, does this violate the regulation?\", \n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 8(2)(b)(i) requires listing the active ingredients under the 'Active ingredients' heading. However, section 8(2)(c) specifies that including the pharmacological category or principal intended actions under 8(2)(b)(i) is optional and not required by the regulation.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription drug label includes a description of the principal intended actions of the active ingredients, under which of the required headings in 8(2)(b) would this information be permitted?\",\n    \"Answer\": \"Active ingredients\",\n    \"Answer Explanation\": \"Section 8(2)(b) requires specific headings in a defined order, one of which is 'Active ingredients' in 8(2)(b)(i). Section 8(2)(c) then allows optional inclusion of the principal intended actions under the information provided in 8(2)(b)(i), which is the 'Active ingredients' heading.\"\n  },\n  {\n    \"Question\": \"Assuming a non-prescription drug label includes the pharmacological category and principal intended actions, but lists them under the 'Indications' heading defined in 8(2)(b)(ii), would this be permitted under the regulation?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"While section 8(2)(c) allows optionally including the pharmacological category and principal intended actions, it specifies this information may be included under paragraph 8(2)(b)(i), which is the 'Active ingredients' heading. Listing this information under the 'Indications' heading in 8(2)(b)(ii) would not comply with the permitted location specified in 8(2)(c).\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "use",
                    "label",
                    "pharmacological category"
                ]
            ]
        }
    },
    {
        "path": [
            601150000,
            801100000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (j) where: (i) a substance or substance within the group of substances referred to in Column 1 of Schedule 1 to this Order is present in the medicine; (ii) the circumstances as set out in Column 2 of Schedule 1 exist in relation to such a substance or no circumstances are set out in Column 2; and (iii) the medicine is intended to be administered via any one or more of the route(s) of administration referred to in Column 3 of Schedule 1, then: (iv) a statement: (A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1; and (B) where any of the circumstances and requirements set out in Column 2 of Schedule 1 exist in relation to the substance \u2013 a statement of the kind referred to as a \u2018requirement\u2019 in that Column (if any); and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Based on the circumstances and requirements set out in Schedule 1, what information is required to be on the label of a medicine intended for a specified route of administration that contains a substance listed in Column 1 of Schedule 1, assuming the medicine is self-selected by a consumer?",
                    "Answer": "The label must include a statement indicating that the medicine contains the substance using the name stated in Column 4 of Schedule 1, and if applicable, a statement of the kind referred to as a 'requirement' in Column 2 of Schedule 1. This information is considered critical health information for safe use.",
                    "Answer Explanation": "Section 8(1)(j) requires that if a medicine contains a substance from Column 1 of Schedule 1, is intended to be administered via a route in Column 3, and meets any circumstances in Column 2 (or none are specified), the label must state the medicine contains the substance using the name in Column 4 and include any 'requirement' statements from Column 2. Section 6 defines statements required under 8(1)(j) as 'critical health information' for medicines self-selected by consumers."
                },
                {
                    "Question": "Assuming a non-prescription medicine contains a substance listed in Column 1 of Schedule 1 and the circumstances in Column 2 exist, what information must be included on the label to enable safe use by a consumer who self-selects the medicine?",
                    "Answer": "The label must include a statement indicating the medicine contains the substance, using the name stated in Column 4 of Schedule 1, as well as any statements referred to as a 'requirement' in Column 2 of Schedule 1. This is considered critical health information for safe use.",
                    "Answer Explanation": "Paragraph 8(1)(j) mandates that if a substance from Column 1 of Schedule 1 is present, any Column 2 circumstances exist, and the route of administration is listed in Column 3, the label must state the medicine contains the substance using the Column 4 name and include any Column 2 'requirement' statements. Section 6 defines 8(1)(j) information as 'critical health information' for safe use of self-selected medicines."
                },
                {
                    "Question": "For a non-prescription medicine self-selected by a consumer, what information required under paragraph 8(1)(j) is considered critical health information for safe use of the medicine, assuming the conditions in 8(1)(j)(i)-(iii) are met?",
                    "Answer": "The statement indicating the medicine contains the substance, using the name stated in Column 4 of Schedule 1, and any statements referred to as a 'requirement' in Column 2 of Schedule 1 are considered critical health information for safe use when required under paragraph 8(1)(j).",
                    "Answer Explanation": "Section 6 defines 'critical health information' as information required under certain paragraphs of section 8(1), including (j), for safe use of self-selected medicines. Paragraph 8(1)(j) requires substance and requirement statements on the label when a Schedule 1 substance is present, Column 2 circumstances exist, and the route of administration is in Column 3."
                },
                {
                    "Question": "Assuming a self-selected non-prescription medicine meets the criteria in 8(1)(j)(i)-(iii) regarding substances in Schedule 1, what specific labeling information required by 8(1)(j)(iv) is considered critical for the consumer to safely use the medicine under the definition in section 6?",
                    "Answer": "The statement expressing that the medicine contains the substance using the name in Column 4 of Schedule 1, and any statements of the kind referred to as a 'requirement' in Column 2 of Schedule 1, are considered critical health information for safe use by the consumer, as defined in section 6.",
                    "Answer Explanation": "Section 6 states that information required under 8(1)(j) is 'critical health information' for safe use of self-selected medicines. 8(1)(j) requires that if (i) a substance from Column 1 of Schedule 1 is present, (ii) Column 2 circumstances exist or none are specified, and (iii) the route is in Column 3, then (iv) the label must state the medicine contains the substance using the Column 4 name and include any Column 2 'requirement' statements."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Based on the circumstances and requirements set out in Schedule 1, what information is required to be on the label of a medicine intended for a specified route of administration that contains a substance listed in Column 1 of Schedule 1, assuming the medicine is self-selected by a consumer?\", \"Answer\": \"The label must include a statement indicating that the medicine contains the substance using the name stated in Column 4 of Schedule 1, and if applicable, a statement of the kind referred to as a 'requirement' in Column 2 of Schedule 1. This information is considered critical health information for safe use.\", \"Answer Explanation\": \"Section 8(1)(j) requires that if a medicine contains a substance from Column 1 of Schedule 1, is intended to be administered via a route in Column 3, and meets any circumstances in Column 2 (or none are specified), the label must state the medicine contains the substance using the name in Column 4 and include any 'requirement' statements from Column 2. Section 6 defines statements required under 8(1)(j) as 'critical health information' for medicines self-selected by consumers.\"}, {\"Question\": \"Assuming a non-prescription medicine contains a substance listed in Column 1 of Schedule 1 and the circumstances in Column 2 exist, what information must be included on the label to enable safe use by a consumer who self-selects the medicine?\", \"Answer\": \"The label must include a statement indicating the medicine contains the substance, using the name stated in Column 4 of Schedule 1, as well as any statements referred to as a 'requirement' in Column 2 of Schedule 1. This is considered critical health information for safe use.\", \"Answer Explanation\": \"Paragraph 8(1)(j) mandates that if a substance from Column 1 of Schedule 1 is present, any Column 2 circumstances exist, and the route of administration is listed in Column 3, the label must state the medicine contains the substance using the Column 4 name and include any Column 2 'requirement' statements. Section 6 defines 8(1)(j) information as 'critical health information' for safe use of self-selected medicines.\"}, {\"Question\": \"For a non-prescription medicine self-selected by a consumer, what information required under paragraph 8(1)(j) is considered critical health information for safe use of the medicine, assuming the conditions in 8(1)(j)(i)-(iii) are met?\", \"Answer\": \"The statement indicating the medicine contains the substance, using the name stated in Column 4 of Schedule 1, and any statements referred to as a 'requirement' in Column 2 of Schedule 1 are considered critical health information for safe use when required under paragraph 8(1)(j).\", \"Answer Explanation\": \"Section 6 defines 'critical health information' as information required under certain paragraphs of section 8(1), including (j), for safe use of self-selected medicines. Paragraph 8(1)(j) requires substance and requirement statements on the label when a Schedule 1 substance is present, Column 2 circumstances exist, and the route of administration is in Column 3.\"}, {\"Question\": \"Assuming a self-selected non-prescription medicine meets the criteria in 8(1)(j)(i)-(iii) regarding substances in Schedule 1, what specific labeling information required by 8(1)(j)(iv) is considered critical for the consumer to safely use the medicine under the definition in section 6?\", \"Answer\": \"The statement expressing that the medicine contains the substance using the name in Column 4 of Schedule 1, and any statements of the kind referred to as a 'requirement' in Column 2 of Schedule 1, are considered critical health information for safe use by the consumer, as defined in section 6.\", \"Answer Explanation\": \"Section 6 states that information required under 8(1)(j) is 'critical health information' for safe use of self-selected medicines. 8(1)(j) requires that if (i) a substance from Column 1 of Schedule 1 is present, (ii) Column 2 circumstances exist or none are specified, and (iii) the route is in Column 3, then (iv) the label must state the medicine contains the substance using the Column 4 name and include any Column 2 'requirement' statements.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "safe use",
                    "medicine",
                    "circumstance"
                ]
            ]
        }
    },
    {
        "path": [
            910000000,
            909000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
            " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is intended to be registered goods, contains an active ingredient listed in Schedule 2, and is supplied in a small container, what is the minimum text size required for the names and quantities of all active ingredients on the main label before 1 May 2026?",
                    "Answer": "2.5 millimetres",
                    "Answer Explanation": "According to subsection 9(9), if a medicine is intended to be registered goods and contains an active ingredient listed in Schedule 2, the names and quantities of all active ingredients must be displayed in a text size of at least 2.5 millimetres. Subsection 9(10)(b) states that subsection 9(9) does not apply to medicines not supplied in a small container and labelled according to 9(11) and Part 1 of Schedule 2, but only after 30 April 2026. Therefore, before 1 May 2026, the minimum text size requirement of 2.5 millimetres applies to medicines in small containers that meet the criteria in 9(9)."
                },
                {
                    "Question": "Assuming a medicine is registered goods, contains an active ingredient from Schedule 2, and is not supplied in a small container, what labelling requirements must be met to be exempt from the text size requirement in subsection 9(9) after 30 April 2026?",
                    "Answer": "The medicine must be labelled in accordance with subsection 9(11) and Part 1 of Schedule 2.",
                    "Answer Explanation": "Subsection 9(10)(b) provides an exemption from the text size requirement in 9(9) for medicines that are not supplied in a small container, but only if they are labelled according to subsection 9(11) and Part 1 of Schedule 2. This exemption applies after 30 April 2026."
                },
                {
                    "Question": "Assuming a medicine is intended to be registered goods and contains an active ingredient listed in Schedule 2, does the text size requirement in subsection 9(9) apply if the medicine is supplied in a small container after 30 April 2026?",
                    "Answer": "Yes, the text size requirement in subsection 9(9) still applies.",
                    "Answer Explanation": "Subsection 9(10)(b) provides an exemption from the text size requirement in 9(9) after 30 April 2026, but only for medicines that are not supplied in a small container and are labelled according to 9(11) and Part 1 of Schedule 2. Therefore, medicines supplied in small containers are not exempt and must still comply with the 2.5 millimetre text size requirement in 9(9) after 30 April 2026."
                },
                {
                    "Question": "Assuming a medicine is not intended to be registered goods but contains an active ingredient listed in Schedule 2, does the text size requirement in subsection 9(9) apply if the medicine is supplied in a small container before 1 May 2026?",
                    "Answer": "No, the text size requirement in subsection 9(9) does not apply.",
                    "Answer Explanation": "Subsection 9(9) specifies that the text size requirement only applies to medicines that are intended to be, or are, registered goods. If a medicine is not intended to be registered goods, even if it contains an active ingredient from Schedule 2 and is supplied in a small container, the 2.5 millimetre text size requirement does not apply, regardless of the date."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is intended to be registered goods, contains an active ingredient listed in Schedule 2, and is supplied in a small container, what is the minimum text size required for the names and quantities of all active ingredients on the main label before 1 May 2026?\", \"Answer\": \"2.5 millimetres\", \"Answer Explanation\": \"According to subsection 9(9), if a medicine is intended to be registered goods and contains an active ingredient listed in Schedule 2, the names and quantities of all active ingredients must be displayed in a text size of at least 2.5 millimetres. Subsection 9(10)(b) states that subsection 9(9) does not apply to medicines not supplied in a small container and labelled according to 9(11) and Part 1 of Schedule 2, but only after 30 April 2026. Therefore, before 1 May 2026, the minimum text size requirement of 2.5 millimetres applies to medicines in small containers that meet the criteria in 9(9).\"}, {\"Question\": \"Assuming a medicine is registered goods, contains an active ingredient from Schedule 2, and is not supplied in a small container, what labelling requirements must be met to be exempt from the text size requirement in subsection 9(9) after 30 April 2026?\", \"Answer\": \"The medicine must be labelled in accordance with subsection 9(11) and Part 1 of Schedule 2.\", \"Answer Explanation\": \"Subsection 9(10)(b) provides an exemption from the text size requirement in 9(9) for medicines that are not supplied in a small container, but only if they are labelled according to subsection 9(11) and Part 1 of Schedule 2. This exemption applies after 30 April 2026.\"}, {\"Question\": \"Assuming a medicine is intended to be registered goods and contains an active ingredient listed in Schedule 2, does the text size requirement in subsection 9(9) apply if the medicine is supplied in a small container after 30 April 2026?\", \"Answer\": \"Yes, the text size requirement in subsection 9(9) still applies.\", \"Answer Explanation\": \"Subsection 9(10)(b) provides an exemption from the text size requirement in 9(9) after 30 April 2026, but only for medicines that are not supplied in a small container and are labelled according to 9(11) and Part 1 of Schedule 2. Therefore, medicines supplied in small containers are not exempt and must still comply with the 2.5 millimetre text size requirement in 9(9) after 30 April 2026.\"}, {\"Question\": \"Assuming a medicine is not intended to be registered goods but contains an active ingredient listed in Schedule 2, does the text size requirement in subsection 9(9) apply if the medicine is supplied in a small container before 1 May 2026?\", \"Answer\": \"No, the text size requirement in subsection 9(9) does not apply.\", \"Answer Explanation\": \"Subsection 9(9) specifies that the text size requirement only applies to medicines that are intended to be, or are, registered goods. If a medicine is not intended to be registered goods, even if it contains an active ingredient from Schedule 2 and is supplied in a small container, the 2.5 millimetre text size requirement does not apply, regardless of the date.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "text size",
                    "medicine",
                    "small container"
                ]
            ]
        }
    },
    {
        "path": [
            1009020000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (n) a statement of the purpose or purposes for which it is intended that the medicine be used, except where: (i) the medicine is: (A) supplied solely to a complementary healthcare practitioner for supply to a person after affixing by the practitioner of an instruction label on the medicine following a consultation with that person; and (B) the label of the medicine includes the words \u2018For Practitioner Dispensing Only\u2019; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is listed goods and contains three active ingredients, is it sufficient for the label on the strip, blister or dial dispenser pack to only display the name of the medicine, batch number, expiry date, and sponsor name to comply with sections 8 and 9?",
                    "Answer": "No",
                    "Answer Explanation": "According to section 10(9)(b)(ii), if a medicine is listed goods and contains two or more active ingredients, then it is sufficient for the label on the strip, blister or dial dispenser pack to display just the name of the medicine, batch number, expiry date, and sponsor name to comply with sections 8 and 9. However, the question states the medicine has three active ingredients, so this provision does not apply and the label must comply with all the requirements in sections 8 and 9."
                },
                {
                    "Question": "For a medicine supplied solely to a complementary healthcare practitioner for dispensing to patients after consultation, assuming the label includes 'For Practitioner Dispensing Only', is it required to include a statement of the intended purpose or purposes of the medicine on the label as per section 8(1)(n)?",
                    "Answer": "No",
                    "Answer Explanation": "Section 8(1)(n) states that the label must include a statement of intended purpose, except where the medicine is supplied solely to a practitioner for dispensing to patients after consultation, and the label includes 'For Practitioner Dispensing Only'. Both of those conditions are met based on the assumptions in the question, so the exception applies and no statement of purpose is required on the label per 8(1)(n)(i)."
                },
                {
                    "Question": "Suppose a medicine is registered goods and has five active ingredients. Assuming it is packaged in a blister pack, would the label on the blister pack be compliant with sections 8 and 9 if it only displayed the medicine name, batch number, expiry date, and registered trademark that readily identifies the sponsor?",
                    "Answer": "Yes",
                    "Answer Explanation": "Section 10(9)(b)(i) provides that for a medicine that is registered goods with four or more active ingredients, the label on a strip, blister or dial dispenser pack is deemed compliant with sections 8 and 9 if it displays the medicine name, batch number, expiry date, and sponsor name or identifying trademark. The question states the medicine is registered goods with five active ingredients and is in a blister pack, so this provision applies and the label described would be sufficient."
                },
                {
                    "Question": "Consider a listed medicine with one active ingredient that is supplied only to healthcare practitioners for dispensing to their patients. Assuming the label states 'For Practitioner Dispensing Only', does section 10(9)(b) allow the label on the blister packs to omit some of the information required by sections 8 and 9?",
                    "Answer": "No",
                    "Answer Explanation": "Section 10(9)(b)(ii) provides a labelling concession for listed medicines in strip, blister or dial dispenser packs, but only if the medicine contains two or more active ingredients. Since this medicine is stated to have only one active ingredient, the concession in 10(9)(b) does not apply, even though the medicine is supplied solely to practitioners for dispensing. The blister pack labels would need to include all information required by sections 8 and 9."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine is listed goods and contains three active ingredients, is it sufficient for the label on the strip, blister or dial dispenser pack to only display the name of the medicine, batch number, expiry date, and sponsor name to comply with sections 8 and 9?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"According to section 10(9)(b)(ii), if a medicine is listed goods and contains two or more active ingredients, then it is sufficient for the label on the strip, blister or dial dispenser pack to display just the name of the medicine, batch number, expiry date, and sponsor name to comply with sections 8 and 9. However, the question states the medicine has three active ingredients, so this provision does not apply and the label must comply with all the requirements in sections 8 and 9.\"\n  },\n  {\n    \"Question\": \"For a medicine supplied solely to a complementary healthcare practitioner for dispensing to patients after consultation, assuming the label includes 'For Practitioner Dispensing Only', is it required to include a statement of the intended purpose or purposes of the medicine on the label as per section 8(1)(n)?\", \n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 8(1)(n) states that the label must include a statement of intended purpose, except where the medicine is supplied solely to a practitioner for dispensing to patients after consultation, and the label includes 'For Practitioner Dispensing Only'. Both of those conditions are met based on the assumptions in the question, so the exception applies and no statement of purpose is required on the label per 8(1)(n)(i).\"\n  },\n  {\n    \"Question\": \"Suppose a medicine is registered goods and has five active ingredients. Assuming it is packaged in a blister pack, would the label on the blister pack be compliant with sections 8 and 9 if it only displayed the medicine name, batch number, expiry date, and registered trademark that readily identifies the sponsor?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"Section 10(9)(b)(i) provides that for a medicine that is registered goods with four or more active ingredients, the label on a strip, blister or dial dispenser pack is deemed compliant with sections 8 and 9 if it displays the medicine name, batch number, expiry date, and sponsor name or identifying trademark. The question states the medicine is registered goods with five active ingredients and is in a blister pack, so this provision applies and the label described would be sufficient.\"\n  },\n  {\n    \"Question\": \"Consider a listed medicine with one active ingredient that is supplied only to healthcare practitioners for dispensing to their patients. Assuming the label states 'For Practitioner Dispensing Only', does section 10(9)(b) allow the label on the blister packs to omit some of the information required by sections 8 and 9?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"Section 10(9)(b)(ii) provides a labelling concession for listed medicines in strip, blister or dial dispenser packs, but only if the medicine contains two or more active ingredients. Since this medicine is stated to have only one active ingredient, the concession in 10(9)(b) does not apply, even though the medicine is supplied solely to practitioners for dispensing. The blister pack labels would need to include all information required by sections 8 and 9.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "practitioner",
                    "medicine",
                    "sponsor"
                ]
            ]
        }
    },
    {
        "path": [
            908040000,
            906020000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
            " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
        ],
        "result_dict": {},
        "result_str": "Here is my attempt at generating 4 question-answer pairs requiring multi-hop reasoning across the given regulation sections, formatted as a JSON object:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"For a composite pack or medicine kit containing multiple formulations of medicine, where must the quantity or proportion of active ingredients for each formulation be provided, assuming the medicine is listed goods with 4 or more active ingredients?\",\n      \"Answer\": \"The quantity or proportion of active ingredients for each formulation of medicine in a composite pack or medicine kit must be provided separately, and may appear on a side panel, side label, rear panel or rear label.\",\n      \"Answer Explanation\": \"Section 9(8)(d) states that for a composite pack or medicine kit, the information required under 9(6)(b) or 9(7) must be provided separately for each formulation of medicine. 9(6)(b) further specifies that for listed medicines with 4 or more active ingredients, the quantity or proportion of each active ingredient may appear on a side panel, side label, rear panel or rear label.\"\n    },\n    {\n      \"Question\": \"Assuming a non-prescription medicine is listed goods and contains 5 active ingredients, is it required to include the name and quantity of every active ingredient on the main label? If not, where may this information be provided?\",\n      \"Answer\": \"No, it is not required to include the name and quantity of every active ingredient on the main label for a listed medicine with 5 active ingredients. This information may instead appear on a side panel, side label, rear panel or rear label.\", \n      \"Answer Explanation\": \"Per section 9(6)(b), for a listed medicine with four or more active ingredients, the name and quantity or proportion of every active ingredient is not required on the main label, and may instead appear on a side panel, side label, rear panel or rear label.\"\n    },\n    {\n      \"Question\": \"For a medicine kit containing 3 different formulations of listed medicines, each with 6 active ingredients, what information must be provided separately for each formulation, and where may this information be located on the labeling?\",\n      \"Answer\": \"For a medicine kit containing 3 formulations of listed medicines, each with 6 active ingredients, the name and quantity or proportion of every active ingredient must be provided separately for each formulation. This information may appear on a side panel, side label, rear panel or rear label for each formulation.\",\n      \"Answer Explanation\": \"Section 9(8)(d) requires that for medicine kits, the information under 9(6)(b) must be provided separately for each formulation of medicine. 9(6)(b) states that for listed medicines with four or more active ingredients, the name and quantity or proportion of every active ingredient may appear on a side panel, side label, rear panel or rear label, rather than the main label.\"\n    },\n    {\n      \"Question\": \"Consider a composite pack with 2 formulations of non-prescription medicine, each being listed goods with 5 active ingredients. Assuming the name and quantity of each active ingredient is not on the main label, where must this information be provided to meet the labeling requirements?\",\n      \"Answer\": \"For a composite pack with 2 formulations of listed medicine, each with 5 active ingredients, the name and quantity of every active ingredient for each formulation must be provided on either a side panel, side label, rear panel or rear label, separately for each formulation. It is not required on the main label.\",\n      \"Answer Explanation\": \"This scenario invokes both section 9(8)(d) for composite packs and 9(6)(b) for listed medicines with 4 or more active ingredients. 9(8)(d) requires the information under 9(6)(b) to be provided separately for each formulation in the composite pack. 9(6)(b) allows the name and quantity of actives to be on a side or rear panel\/label rather than the main label for listed medicines with 4+ active ingredients.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "quantity",
                    "medicine",
                    "medicine kit"
                ]
            ]
        }
    },
    {
        "path": [
            1103030000,
            1103020000
        ],
        "contexts": [
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or"
        ],
        "result_dict": null,
        "result_str": null,
        "misc_info": null
    },
    {
        "path": [
            903020000,
            1105000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
            " 11 How information is to be expressed (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either: (b) on a separate line of text - immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine contains an active ingredient that is a vitamin, can the word 'vitamin' appear on the main label of the medicine immediately below the related name and quantity of the active ingredient that is a vitamin, on a separate line of text?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to subsection 11(5)(b), if a medicine contains an active ingredient that is a vitamin, the word 'vitamin' or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine on a separate line of text, immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient."
                },
                {
                    "Question": "Assuming no additional information is required or permitted by other paragraphs or subsections, can the name of the medicine and the name(s) of active ingredient(s) on the main label be separated by any text or graphics?",
                    "Answer": "No",
                    "Answer Explanation": "According to paragraph 9(3)(b), the name of the medicine and the name(s) of active ingredient(s) on the main label must not be separated by any text or graphics, except where additional information is required or permitted by specific paragraphs or subsections, namely paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5)."
                },
                {
                    "Question": "Assuming a medicine contains vitamin C as an active ingredient, can the name 'Vitamin C' appear on the main label immediately below the related name and quantity of ascorbic acid, which is the active ingredient?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to subsection 11(5), if a medicine contains an active ingredient that is a vitamin, the word 'vitamin' together with the common name of that vitamin (in this case, Vitamin C) may appear on the main label of the medicine on a separate line of text, immediately below the related name of the active ingredient (ascorbic acid) and the quantity of that active ingredient, as per 11(5)(b). This is an exception to the rule in paragraph 9(3)(b) which states that the name of the medicine and the name(s) of active ingredient(s) on the main label must not be separated by any text or graphics."
                },
                {
                    "Question": "Assuming a composite pack contains different formulations of a medicine, can the names of the different formulations be separated from the name of the medicine on the main label by text or graphics?",
                    "Answer": "Yes",
                    "Answer Explanation": "According to paragraph 9(3)(b)(ii), the name of the medicine and the name(s) of active ingredient(s) on the main label can be separated by text or graphics if the additional information is in relation to identifying the different formulations of the medicines contained in a composite pack. This is an exception to the general rule stated in 9(3)(b) that the name of the medicine and names of active ingredients must not be separated by any text or graphics."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming a medicine contains an active ingredient that is a vitamin, can the word 'vitamin' appear on the main label of the medicine immediately below the related name and quantity of the active ingredient that is a vitamin, on a separate line of text?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"According to subsection 11(5)(b), if a medicine contains an active ingredient that is a vitamin, the word 'vitamin' or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine on a separate line of text, immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient.\"\n  },\n  {\n    \"Question\": \"Assuming no additional information is required or permitted by other paragraphs or subsections, can the name of the medicine and the name(s) of active ingredient(s) on the main label be separated by any text or graphics?\",\n    \"Answer\": \"No\",\n    \"Answer Explanation\": \"According to paragraph 9(3)(b), the name of the medicine and the name(s) of active ingredient(s) on the main label must not be separated by any text or graphics, except where additional information is required or permitted by specific paragraphs or subsections, namely paragraph 11(2)(h), subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A), or subsection 11(5).\"\n  },\n  {\n    \"Question\": \"Assuming a medicine contains vitamin C as an active ingredient, can the name 'Vitamin C' appear on the main label immediately below the related name and quantity of ascorbic acid, which is the active ingredient?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"According to subsection 11(5), if a medicine contains an active ingredient that is a vitamin, the word 'vitamin' together with the common name of that vitamin (in this case, Vitamin C) may appear on the main label of the medicine on a separate line of text, immediately below the related name of the active ingredient (ascorbic acid) and the quantity of that active ingredient, as per 11(5)(b). This is an exception to the rule in paragraph 9(3)(b) which states that the name of the medicine and the name(s) of active ingredient(s) on the main label must not be separated by any text or graphics.\"\n  },\n  {\n    \"Question\": \"Assuming a composite pack contains different formulations of a medicine, can the names of the different formulations be separated from the name of the medicine on the main label by text or graphics?\",\n    \"Answer\": \"Yes\",\n    \"Answer Explanation\": \"According to paragraph 9(3)(b)(ii), the name of the medicine and the name(s) of active ingredient(s) on the main label can be separated by text or graphics if the additional information is in relation to identifying the different formulations of the medicines contained in a composite pack. This is an exception to the general rule stated in 9(3)(b) that the name of the medicine and names of active ingredients must not be separated by any text or graphics.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "names",
                    "medicine",
                    "vitamin"
                ]
            ]
        }
    },
    {
        "path": [
            1007000000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (7) Small containers If: (j) the expiry date of the medicine preceded by the expiry date prefix; and",
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;"
        ],
        "result_dict": {},
        "result_str": "Here is my attempt at the question-answer pairs in the requested JSON format:\n\n{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine kit contains small containers of medicines, can the expiry date prefix and expiry date be printed on the main label of the small containers instead of the full expiry date?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"According to section 10(7)(j), for small containers, the expiry date of the medicine can be preceded by just the expiry date prefix rather than the full expiry date. Section 9(3)(b)(ii) allows separating the medicine name and active ingredients on the main label with additional information related to identifying different medicines in a medicine kit. Together, these sections indicate the expiry date prefix and date can go on the main label of small containers in a medicine kit.\"\n    },\n    {\n      \"Question\": \"For medicines in small containers within a medicine kit, is it permitted for the expiry date prefix and expiry date to be separated from the medicine name on the main label by other text identifying the different medicines?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 10(7)(j) allows using just the expiry date prefix before the expiry date for medicines in small containers. Per section 9(3)(b)(ii), the medicine name and active ingredients can be separated on the main label by additional information related to identifying the different medicines contained in a medicine kit. So for small containers in a kit, the expiry prefix and date can be separated from the medicine name by text identifying the medicines.\"\n    },\n    {\n      \"Question\": \"On the main label of a small medicine container inside a kit, can the expiry date prefix and date be printed in between the medicine name and the active ingredients?\",\n      \"Answer\": \"Yes\",\n      \"Answer Explanation\": \"Section 10(7)(j) permits using the expiry date prefix before the expiry date on small medicine containers. According to section 9(3)(b)(ii), additional information related to identifying different medicines within a kit is allowed to be placed between the medicine name and active ingredients on the main label. Therefore, on small containers inside a medicine kit, the expiry prefix and date can separate the medicine name and active ingredients on the main label.\"\n    },\n    {\n      \"Question\": \"For a medicine kit holding small containers of different medicines, is the main label of each small container required to have the full expiry date printed, or can it display the expiry date prefix before just the date?\",\n      \"Answer\": \"Just the expiry date prefix and date can be used\",\n      \"Answer Explanation\": \"Section 10(7)(j) states that for small containers, the medicine expiry date can be preceded by only the expiry date prefix rather than spelling out the full expiry date. Additionally, section 9(3)(b)(ii) allows the medicine name and active ingredients to be separated on the main label by added information to identify the various medicines in a kit. So for the small containers inside a medicine kit, the main label can display the expiry prefix and date without the full expiry date spelled out.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "expiry date prefix",
                    "medicine",
                    "medicine kit"
                ]
            ]
        }
    },
    {
        "path": [
            301000000,
            400000000
        ],
        "contexts": [
            "3 Application - Therapeutic goods to which this Order applies(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
            "4 Transition arrangements (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017)."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine that is not a prescription medicine was supplied in Australia on 1 October 2020, and the medicine was manufactured in Australia before 1 September 2020, which labelling standard applies to the medicine?",
                    "Answer": "TGO 69 (2017)",
                    "Answer Explanation": "According to section 4(3), if a medicine was imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date, it must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine in question was manufactured before 1 September 2020 and supplied after that date, TGO 69 (2017) applies."
                },
                {
                    "Question": "Assuming a related medicine is supplied in Australia on 1 November 2020, and the medicine is not specified under section 3 of the Therapeutic Goods Order No. 91, which labelling standard applies to the medicine?",
                    "Answer": "This Order (Therapeutic Goods Order No. 92)",
                    "Answer Explanation": "According to section 3(1), this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the related medicine is supplied in Australia and not specified under TGO 91, this Order (TGO 92) applies."
                },
                {
                    "Question": "Assuming a medicine was manufactured in Australia on 1 August 2020 and supplied by the sponsor on 1 October 2020, which labelling standard applies to the medicine?",
                    "Answer": "This Order (Therapeutic Goods Order No. 92)",
                    "Answer Explanation": "According to section 4(1) and 4(2), medicines released for supply on or after 1 September 2020 must comply with this Order (TGO 92). Section 4(3) provides an exception for medicines manufactured before 1 September 2020 and supplied by a person other than the sponsor after that date. However, since the medicine in question was supplied by the sponsor, the exception does not apply, and this Order (TGO 92) applies."
                },
                {
                    "Question": "Assuming a related medicine is supplied in Australia on 1 December 2020, and the medicine was imported into Australia on 1 August 2020 and supplied by a person other than the sponsor, which labelling standard applies to the medicine?",
                    "Answer": "TGO 69 (2017)",
                    "Answer Explanation": "According to section 3(1), this Order (TGO 92) generally applies to medicines supplied in Australia. However, section 4(3) provides an exception for medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date. In this case, the related medicine must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine that is not a prescription medicine was supplied in Australia on 1 October 2020, and the medicine was manufactured in Australia before 1 September 2020, which labelling standard applies to the medicine?\", \"Answer\": \"TGO 69 (2017)\", \"Answer Explanation\": \"According to section 4(3), if a medicine was imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date, it must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017). Since the medicine in question was manufactured before 1 September 2020 and supplied after that date, TGO 69 (2017) applies.\"}, {\"Question\": \"Assuming a related medicine is supplied in Australia on 1 November 2020, and the medicine is not specified under section 3 of the Therapeutic Goods Order No. 91, which labelling standard applies to the medicine?\", \"Answer\": \"This Order (Therapeutic Goods Order No. 92)\", \"Answer Explanation\": \"According to section 3(1), this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91. Since the related medicine is supplied in Australia and not specified under TGO 91, this Order (TGO 92) applies.\"}, {\"Question\": \"Assuming a medicine was manufactured in Australia on 1 August 2020 and supplied by the sponsor on 1 October 2020, which labelling standard applies to the medicine?\", \"Answer\": \"This Order (Therapeutic Goods Order No. 92)\", \"Answer Explanation\": \"According to section 4(1) and 4(2), medicines released for supply on or after 1 September 2020 must comply with this Order (TGO 92). Section 4(3) provides an exception for medicines manufactured before 1 September 2020 and supplied by a person other than the sponsor after that date. However, since the medicine in question was supplied by the sponsor, the exception does not apply, and this Order (TGO 92) applies.\"}, {\"Question\": \"Assuming a related medicine is supplied in Australia on 1 December 2020, and the medicine was imported into Australia on 1 August 2020 and supplied by a person other than the sponsor, which labelling standard applies to the medicine?\", \"Answer\": \"TGO 69 (2017)\", \"Answer Explanation\": \"According to section 3(1), this Order (TGO 92) generally applies to medicines supplied in Australia. However, section 4(3) provides an exception for medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date. In this case, the related medicine must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017).\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "related medicine",
                    "medicine",
                    "sponsor"
                ]
            ]
        }
    },
    {
        "path": [
            1008020000,
            900000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (8) Individually wrapped medicines (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.",
            " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine consists only of pastilles or lozenges, with each dosage unit enclosed in an individual unsealed wrapper and then enclosed in a primary pack that complies with sections 8 and 9, what information must be displayed on the label of each individual wrapper to comply with those sections?",
                    "Answer": "The name of the medicine.",
                    "Answer Explanation": "According to section 10(8)(b), if a medicine consists only of pastilles or lozenges, with each dosage unit enclosed in an unsealed individual wrapper and then enclosed in a compliant primary pack, then it is sufficient for the label on each individual wrapper to display just the name of the medicine in order to comply with sections 8 and 9."
                },
                {
                    "Question": "Assuming a registered medicine contains an active ingredient whose name is specified in Schedule 2 to this Order, what information about the active ingredients must be displayed on the main label and in what minimum text size?",
                    "Answer": "The names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.",
                    "Answer Explanation": "Section 9(9) states that if a registered medicine contains an active ingredient whose name is specified in Schedule 2 to this Order, then the names of all active ingredients, along with their quantity or proportion, must be displayed on the main label in a text size of at least 2.5 millimetres."
                },
                {
                    "Question": "Assuming a registered medicine consists only of lozenges, with each lozenge wrapped individually in an unsealed wrapper and then enclosed in a primary pack, and the medicine contains an active ingredient listed in Schedule 2, what information must be on the individual wrapper labels and the primary pack label respectively?",
                    "Answer": "The individual wrapper labels must display at least the name of the medicine. The primary pack label must display the names of all active ingredients along with their quantity or proportion, in a text size of at least 2.5 millimetres.",
                    "Answer Explanation": "Combining the requirements from sections 10(8)(b) and 9(9): 10(8)(b) allows the individual unsealed wrapper labels to display just the medicine name, provided the lozenges are in a compliant primary pack. 9(9) requires the primary pack label to list all active ingredients and their quantities\/proportions in minimum 2.5mm text, since the medicine contains a Schedule 2 ingredient and is registered."
                },
                {
                    "Question": "Assuming an individually wrapped registered medicine consists of lozenges and contains a Schedule 2 ingredient, and the primary pack label lists all active ingredients with their quantities in 2.5mm text, is any other information required on the individual wrapper labels for them to be compliant?",
                    "Answer": "No, no other information is required on the individual wrapper labels in this case.",
                    "Answer Explanation": "Section 10(8)(b) states that for individually wrapped lozenges in a compliant primary pack, it is sufficient for the individual wrapper labels to display just the name of the medicine to be considered compliant with sections 8 and 9. Since section 9(9)'s requirements for Schedule 2 ingredients are met on the primary pack label, no additional information beyond the medicine name is needed on the individual wrappers."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine consists only of pastilles or lozenges, with each dosage unit enclosed in an individual unsealed wrapper and then enclosed in a primary pack that complies with sections 8 and 9, what information must be displayed on the label of each individual wrapper to comply with those sections?\", \"Answer\": \"The name of the medicine.\", \"Answer Explanation\": \"According to section 10(8)(b), if a medicine consists only of pastilles or lozenges, with each dosage unit enclosed in an unsealed individual wrapper and then enclosed in a compliant primary pack, then it is sufficient for the label on each individual wrapper to display just the name of the medicine in order to comply with sections 8 and 9.\"}, {\"Question\": \"Assuming a registered medicine contains an active ingredient whose name is specified in Schedule 2 to this Order, what information about the active ingredients must be displayed on the main label and in what minimum text size?\", \"Answer\": \"The names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres.\", \"Answer Explanation\": \"Section 9(9) states that if a registered medicine contains an active ingredient whose name is specified in Schedule 2 to this Order, then the names of all active ingredients, along with their quantity or proportion, must be displayed on the main label in a text size of at least 2.5 millimetres.\"}, {\"Question\": \"Assuming a registered medicine consists only of lozenges, with each lozenge wrapped individually in an unsealed wrapper and then enclosed in a primary pack, and the medicine contains an active ingredient listed in Schedule 2, what information must be on the individual wrapper labels and the primary pack label respectively?\", \"Answer\": \"The individual wrapper labels must display at least the name of the medicine. The primary pack label must display the names of all active ingredients along with their quantity or proportion, in a text size of at least 2.5 millimetres.\", \"Answer Explanation\": \"Combining the requirements from sections 10(8)(b) and 9(9): 10(8)(b) allows the individual unsealed wrapper labels to display just the medicine name, provided the lozenges are in a compliant primary pack. 9(9) requires the primary pack label to list all active ingredients and their quantities\/proportions in minimum 2.5mm text, since the medicine contains a Schedule 2 ingredient and is registered.\"}, {\"Question\": \"Assuming an individually wrapped registered medicine consists of lozenges and contains a Schedule 2 ingredient, and the primary pack label lists all active ingredients with their quantities in 2.5mm text, is any other information required on the individual wrapper labels for them to be compliant?\", \"Answer\": \"No, no other information is required on the individual wrapper labels in this case.\", \"Answer Explanation\": \"Section 10(8)(b) states that for individually wrapped lozenges in a compliant primary pack, it is sufficient for the individual wrapper labels to display just the name of the medicine to be considered compliant with sections 8 and 9. Since section 9(9)'s requirements for Schedule 2 ingredients are met on the primary pack label, no additional information beyond the medicine name is needed on the individual wrappers.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "proportion",
                    "medicine",
                    "primary pack"
                ]
            ]
        }
    },
    {
        "path": [
            1005000000,
            800000000
        ],
        "contexts": [
            " 10 Qualifications and special requirements (5) Sunscreen preparations If: (a) the medicine is a sunscreen preparation; and",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a sunscreen preparation medicine has a primary pack container with insufficient space on the label to include directions for use, and those directions are instead provided in a package insert, what statement must be included on the label of the container or primary pack that does not include the directions?",
                    "Answer": "A statement that the directions for use are set out in the package insert must be included on whichever label (on the container or primary pack) that does not set out the directions for use itself.",
                    "Answer Explanation": "Section 8(1)(l)(ii)(B) states that if there is insufficient space on the label of either the container or the primary pack to include directions for use, and those directions are set out in a package insert, a statement must be included on whichever label (on the container or primary pack) that does not set out the directions for use itself, indicating that the directions are in the package insert."
                },
                {
                    "Question": "Assuming a medicine is a sunscreen preparation, and the dose is usually determined for each individual patient by an authorized health professional, are the directions for use of the medicine required to be included on the label of the primary pack?",
                    "Answer": "No, the directions for use are not required on the label of the primary pack in this case.",
                    "Answer Explanation": "Section 8(1)(l)(i) provides an exception to the requirement to include directions for use on medicine labels if the dose is usually determined for each individual patient by an authorized health professional. Section 10(5)(a) specifies that this applies if the medicine is a sunscreen preparation."
                },
                {
                    "Question": "Assuming a sunscreen preparation medicine has a primary pack with sufficient space on the label to include full directions for use, are those directions required to be on the label of the primary pack?",
                    "Answer": "Yes, the directions for use must be included on the label of the primary pack in this case.",
                    "Answer Explanation": "Section 8(1)(l) requires directions for use to be included on medicine labels, subject to the exceptions in 8(1)(l)(i) and (ii). Those exceptions only apply if the dose is individually determined by a health professional, or if there is insufficient label space and the directions are in a package insert. Neither exception applies here for a sunscreen preparation with sufficient label space, so the general requirement to include directions on the primary pack label remains in effect per 8(1)(l)."
                },
                {
                    "Question": "Assuming a sunscreen preparation medicine has a dose that is not usually individually determined by a health professional, but the primary pack has insufficient label space for full directions, what are the two requirements that must be met regarding the directions for use?",
                    "Answer": "The two requirements are: 1) The full directions for use must be set out in a package insert provided in the primary pack. 2) A statement must be included on the label of either the container or primary pack (whichever does not have the full directions) indicating that the directions are provided in the package insert.",
                    "Answer Explanation": "Section 8(1)(l)(ii) allows the directions to be omitted from the label only if: (A) the directions are set out in a package insert in the primary pack, and (B) there is a statement on either the container or primary pack label (whichever one does not have the full directions) stating that the directions are in the package insert. Both of these requirements must be met for a sunscreen preparation where the dose is not individually determined, but there is insufficient label space for the directions, per the combination of Sections 8(1)(l)(ii) and 10(5)(a)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a sunscreen preparation medicine has a primary pack container with insufficient space on the label to include directions for use, and those directions are instead provided in a package insert, what statement must be included on the label of the container or primary pack that does not include the directions?\", \"Answer\": \"A statement that the directions for use are set out in the package insert must be included on whichever label (on the container or primary pack) that does not set out the directions for use itself.\", \"Answer Explanation\": \"Section 8(1)(l)(ii)(B) states that if there is insufficient space on the label of either the container or the primary pack to include directions for use, and those directions are set out in a package insert, a statement must be included on whichever label (on the container or primary pack) that does not set out the directions for use itself, indicating that the directions are in the package insert.\"}, {\"Question\": \"Assuming a medicine is a sunscreen preparation, and the dose is usually determined for each individual patient by an authorized health professional, are the directions for use of the medicine required to be included on the label of the primary pack?\", \"Answer\": \"No, the directions for use are not required on the label of the primary pack in this case.\", \"Answer Explanation\": \"Section 8(1)(l)(i) provides an exception to the requirement to include directions for use on medicine labels if the dose is usually determined for each individual patient by an authorized health professional. Section 10(5)(a) specifies that this applies if the medicine is a sunscreen preparation.\"}, {\"Question\": \"Assuming a sunscreen preparation medicine has a primary pack with sufficient space on the label to include full directions for use, are those directions required to be on the label of the primary pack?\", \"Answer\": \"Yes, the directions for use must be included on the label of the primary pack in this case.\", \"Answer Explanation\": \"Section 8(1)(l) requires directions for use to be included on medicine labels, subject to the exceptions in 8(1)(l)(i) and (ii). Those exceptions only apply if the dose is individually determined by a health professional, or if there is insufficient label space and the directions are in a package insert. Neither exception applies here for a sunscreen preparation with sufficient label space, so the general requirement to include directions on the primary pack label remains in effect per 8(1)(l).\"}, {\"Question\": \"Assuming a sunscreen preparation medicine has a dose that is not usually individually determined by a health professional, but the primary pack has insufficient label space for full directions, what are the two requirements that must be met regarding the directions for use?\", \"Answer\": \"The two requirements are: 1) The full directions for use must be set out in a package insert provided in the primary pack. 2) A statement must be included on the label of either the container or primary pack (whichever does not have the full directions) indicating that the directions are provided in the package insert.\", \"Answer Explanation\": \"Section 8(1)(l)(ii) allows the directions to be omitted from the label only if: (A) the directions are set out in a package insert in the primary pack, and (B) there is a statement on either the container or primary pack label (whichever one does not have the full directions) stating that the directions are in the package insert. Both of these requirements must be met for a sunscreen preparation where the dose is not individually determined, but there is insufficient label space for the directions, per the combination of Sections 8(1)(l)(ii) and 10(5)(a).\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "primary pack",
                    "medicine",
                    "sunscreen preparation"
                ]
            ]
        }
    },
    {
        "path": [
            601150000,
            801020000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (b) the name(s) of all active ingredients in the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming the label for an adult cold medicine is compliant with the Order, what information about the medicine's active ingredients must be included on the label?",
                    "Answer": "The names of all active ingredients in the medicine must be included on the label.",
                    "Answer Explanation": "According to paragraph 8(1)(b) of the Order, the labels of a medicine must include the name(s) of all active ingredients in the medicine, subject to the qualifications and requirements specified in subsections 8(2), 8(3), and sections 9 and 10. This information is considered critical health information as per paragraph 6 of the Order."
                },
                {
                    "Question": "Based on the given sections of the Order, if a consumer is self-selecting an over-the-counter pain relief medicine, what critical health information must be present on the label to ensure safe use?",
                    "Answer": "The label must include the names of all active ingredients in the medicine.",
                    "Answer Explanation": "Paragraph 6 of the Order defines 'critical health information' as information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), which is critical for safe use of medicines that are self-selected by a consumer. Paragraph 8(1)(b) specifically requires the label to include the name(s) of all active ingredients in the medicine, subject to subsections 8(2), 8(3), and sections 9 and 10."
                },
                {
                    "Question": "Under the assumption that no exemptions or additional requirements apply, what information does the Order mandate to be on the label of a non-prescription medicine to ensure consumers can identify the active ingredients?",
                    "Answer": "The label must include the names of all active ingredients in the medicine.",
                    "Answer Explanation": "Paragraph 8(1)(b) of the Order states that, subject to the qualifications and requirements specified in subsections 8(2), 8(3), and sections 9 and 10, the labels of a medicine must include the name(s) of all active ingredients in the medicine. This information is considered critical health information according to paragraph 6, as it is required for the safe use of medicines that are self-selected by a consumer."
                },
                {
                    "Question": "Supposing a consumer is selecting an over-the-counter allergy medicine without the assistance of a healthcare professional, and assuming no additional requirements or exemptions apply, what critical information must be on the label to ensure the consumer can safely use the medicine?",
                    "Answer": "The label must include the names of all active ingredients in the allergy medicine.",
                    "Answer Explanation": "Paragraph 6 of the Order defines 'critical health information' as information that is critical for the safe use of medicines self-selected by a consumer, which includes the information required under paragraph 8(1)(b). Paragraph 8(1)(b) mandates that, subject to subsections 8(2), 8(3), and sections 9 and 10, the label must include the name(s) of all active ingredients in the medicine."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming the label for an adult cold medicine is compliant with the Order, what information about the medicine's active ingredients must be included on the label?\", \"Answer\": \"The names of all active ingredients in the medicine must be included on the label.\", \"Answer Explanation\": \"According to paragraph 8(1)(b) of the Order, the labels of a medicine must include the name(s) of all active ingredients in the medicine, subject to the qualifications and requirements specified in subsections 8(2), 8(3), and sections 9 and 10. This information is considered critical health information as per paragraph 6 of the Order.\"}, {\"Question\": \"Based on the given sections of the Order, if a consumer is self-selecting an over-the-counter pain relief medicine, what critical health information must be present on the label to ensure safe use?\", \"Answer\": \"The label must include the names of all active ingredients in the medicine.\", \"Answer Explanation\": \"Paragraph 6 of the Order defines 'critical health information' as information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n), which is critical for safe use of medicines that are self-selected by a consumer. Paragraph 8(1)(b) specifically requires the label to include the name(s) of all active ingredients in the medicine, subject to subsections 8(2), 8(3), and sections 9 and 10.\"}, {\"Question\": \"Under the assumption that no exemptions or additional requirements apply, what information does the Order mandate to be on the label of a non-prescription medicine to ensure consumers can identify the active ingredients?\", \"Answer\": \"The label must include the names of all active ingredients in the medicine.\", \"Answer Explanation\": \"Paragraph 8(1)(b) of the Order states that, subject to the qualifications and requirements specified in subsections 8(2), 8(3), and sections 9 and 10, the labels of a medicine must include the name(s) of all active ingredients in the medicine. This information is considered critical health information according to paragraph 6, as it is required for the safe use of medicines that are self-selected by a consumer.\"}, {\"Question\": \"Supposing a consumer is selecting an over-the-counter allergy medicine without the assistance of a healthcare professional, and assuming no additional requirements or exemptions apply, what critical information must be on the label to ensure the consumer can safely use the medicine?\", \"Answer\": \"The label must include the names of all active ingredients in the allergy medicine.\", \"Answer Explanation\": \"Paragraph 6 of the Order defines 'critical health information' as information that is critical for the safe use of medicines self-selected by a consumer, which includes the information required under paragraph 8(1)(b). Paragraph 8(1)(b) mandates that, subject to subsections 8(2), 8(3), and sections 9 and 10, the label must include the name(s) of all active ingredients in the medicine.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "label",
                    "medicine",
                    "consumer"
                ]
            ]
        }
    },
    {
        "path": [
            903030000,
            903010000
        ],
        "contexts": [
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
            " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine is supplied in a small container and contains multiple active ingredients, what are the requirements for displaying the names and quantities of the active ingredients on the main label in order to be compliant with the regulation?",
                    "Answer": "The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text.",
                    "Answer Explanation": "According to paragraph 9(3)(c), if a medicine is supplied in either a small or medium container and contains multiple active ingredients, then in relation to compliance with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line or lines of text."
                },
                {
                    "Question": "Assuming a medicine is supplied in a large container and contains a single active ingredient, what are the requirements for displaying the name and quantity of the active ingredient on the main label in order to be compliant with the regulation?",
                    "Answer": "The name and quantity of the active ingredient must appear as a cohesive unit, either immediately below the name of the medicine or adjacent to the name of the medicine if the trademark might be disrupted or obscured.",
                    "Answer Explanation": "According to paragraph 9(3)(a), the name of the medicine and the name(s) of active ingredient(s) on the main label must appear as a cohesive unit by placing the name and quantity of each active ingredient together on separate lines of text either immediately below the name of the medicine or, where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine. Paragraph 9(3)(c) provides an exception for medicines in small or medium containers with multiple active ingredients, but this question assumes a large container with a single active ingredient, so paragraph 9(3)(a) applies."
                },
                {
                    "Question": "Assuming a medicine is supplied in a medium container, contains multiple active ingredients, and has a trademark that might be disrupted by placing the active ingredients immediately below the medicine name, what are the requirements for displaying the names and quantities of the active ingredients on the main label in order to be compliant with the regulation?",
                    "Answer": "The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text adjacent to the name of the medicine.",
                    "Answer Explanation": "According to paragraph 9(3)(a), the name of the medicine and the name(s) of active ingredient(s) on the main label must appear as a cohesive unit either immediately below the name of the medicine or, where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine. Paragraph 9(3)(c) provides an additional option for medicines in small or medium containers with multiple active ingredients, allowing the names and quantities to be presented together on a continuous line or lines of text. Since this question assumes a medium container with multiple active ingredients and a trademark that might be disrupted, the names and quantities may be placed adjacent to the name of the medicine on a continuous line or lines of text to maintain compliance."
                },
                {
                    "Question": "Assuming a medicine is supplied in a large container and contains multiple active ingredients, what are the requirements for displaying the names and quantities of the active ingredients on the main label in order to be compliant with the regulation?",
                    "Answer": "The name and quantity of each active ingredient must appear as a cohesive unit on separate lines of text, either immediately below the name of the medicine or adjacent to the name of the medicine if the trademark might be disrupted or obscured.",
                    "Answer Explanation": "According to paragraph 9(3)(a), the name of the medicine and the name(s) of active ingredient(s) on the main label must appear as a cohesive unit by placing the name and quantity of each active ingredient together on separate lines of text either immediately below the name of the medicine or, where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine. Paragraph 9(3)(c) provides an exception for medicines in small or medium containers with multiple active ingredients, but this question assumes a large container, so paragraph 9(3)(a) applies, requiring the name and quantity of each active ingredient to be on separate lines of text."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine is supplied in a small container and contains multiple active ingredients, what are the requirements for displaying the names and quantities of the active ingredients on the main label in order to be compliant with the regulation?\", \"Answer\": \"The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text.\", \"Answer Explanation\": \"According to paragraph 9(3)(c), if a medicine is supplied in either a small or medium container and contains multiple active ingredients, then in relation to compliance with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line or lines of text.\"}, {\"Question\": \"Assuming a medicine is supplied in a large container and contains a single active ingredient, what are the requirements for displaying the name and quantity of the active ingredient on the main label in order to be compliant with the regulation?\", \"Answer\": \"The name and quantity of the active ingredient must appear as a cohesive unit, either immediately below the name of the medicine or adjacent to the name of the medicine if the trademark might be disrupted or obscured.\", \"Answer Explanation\": \"According to paragraph 9(3)(a), the name of the medicine and the name(s) of active ingredient(s) on the main label must appear as a cohesive unit by placing the name and quantity of each active ingredient together on separate lines of text either immediately below the name of the medicine or, where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine. Paragraph 9(3)(c) provides an exception for medicines in small or medium containers with multiple active ingredients, but this question assumes a large container with a single active ingredient, so paragraph 9(3)(a) applies.\"}, {\"Question\": \"Assuming a medicine is supplied in a medium container, contains multiple active ingredients, and has a trademark that might be disrupted by placing the active ingredients immediately below the medicine name, what are the requirements for displaying the names and quantities of the active ingredients on the main label in order to be compliant with the regulation?\", \"Answer\": \"The names and quantities of the multiple active ingredients may be presented together on a continuous line or lines of text adjacent to the name of the medicine.\", \"Answer Explanation\": \"According to paragraph 9(3)(a), the name of the medicine and the name(s) of active ingredient(s) on the main label must appear as a cohesive unit either immediately below the name of the medicine or, where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine. Paragraph 9(3)(c) provides an additional option for medicines in small or medium containers with multiple active ingredients, allowing the names and quantities to be presented together on a continuous line or lines of text. Since this question assumes a medium container with multiple active ingredients and a trademark that might be disrupted, the names and quantities may be placed adjacent to the name of the medicine on a continuous line or lines of text to maintain compliance.\"}, {\"Question\": \"Assuming a medicine is supplied in a large container and contains multiple active ingredients, what are the requirements for displaying the names and quantities of the active ingredients on the main label in order to be compliant with the regulation?\", \"Answer\": \"The name and quantity of each active ingredient must appear as a cohesive unit on separate lines of text, either immediately below the name of the medicine or adjacent to the name of the medicine if the trademark might be disrupted or obscured.\", \"Answer Explanation\": \"According to paragraph 9(3)(a), the name of the medicine and the name(s) of active ingredient(s) on the main label must appear as a cohesive unit by placing the name and quantity of each active ingredient together on separate lines of text either immediately below the name of the medicine or, where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine. Paragraph 9(3)(c) provides an exception for medicines in small or medium containers with multiple active ingredients, but this question assumes a large container, so paragraph 9(3)(a) applies, requiring the name and quantity of each active ingredient to be on separate lines of text.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "quantity",
                    "medicine",
                    "compliance"
                ]
            ]
        }
    },
    {
        "path": [
            1103030000,
            1103010000
        ],
        "contexts": [
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
            " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a homoeopathic medicine contains a single, fully potentised ingredient, what information must be included on the label of the container and primary pack regarding the quantity or proportion of active ingredients?",
                    "Answer": "The name of the active ingredient.",
                    "Answer Explanation": "According to section 11(3)(a), if a homoeopathic medicine contains a single, fully potentised ingredient and it is clear that the ingredient comprises 100% of the medicine, the label on the container and primary pack must include the name of the active ingredient."
                },
                {
                    "Question": "In cases where a homoeopathic medicine does not meet the criteria in section 11(3)(a) or 11(3)(b), what information must be included on the label of the container and primary pack regarding the quantity or proportion of the homoeopathic preparation?",
                    "Answer": "The quantity of the preparation in one millilitre or in one gram of the medicine.",
                    "Answer Explanation": "Section 11(3)(c) states that where paragraphs (a) and (b) do not apply, the label on the container and primary pack of a medicine that contains a homoeopathic preparation must include the quantity of the preparation in one millilitre or in one gram of the medicine."
                },
                {
                    "Question": "Assuming a homoeopathic medicine contains a single, fully potentised ingredient, and it is unclear that the ingredient comprises 100% of the medicine, what information must be included on the label of the container and primary pack regarding the quantity or proportion of active ingredients?",
                    "Answer": "The quantity of the preparation in one millilitre or in one gram of the medicine.",
                    "Answer Explanation": "According to section 11(3)(a), the name of the active ingredient is only required on the label if the homoeopathic medicine contains a single, fully potentised ingredient and it is clear that the ingredient comprises 100% of the medicine. If it is unclear that the ingredient comprises 100% of the medicine, section 11(3)(c) applies, requiring the label to include the quantity of the preparation in one millilitre or in one gram of the medicine."
                },
                {
                    "Question": "Assuming a homoeopathic medicine does not contain a single, fully potentised ingredient, what information must be included on the label of the container and primary pack regarding the quantity or proportion of the homoeopathic preparation?",
                    "Answer": "The quantity of the preparation in one millilitre or in one gram of the medicine.",
                    "Answer Explanation": "Section 11(3)(a) only applies to homoeopathic medicines containing a single, fully potentised ingredient. If the medicine does not meet this criterion, section 11(3)(c) applies, requiring the label on the container and primary pack to include the quantity of the preparation in one millilitre or in one gram of the medicine."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a homoeopathic medicine contains a single, fully potentised ingredient, what information must be included on the label of the container and primary pack regarding the quantity or proportion of active ingredients?\", \"Answer\": \"The name of the active ingredient.\", \"Answer Explanation\": \"According to section 11(3)(a), if a homoeopathic medicine contains a single, fully potentised ingredient and it is clear that the ingredient comprises 100% of the medicine, the label on the container and primary pack must include the name of the active ingredient.\"}, {\"Question\": \"In cases where a homoeopathic medicine does not meet the criteria in section 11(3)(a) or 11(3)(b), what information must be included on the label of the container and primary pack regarding the quantity or proportion of the homoeopathic preparation?\", \"Answer\": \"The quantity of the preparation in one millilitre or in one gram of the medicine.\", \"Answer Explanation\": \"Section 11(3)(c) states that where paragraphs (a) and (b) do not apply, the label on the container and primary pack of a medicine that contains a homoeopathic preparation must include the quantity of the preparation in one millilitre or in one gram of the medicine.\"}, {\"Question\": \"Assuming a homoeopathic medicine contains a single, fully potentised ingredient, and it is unclear that the ingredient comprises 100% of the medicine, what information must be included on the label of the container and primary pack regarding the quantity or proportion of active ingredients?\", \"Answer\": \"The quantity of the preparation in one millilitre or in one gram of the medicine.\", \"Answer Explanation\": \"According to section 11(3)(a), the name of the active ingredient is only required on the label if the homoeopathic medicine contains a single, fully potentised ingredient and it is clear that the ingredient comprises 100% of the medicine. If it is unclear that the ingredient comprises 100% of the medicine, section 11(3)(c) applies, requiring the label to include the quantity of the preparation in one millilitre or in one gram of the medicine.\"}, {\"Question\": \"Assuming a homoeopathic medicine does not contain a single, fully potentised ingredient, what information must be included on the label of the container and primary pack regarding the quantity or proportion of the homoeopathic preparation?\", \"Answer\": \"The quantity of the preparation in one millilitre or in one gram of the medicine.\", \"Answer Explanation\": \"Section 11(3)(a) only applies to homoeopathic medicines containing a single, fully potentised ingredient. If the medicine does not meet this criterion, section 11(3)(c) applies, requiring the label on the container and primary pack to include the quantity of the preparation in one millilitre or in one gram of the medicine.\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "preparation",
                    "expression",
                    "homoeopathic medicine"
                ]
            ]
        }
    },
    {
        "path": [
            601150000,
            801120000
        ],
        "contexts": [
            "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
            " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine's label does not contain directions for use and there is insufficient space on the container and primary pack labels to include them, what two conditions must be met for the medicine to still comply with the regulation?",
                    "Answer": "The medicine label can omit directions for use if there is insufficient label space, provided that: (A) the directions are included in a package insert in the primary pack, and (B) the label that lacks the directions includes a statement referring to the package insert.",
                    "Answer Explanation": "Section 8(1)(l)(ii) allows directions for use to be omitted from the label if space is insufficient, as long as the specified conditions (A) and (B) are satisfied. Condition (A) requires the directions to be provided in a package insert, and condition (B) requires the label to include a statement pointing to that insert."
                },
                {
                    "Question": "Assuming a medicine's dose is usually determined for each patient by an authorized health professional, is the medicine's label required to include directions for use?",
                    "Answer": "No, the label is not required to include directions for use in this case.",
                    "Answer Explanation": "Section 8(1)(l)(i) provides an exception to the general requirement that labels include directions for use. If the dose is usually determined for each patient by an appropriately authorized health professional, the directions for use may be omitted from the label."
                },
                {
                    "Question": "Assuming there is sufficient label space, a medicine's dose is not individually determined, and no other exceptions apply, what specific information regarding directions for use of the medicine is required on the label to ensure safe use by consumers?",
                    "Answer": "The label must include directions for use of the medicine, as this is critical health information required for safe use by consumers who self-select the medicine.",
                    "Answer Explanation": "Section 8(1)(l) requires labels to include directions for use, subject to specific exceptions. Section 6 defines \"critical health information\" that is required for safe use of self-selected medicines as including the information under 8(1)(l). Therefore, assuming no exceptions apply, the directions for use must be on the label to meet the critical health information requirement."
                },
                {
                    "Question": "Assuming a medicine label omits directions for use under the exception in 8(1)(l)(ii), what specific label statement regarding the location of the directions is necessary to comply with the regulation's critical health information requirements for safe use?",
                    "Answer": "When directions for use are omitted from a label under 8(1)(l)(ii), the label must include a statement that the directions are provided in the package insert, in order to meet the regulation's critical health information requirements for safe use defined in section 6.",
                    "Answer Explanation": "Section 8(1)(l)(ii)(B) requires a statement on the label pointing to the package insert when directions are omitted due to insufficient space. Section 6 specifies that the 8(1)(l) directions are \"critical health information\" for safe use. Therefore, the mandated statement is necessary to satisfy the section 6 requirements in this circumstance."
                }
            ]
        },
        "result_str": "{\n  \"QuestionAnswers\": [\n    {\n      \"Question\": \"Assuming a medicine's label does not contain directions for use and there is insufficient space on the container and primary pack labels to include them, what two conditions must be met for the medicine to still comply with the regulation?\",\n      \"Answer\": \"The medicine label can omit directions for use if there is insufficient label space, provided that: (A) the directions are included in a package insert in the primary pack, and (B) the label that lacks the directions includes a statement referring to the package insert.\",\n      \"Answer Explanation\": \"Section 8(1)(l)(ii) allows directions for use to be omitted from the label if space is insufficient, as long as the specified conditions (A) and (B) are satisfied. Condition (A) requires the directions to be provided in a package insert, and condition (B) requires the label to include a statement pointing to that insert.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine's dose is usually determined for each patient by an authorized health professional, is the medicine's label required to include directions for use?\",\n      \"Answer\": \"No, the label is not required to include directions for use in this case.\",\n      \"Answer Explanation\": \"Section 8(1)(l)(i) provides an exception to the general requirement that labels include directions for use. If the dose is usually determined for each patient by an appropriately authorized health professional, the directions for use may be omitted from the label.\"\n    },\n    {\n      \"Question\": \"Assuming there is sufficient label space, a medicine's dose is not individually determined, and no other exceptions apply, what specific information regarding directions for use of the medicine is required on the label to ensure safe use by consumers?\",\n      \"Answer\": \"The label must include directions for use of the medicine, as this is critical health information required for safe use by consumers who self-select the medicine.\",\n      \"Answer Explanation\": \"Section 8(1)(l) requires labels to include directions for use, subject to specific exceptions. Section 6 defines \\\"critical health information\\\" that is required for safe use of self-selected medicines as including the information under 8(1)(l). Therefore, assuming no exceptions apply, the directions for use must be on the label to meet the critical health information requirement.\"\n    },\n    {\n      \"Question\": \"Assuming a medicine label omits directions for use under the exception in 8(1)(l)(ii), what specific label statement regarding the location of the directions is necessary to comply with the regulation's critical health information requirements for safe use?\",\n      \"Answer\": \"When directions for use are omitted from a label under 8(1)(l)(ii), the label must include a statement that the directions are provided in the package insert, in order to meet the regulation's critical health information requirements for safe use defined in section 6.\",\n      \"Answer Explanation\": \"Section 8(1)(l)(ii)(B) requires a statement on the label pointing to the package insert when directions are omitted due to insufficient space. Section 6 specifies that the 8(1)(l) directions are \\\"critical health information\\\" for safe use. Therefore, the mandated statement is necessary to satisfy the section 6 requirements in this circumstance.\"\n    }\n  ]\n}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "safe use",
                    "medicine",
                    "use"
                ]
            ]
        }
    },
    {
        "path": [
            802050000,
            802020000
        ],
        "contexts": [
            " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
            " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming that 'Active ingredients', 'Indications', 'Warnings', and 'Directions for use' are considered critical health information in subsections 8(2)(c), what order must this critical health information appear in on the label according to the regulation?",
                    "Answer": "The critical health information must appear in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use.",
                    "Answer Explanation": "Section 8(2)(b) states that the critical health information must be presented under appropriate headings and in the specified order of (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. This directly answers the question of what order the critical health information must appear in."
                },
                {
                    "Question": "Based on the information in subsections 8(2)(b), 8(2)(c) and 8(2)(e), under what heading should sponsor or distributor contact details be placed on the label, assuming they are not considered critical health information?",
                    "Answer": "Sponsor or distributor contact details should be placed under the 'Other information' heading or under another separate appropriate heading that follows immediately below the critical health information headings.",
                    "Answer Explanation": "Subsection 8(2)(b) specifies the order of critical health information headings. Subsection 8(2)(e) then states that if information other than the critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, it must be placed under the 'Other information' heading or another appropriate heading that follows immediately below the critical health information headings. Sponsor or distributor contact details are listed as an example of such other information in 8(2)(e)."
                },
                {
                    "Question": "Assuming the names of all excipients are not considered critical health information or the type of information described in subsections 8(2)(c) and 8(2)(d), under what heading should the excipient names appear according to the regulation order specified in subsections 8(2)(b) and 8(2)(e)?",
                    "Answer": "The names of all excipients should appear under the 'Other information' heading or under another separate appropriate heading that follows immediately below the critical health information headings specified in 8(2)(b).",
                    "Answer Explanation": "Subsection 8(2)(b) lists the order of critical health information headings. Subsection 8(2)(e) states that information not considered critical health information or the information in 8(2)(c) and 8(2)(d) must be placed under 'Other information' or another appropriate heading following the critical health information headings. 8(2)(e) lists 'names of all excipients' as an example of such other information."
                },
                {
                    "Question": "Based on subsections 8(2)(b), 8(2)(c) and 8(2)(e), if 'Directions for use' is considered critical health information but information about package features to prevent tampering is not, in what order should those two types of information appear on the label?",
                    "Answer": "'Directions for use' should appear before information about package features to prevent tampering on the label.",
                    "Answer Explanation": "Subsection 8(2)(b) specifies that critical health information like 'Directions for use' must appear in the listed order, with 'Directions for use' as the fourth item. Then 8(2)(e) states that other information not considered critical health information, with package tampering features given as an example, must be placed under 'Other information' or another heading that follows after the critical health information headings from 8(2)(b). Therefore, 'Directions for use' would come before the tamper evident packaging information on the label."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [\n  {\n    \"Question\": \"Assuming that 'Active ingredients', 'Indications', 'Warnings', and 'Directions for use' are considered critical health information in subsections 8(2)(c), what order must this critical health information appear in on the label according to the regulation?\",\n    \"Answer\": \"The critical health information must appear in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use.\",\n    \"Answer Explanation\": \"Section 8(2)(b) states that the critical health information must be presented under appropriate headings and in the specified order of (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information. This directly answers the question of what order the critical health information must appear in.\"\n  },\n  {\n    \"Question\": \"Based on the information in subsections 8(2)(b), 8(2)(c) and 8(2)(e), under what heading should sponsor or distributor contact details be placed on the label, assuming they are not considered critical health information?\", \n    \"Answer\": \"Sponsor or distributor contact details should be placed under the 'Other information' heading or under another separate appropriate heading that follows immediately below the critical health information headings.\",\n    \"Answer Explanation\": \"Subsection 8(2)(b) specifies the order of critical health information headings. Subsection 8(2)(e) then states that if information other than the critical health information or information mentioned in 8(2)(c) or 8(2)(d) is included, it must be placed under the 'Other information' heading or another appropriate heading that follows immediately below the critical health information headings. Sponsor or distributor contact details are listed as an example of such other information in 8(2)(e).\"\n  },\n  {\n    \"Question\": \"Assuming the names of all excipients are not considered critical health information or the type of information described in subsections 8(2)(c) and 8(2)(d), under what heading should the excipient names appear according to the regulation order specified in subsections 8(2)(b) and 8(2)(e)?\",\n    \"Answer\": \"The names of all excipients should appear under the 'Other information' heading or under another separate appropriate heading that follows immediately below the critical health information headings specified in 8(2)(b).\",\n    \"Answer Explanation\": \"Subsection 8(2)(b) lists the order of critical health information headings. Subsection 8(2)(e) states that information not considered critical health information or the information in 8(2)(c) and 8(2)(d) must be placed under 'Other information' or another appropriate heading following the critical health information headings. 8(2)(e) lists 'names of all excipients' as an example of such other information.\"\n  },\n  {\n    \"Question\": \"Based on subsections 8(2)(b), 8(2)(c) and 8(2)(e), if 'Directions for use' is considered critical health information but information about package features to prevent tampering is not, in what order should those two types of information appear on the label?\",\n    \"Answer\": \"'Directions for use' should appear before information about package features to prevent tampering on the label.\",\n    \"Answer Explanation\": \"Subsection 8(2)(b) specifies that critical health information like 'Directions for use' must appear in the listed order, with 'Directions for use' as the fourth item. Then 8(2)(e) states that other information not considered critical health information, with package tampering features given as an example, must be placed under 'Other information' or another heading that follows after the critical health information headings from 8(2)(b). Therefore, 'Directions for use' would come before the tamper evident packaging information on the label.\"\n  }\n]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "subsections c",
                    "critical health information",
                    "following order"
                ]
            ]
        }
    },
    {
        "path": [
            908040000,
            907000000
        ],
        "contexts": [
            " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
            " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or"
        ],
        "result_dict": {
            "QuestionAnswers": [
                {
                    "Question": "Assuming a medicine kit contains two different formulations of medicine that are registered goods, and one of the formulations contains five active ingredients with subsection 8(2) applying, what information must be provided on the main label for each formulation to ensure compliance?",
                    "Answer": "The medicine kit must provide the information required under either paragraph 9(6)(b) or subsection 9(7) separately for each formulation. However, for the formulation with five active ingredients where subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
                    "Answer Explanation": "Subsection 9(8)(d) states that for a composite pack or medicine kit, the information required under 9(6)(b) or 9(7) must be provided separately for each medicine formulation. Subsection 9(7)(c) specifies that for registered goods with four or more active ingredients where 8(2) applies, compliance with 9(1)(b) and 9(1)(c) is not required."
                },
                {
                    "Question": "For a registered composite pack containing three medicines, two with three active ingredients each and one with five active ingredients where subsection 8(2) applies, what labeling is required to ensure compliance?",
                    "Answer": "The composite pack must provide the information required under either 9(6)(b) or 9(7) separately for each of the three medicines. For the two medicines with three active ingredients, 9(1)(b) and 9(1)(c) must be complied with. For the medicine with five active ingredients where 8(2) applies, 9(1)(b) and 9(1)(c) compliance is not required.",
                    "Answer Explanation": "Per 9(8)(d), a composite pack must provide the 9(6)(b) or 9(7) information separately for each medicine. 9(7)(c) waives the 9(1)(b) and 9(1)(c) requirements only for registered medicines with four or more active ingredients where 8(2) applies. The two 3-ingredient medicines do not meet this criteria and must follow 9(1)(b) and 9(1)(c)."
                },
                {
                    "Question": "Assuming a registered composite pack contains two medicines, both with six active ingredients and subsection 8(2) applying to each, what main label information is needed for compliance?",
                    "Answer": "The composite pack must provide the information required under either paragraph 9(6)(b) or subsection 9(7) separately for each of the two component medicines. Since both medicines contain more than four active ingredients and 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required for either medicine.",
                    "Answer Explanation": "9(8)(d) requires composite packs to separately provide the 9(6)(b) or 9(7) information for each component medicine. Per 9(7)(c), registered medicines with four or more active ingredients where 8(2) applies do not need to comply with 9(1)(b) and 9(1)(c). Since both medicines in the pack meet this criteria, neither needs to follow 9(1)(b) and 9(1)(c)."
                },
                {
                    "Question": "For an unregistered medicine kit with two formulations, one containing three and the other seven active ingredients, and subsection 8(2) applying to the 7-ingredient formulation, what main label information ensures compliance?",
                    "Answer": "The medicine kit must provide the information required under paragraph 9(6)(b) separately for each formulation, as subsection 9(7) only applies to registered goods. This means paragraphs 9(1)(b) and 9(1)(c) must be complied with for both the 3-ingredient and 7-ingredient formulations, even though 8(2) applies to the 7-ingredient one.",
                    "Answer Explanation": "9(8)(d) requires medicine kits to provide the 9(6)(b) information separately for each component medicine formulation. The 9(7)(c) exception that waives 9(1)(b) and 9(1)(c) compliance for medicines with 4+ ingredients where 8(2) applies is limited to registered goods only. As this kit is unregistered, both formulations must follow 9(1)(b) and 9(1)(c)."
                }
            ]
        },
        "result_str": "{\"QuestionAnswers\": [{\"Question\": \"Assuming a medicine kit contains two different formulations of medicine that are registered goods, and one of the formulations contains five active ingredients with subsection 8(2) applying, what information must be provided on the main label for each formulation to ensure compliance?\", \"Answer\": \"The medicine kit must provide the information required under either paragraph 9(6)(b) or subsection 9(7) separately for each formulation. However, for the formulation with five active ingredients where subsection 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.\", \"Answer Explanation\": \"Subsection 9(8)(d) states that for a composite pack or medicine kit, the information required under 9(6)(b) or 9(7) must be provided separately for each medicine formulation. Subsection 9(7)(c) specifies that for registered goods with four or more active ingredients where 8(2) applies, compliance with 9(1)(b) and 9(1)(c) is not required.\"}, {\"Question\": \"For a registered composite pack containing three medicines, two with three active ingredients each and one with five active ingredients where subsection 8(2) applies, what labeling is required to ensure compliance?\", \"Answer\": \"The composite pack must provide the information required under either 9(6)(b) or 9(7) separately for each of the three medicines. For the two medicines with three active ingredients, 9(1)(b) and 9(1)(c) must be complied with. For the medicine with five active ingredients where 8(2) applies, 9(1)(b) and 9(1)(c) compliance is not required.\", \"Answer Explanation\": \"Per 9(8)(d), a composite pack must provide the 9(6)(b) or 9(7) information separately for each medicine. 9(7)(c) waives the 9(1)(b) and 9(1)(c) requirements only for registered medicines with four or more active ingredients where 8(2) applies. The two 3-ingredient medicines do not meet this criteria and must follow 9(1)(b) and 9(1)(c).\"}, {\"Question\": \"Assuming a registered composite pack contains two medicines, both with six active ingredients and subsection 8(2) applying to each, what main label information is needed for compliance?\", \"Answer\": \"The composite pack must provide the information required under either paragraph 9(6)(b) or subsection 9(7) separately for each of the two component medicines. Since both medicines contain more than four active ingredients and 8(2) applies, compliance with paragraphs 9(1)(b) and 9(1)(c) is not required for either medicine.\", \"Answer Explanation\": \"9(8)(d) requires composite packs to separately provide the 9(6)(b) or 9(7) information for each component medicine. Per 9(7)(c), registered medicines with four or more active ingredients where 8(2) applies do not need to comply with 9(1)(b) and 9(1)(c). Since both medicines in the pack meet this criteria, neither needs to follow 9(1)(b) and 9(1)(c).\"}, {\"Question\": \"For an unregistered medicine kit with two formulations, one containing three and the other seven active ingredients, and subsection 8(2) applying to the 7-ingredient formulation, what main label information ensures compliance?\", \"Answer\": \"The medicine kit must provide the information required under paragraph 9(6)(b) separately for each formulation, as subsection 9(7) only applies to registered goods. This means paragraphs 9(1)(b) and 9(1)(c) must be complied with for both the 3-ingredient and 7-ingredient formulations, even though 8(2) applies to the 7-ingredient one.\", \"Answer Explanation\": \"9(8)(d) requires medicine kits to provide the 9(6)(b) information separately for each component medicine formulation. The 9(7)(c) exception that waives 9(1)(b) and 9(1)(c) compliance for medicines with 4+ ingredients where 8(2) applies is limited to registered goods only. As this kit is unregistered, both formulations must follow 9(1)(b) and 9(1)(c).\"}]}",
        "misc_info": {
            "guided_entity_path": [
                [
                    "compliance",
                    "medicine",
                    "composite pack"
                ]
            ]
        }
    }
]